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ABSTRACT 
ASHLEY J. BEARD:  Cost as a Feature of Medication Management Communication  
in Medical Visits 
(Under the direction of Dr. Betsy Sleath) 
 
Little is known about how patients and physicians discuss medication costs in 
medical visits, if such discussions impact decision making, and if patients are more satisfied 
with their medications if they discuss cost.  The predominance of medication therapy, the 
need for continuous treatment, and the variation in medication costs make it especially 
important to examine the extent to which rheumatoid arthritis (RA) patients discuss issues 
related to medication costs, how they manage their medications with their physicians, and 
how this relates to patient-reported medication satisfaction. 
This is a cross-sectional secondary analysis of survey and clinic visit audiotape data 
that were collected in North Carolina from 2003 to 2005 from 8 rheumatologists and 200 of 
their adult patients with RA.  Qualitative analyses were conducted to examine the content of 
communication about medication costs and management in routine rheumatology clinic 
visits.  Quantitative analyses employing multivariable models were conducted to examine 
the influence of patient, physician, and medication characteristics on visit communication 
about medication costs, management, and satisfaction.   
Results revealed that 34% of medical visits contained medication cost 
communication and the content centered on insurance coverage and strategies to reduce 
patient out-of-pocket medication expenses.  Quantitative results revealed that patients 
identifying as White/Caucasian and those with no prescription drug coverage were 
significantly more likely to discuss medication costs. Results revealed that medication cost 
communication and disclosure of patient-initiated regimen changes were significantly, 
 iv 
positively associated with one another.  In over 20% of visits, patients disclosed self-initiated 
changes to their medication regimens and the communication demonstrated that patients 
were active managers of their medications.  Patients disclosed taking more, less, and 
substituting medications for those prescribed.  Almost unanimously, the regimen changes 
reduced their total RA medication cost burden.  However, neither communication about 
medication costs nor patient medication management significantly predicted medication 
regimen changes in the medical visit and no factors reliably predicted patient-reported 
medication satisfaction.   
These findings have implications for conceptualizing medical visit communication 
about medication costs and management.  Better understanding of these topics provides 
guidance for the development of conceptual frameworks and interventions to improve 
communication, and thereby improve care.   
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CHAPTER ONE:  INTRODUCTION 
 
“It is not to see something first, but to establish solid connections between the previously 
known and hitherto unknown that constitutes the essence of specific discovery.” 
 (Selye, 1956) 
 
 
  The cost of prescription medication in the United States is a critical health and policy 
issue. Americans, especially those with chronic conditions, are not only paying more for 
medications, but they are also using more prescription medications than ever (Alexander, 
Casalino, & Meltzer, 2005; Alexander, Casalino, Tseng, McFadden, & Meltzer, 2004; 
Heisler, Langa et al., 2004).  While it is generally agreed that medication costs should be 
taken into account in prescribing decisions, little is known about how patients and physicians 
discuss medication costs in medical visits, if such discussions impact medical decision 
making, and if patients are more satisfied with their medications if they discuss cost issues 
with physicians (Alexander, Casalino, & Meltzer, 2003; American College of Rheumatology 
Subcommittee on Rheumatoid Arthritis Guidelines, 2002).  
  The predominance of medication therapy, the need for continuous treatment, and the 
variation in medication costs make it especially important to examine the extent to which RA 
patients discuss medication cost issues and how they manage their medications with their 
physicians. RA is a chronic disease primarily treated through long-term continuous use of 
prescription medications.  Out-of-pocket (OOP) costs incurred by patients for RA 
medications vary widely from just a few dollars per month to thousands per month (Lapsley 
et al., 2002).  With medication regimen changes occurring in as many as 90% of 
rheumatology clinic visits, examining discussions of medication cost provides insight into 
management strategies employed by patients and whether discussing such issues improves 
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patient satisfaction with their medications (Chewning et al., 2001; Piette, Heisler, & Wagner, 
2004a).
  To address the issues outlined above, the objective of this research study was to 
examine routine medical visit communication about medication costs and medication 
management between patients with RA and their rheumatologists and assess the impact of 
such communication on medication satisfaction.  This study is a cross-sectional, secondary 
analysis of data that were collected as part of an ongoing National Institute on Aging funded 
study examining patient-physician communication about quality of life and medication 
concerns in rheumatology visits. The data were collected in North Carolina from March 2003 
to December 2005.  Study data include clinic visit audiotapes, patient interviews, medical 
records, and questionnaires.  The three aims of the investigation were to: (1) qualitatively 
examine the content of discussions regarding medication costs and medication 
management between RA patients and rheumatologists, (2) describe relationships among 
patient characteristics, physician characteristics, medication characteristics, and medical 
visit communication about medication costs and management, and (3) examine how 
discussions of medication cost and management in routine medical visits affect patient-
reported medication satisfaction.  
  The broad, long-term objective is to improve physician-patient communication about 
medication costs and medication regimen management in an effort to improve patient 
medication satisfaction and subsequent medication adherence.  Medication satisfaction has 
been shown to be predictive of subsequent medication adherence (Bultman & Svarstad, 
2000).  Further, satisfaction with medication and health care more broadly can also be 
considered an indicator of quality care (Cleary & McNeil, 1988).   
  This study addresses the need to better understand patient-physician communication 
about medication costs and medication management during rheumatology visits and the 
impact of such communication on medication satisfaction.  This will be one of the first 
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studies to examine actual discussions between patients and physicians about medication 
cost and management (Alexander et al., 2004; Chewning & Sleath, 1996; Schafheutle, 
Hassell, Noyce, & Weiss, 2002).  The findings from this study can be used to educate 
physicians and patients about ways they can optimize communication about medications 
during rheumatology visits to improve patient outcomes. 
  This dissertation is organized around the three primary research aims described 
above.  Chapter 2 includes a review of the literature on RA, medication costs, discussions of 
medication costs between patients and providers, patient medication management, and 
patient satisfaction with medications.  The chapter provides a description of how this 
literature informed the specific aims and conceptual framework underlying the dissertation.  
Chapter 3 describes the conceptual framework that guides the study.   Chapter 4 details the 
research methods describing the study setting, patient eligibility, the study data, 
measurements, and analyses by aim.  This is followed by the study results in Chapter 5.  
Finally, Chapter 6 summarizes the major findings from the research, discusses the 
implications, presents a revised conceptual framework, and suggests possible directions for 
future research. 
 
 
 
 
  
 
 
 
 
 
CHAPTER TWO:  BACKGROUND AND SIGNIFICANCE 
 
Overview 
 Few published studies have examined the content of patient-physician 
communication about medication costs as part of medication regimen modification 
discussions in medical visits (Richard & Lussier, 2006; Tarn et al., 2006). To the best of my 
knowledge, there has been no published work examining communication about medication 
costs between rheumatologists and patients with RA. RA is a chronic, systemic disease 
characterized by inflammation of the joints which can lead to irreversible joint damage (Brus, 
van de Laar, Taal, Rasker, & Wiegman, 1999). Current estimates indicate a 1% population 
prevalence of RA (DeWitt, Glick, Albert, Joffe, & Wolfe, 2006). Medication is the dominant 
therapy for RA patients and recent advances in medication therapy have provided patients 
and physicians with new options in treating RA.  These new biologic agents have 
demonstrated efficacy and are being increasingly used in clinical practice (Maradit-Kremers, 
Nicola, Crowson, O'Fallon, & Gabriel, 2006). However, the use of biologic medications has 
driven up the medical costs of RA, with patients taking biologics subject to disproportionately 
greater costs (Michaud, Messer, Choi, & Wolfe, 2003).  While some of these medication 
costs may be offset by health insurance and prescription drug coverage, RA patients in the 
United States generally incur a portion of the total cost as OOP medication costs.  While 
patients may be increasingly burdened by these OOP medication costs, little is known about 
the frequency and content of communication about medication cost as part of medication 
management communication in medical visits (Heisler, Langa et al., 2004).  Therefore, the 
purpose of this research is to examine actual RA patient-rheumatologist communication 
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about medication costs and medication management in routine clinic visits, the patient, 
physician, and medication characteristics that influence such communication, and the 
impact these factors have on patient reported medication satisfaction.   
 The following section examines relevant literature on RA, medication costs, 
discussions of medication cost between patients and providers, patient medication 
management, and patient satisfaction with medications.  
 
Rheumatoid Arthritis 
RA is a chronic, systemic disease characterized by inflammation of the joints.  The 
disease is incurable and while the inflammation is reversible it can lead to irreversible joint 
damage (Brus et al., 1999).  Current estimates indicate that there is an overall 1% 
population prevalence of RA and approximate 2% population prevalence of RA among 
individuals age 60 and older in the United States, meaning nearly 10 million US adults age 
60 and older are affected by RA (DeWitt et al., 2006; Rasch, Hirsch, Paulose-Ram, & 
Hochberg, 2003).  RA is generally more prevalent among women, persons with less 
education, and older persons (Rasch et al., 2003).  
Recommended treatments for RA include physical exercise, ergonomic measures, 
disease-modifying antirheumatic drugs (DMARDs), nonsteriodal anti-inflammatory drugs 
(NSAIDs), and glucocorticoids (Maradit-Kremers et al., 2006).  Treatment with medication is 
the dominant therapy for RA patients.  The use of medications in the treatment of RA is 
particularly important because the medications have the potential to reduce and prevent 
joint damage and preserve joint integrity and function.  Treatment with DMARD therapy is 
prescribed to change the disease process, and should be used continuously.  However, 
effects of this therapy on the disease, and consequently symptoms, can be expected only 
after weeks or months (Brus et al., 1999). Response to the medications can be highly 
individual with certain patients experiencing potentially serious side effects or receiving little 
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to no benefit, especially over the long term (Maradit-Kremers et al., 2006; Neame & 
Hammond, 2005).  Notably though, recent advances in medication therapy have provided 
patients and physicians new medication options in treating RA.  These new biologic agents 
have demonstrated efficacy and are being increasingly used in clinical practice (Maradit-
Kremers et al., 2006).   
 
Medication Costs  
In 1999, $100 billion was spent on prescription drugs and the Health Care Financing 
Administration (HCFA) has predicted that pharmaceutical costs, which accounted for 9.4% 
of health care expenditures in 1999, will increase to 12.6% per year on average over the 
next decade (Iglehart, 2001).  Older adults often have to spend significant portions of their 
incomes on prescription drugs.  A study by Hwang, Weller, Ireys, and Anderson (2001) 
using 1996 Medical Expenditure Panel Survey data found that OOP spending increased 
with age. Study results indicated that persons 80 years-old and over spent more than 5 
times that of those from birth to 19 years.  For US adults with multiple chronic illnesses, 
OOP prescription medication expenditures can be well over one thousand dollars a year 
(Heisler, Langa, Eby, Fendrick, Kabeto, & Piette, 2004). Even in countries with more 
generous prescription drug coverage than the United States, many patients face financial 
pressure from OOP medication costs and generally report being cost-conscious about their 
prescription medications (Atella, Schafheutle, Noyce, & Hassell, 2005; Ess, Schneeweiss, & 
Szucs, 2003; Krobot et al., 2004; Noyce et al., 2000). 
For patients with RA, medication costs are an especially salient issue. The 
increasing use of biologic medications combined with the predominance of medication 
therapy has driven up the medical costs of RA.  The mean total annual direct medical care 
cost in 2001 for an RA patient was calculated as $9,519, an approximate $4,000 increase 
over the 1998 estimate (Michaud et al., 2003).  Of the $9,519, medication costs accounted 
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for 66% or $6,324.  RA patients taking biologic medication agents were subject to mean 
total annual direct costs of $19,016 per year, while the cost to those not taking biologics was 
$6,164.  While some of these medication costs may be offset by health insurance and 
prescription drug coverage, RA patients in the United States generally incur a portion of the 
total cost as OOP medication costs. 
 
Discussions of Medication Cost between Patients and Physicians 
A nationally representative survey of over 4000 chronically ill adults found that of 
those individuals who restricted their medication use, only 33% reported that they had told 
their doctor that they planned to use fewer medications because of cost in the previous 12 
months (Piette, Heisler, & Wagner, 2004b). A recent examination of actual visit 
communication between patients and physicians about the cost of newly prescribed 
medicines found that among a sample of family physicians, internists, and cardiologists 
medication cost was only discussed for 12% of newly prescribed medications (Tarn et al., 
2006). Alexander et al. (2004) found that 11% of patients and 20% of physicians were able 
to recall a time they wanted to talk about cost but did not. Both patients and physicians 
report numerous barriers to discussing medication costs during medical visits (Alexander et 
al., 2005; Alexander et al., 2004; Piette et al., 2004b; Schafheutle et al., 2002).  Patient-
reported barriers to medication cost discussions are: discomfort discussing OOP costs, 
insufficient time, belief that the physician did not have a viable solution to offer, and 
concerns regarding the impact of discussion on quality of care. Physician-reported barriers 
to discussing medication costs in medical visits have included: insufficient time, belief that 
they did not have solution to offer, discomfort discussing medication cost, and fear of 
compromised quality of care. 
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Despite reported barriers to communication of medication cost between patients and 
physicians, patients who talk with their physicians about medication costs have rated these 
conversations ‘helpful’ (Piette et al., 2004b). Physicians have reported employing a number 
of strategies to address issues of medication cost-related restriction when they are aware 
that it is an issue for patients.  Physician reported strategies to assist patients who were 
burdened by OOP medication costs included: switching patients from brand-name to generic 
drugs, providing patients with medication samples, critically reviewing patients’ medication 
list and discontinuing nonessential ones, switching to different brand name drugs in same 
medication class, and expressing sympathy (Alexander et al., 2005; Piette et al., 2004b).   
 
Medication Management 
Discussions of medication cost can be viewed in the larger context of medication 
management.  Generally, patients are required to manage their medication regimens 
immediately following the interaction with their physician.  Specifically, medication 
management refers to the set of decisions and behaviors patients engage in to evaluate and 
revise, at their discretion, their medication regimens (Chewning & Sleath, 1996).  Patients 
have been shown to be active in managing their medication regimens and, yet, this has 
been an often-overlooked element in patient-physician communication about medications 
(Chewning & Sleath, 1996).   
For chronic-conditions like RA, patient medication management has a potentially 
large impact on the disease experience. RA medications have the potential to reduce pain, 
prevent joint damage, and preserve joint integrity and function. Medication therapy is 
prescribed to change the disease process, and should be used continuously.  However, the 
medications used to treat RA can potentially be harmful to patients and may only be partially 
effective (Neame & Hammond, 2005).  With variability in the side effects and effectiveness 
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of medications, as well as the painful and highly somatic nature of RA, there is a need for 
constant medication calibration (Chewning et al., 2001).  RA patients must make decisions 
about the amount, timing, and quantity of medication to take based on a number of personal 
factors, including the cost of their medications.  In this way, medication cost is a feature of 
medication management, and medication management is something that may or may not be 
discussed in medical visits.  The presence or absence of discussion about medication 
management may have several implications. Without discussion and understanding of how 
patients conceptualize or monitor their RA, physicians are at a disadvantage for 
understanding patients’ judgments and medication decisions (Chewning & Sleath, 1996).  If 
physicians and patients discuss medication management strategies during the medical visit, 
they may agree on a regimen that is tailored on the basis of patients’ financial status.  For 
example, insurance coverage might be discussed and physicians might select preferred 
medications with lower co-payments.  If such discussions do not take place, patients may be 
less satisfied with their medications and may modify their regimens without the input of the 
physician.   
 
Patient Satisfaction with Medication 
Patient satisfaction has become an increasingly important health outcome and can 
be used to evaluate the quality of care as well as identify particular factors of care, such as 
medications, that need to be changed to improve satisfaction (Jackson, Chamberlin, & 
Kroenke, 2001).  Satisfaction has been conceptualized as an attitudinal response to value 
judgments that patients make about their clinical encounters (Kane, Maciejewski, & Finch, 
1997).  From this, medication satisfaction can be conceptualized as patients’ attitudes and 
judgments about the medications they are taking or are supposed to take.  Assessing 
satisfaction with medication as an outcome of communication about medication cost and 
management is especially pertinent since satisfaction has been shown to be associated with 
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the nature of patient-physician communication and with medication adherence (Bultman & 
Svarstad, 2000).  A meta-analysis of 41 studies examining objectively measured patient-
physician behaviors in medical encounters and satisfaction indicated that greater 
satisfaction had statistically significant associations with physician provision of more 
information, greater conversation about topics not directly medical, and more physician 
engagement of patients in decision making (Hall, Roter, & Katz, 1988).  Looking specifically 
at RA, a study of 1,041 patients with RA found that patients who reported greater 
involvement in medical decision-making were significantly more satisfied with their treatment 
than patients who reported being less involved in decision-making (Kjeken et al., 2006).   
Therefore, patients who communicate with their physicians about medication cost and 
medication management may be more likely to perceive their physicians as providing more 
information and engaging them more in medical decision making and are more likely to be 
satisfied with the medications they are supposed to take. 
 
Summary and Significance of the Project 
 In sum, the proposed research will give insight into discussions of medication cost 
and medication management between patients and providers and the effect that such 
discussions have on medication satisfaction.  Examining actual patient-physician 
communication about medication costs and management is important because it is within 
this context that patients obtain their medications and their level of satisfaction with these 
medications has important implications for their subsequent adherence. This will be one of 
the first studies to examine actual discussions between patients and physicians about 
medication cost and management (Alexander et al., 2004; Chewning & Sleath, 1996; 
Schafheutle et al., 2002).  The findings from this study can be used to educate physicians 
and patients about ways they can optimize communication about medications during 
rheumatology visits to improve patient outcomes.
  
 
 
 
 
 
CHAPTER THREE:  CONCEPTUAL FRAMEWORK 
 
Overview and Conceptual Model 
While communication between patients and physicians has been studied for over fifty 
years, examination of communication about medication costs between patients and 
physicians is relatively new and, as such, so is development of conceptual frameworks to 
understand such communication and its impact (Parsons, 1951; Piette, Heisler, Horne, & 
Caleb Alexander, 2006). Since much of the focus of this research is on the nature of 
communication between physicians and patients, typologies of patient-physician interaction 
as well as the antecedents and outcomes of typologies of interaction guide the conceptual 
framework in this study.   
The entry of patient and physician into an exchange, as occurs in medical visits, 
denotes the start of a relationship between the two participants predicated on the 
expectations that each has for the other (D. Roter & Hall, 2006).  Patient and physician enter 
into a fluid system of expectations, roles, and outcomes based on their mutual influence on 
each other within medical visit interactions.  In this way, the medial visit and the interacting 
partners are a dynamic system of interaction of cause and effect, recognizing the primacy of 
the individual positions of patient and physician in interactions (Lewin, 1935).  The individual 
positions that patient and physician assume often take the form of defined roles.  These 
roles influence medical visit communication and have implications for the provision of care, 
satisfaction, and outcomes.  The assumption of defined roles by patient and physician in 
medical visit interactions are the foundation of relationship typologies. 
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Patient-physician interaction typologies are based on the level of physician authority 
and patient autonomy where both elements exist along a spectrum and must be negotiated 
in the patient-physician relationship (Parsons, 1951; D. Roter & Hall, 2006).  These 
typologies are played out in the course of communication and, as conceptualized, can be 
thought of as four hypothetical models of varying levels of control of the interaction on the 
part of the participants.  The expression of power and the dynamics of negotiation have 
been described as assuming the four paradigms of the patient doctor-relationship:  
paternalism, consumerism, mutuality, and default (D. Roter & Hall, 2006). Table 1 displays 
the typologies and associated levels of physician and patient control.   
 
Table 1.  Patient-physician relationship typologies as presented in Roter & Hall, 2006. 
Patient Control  Physician Control 
  Low High 
Low  Default Paternalism 
High  Consumerism Mutuality 
 
The upper right quadrant of Table 1 presents the archetype of paternalism.  It is 
characterized by physician domination of medical visit agenda setting, treatment negotiation, 
and overall control of information and services.  In this model the patient has little control in 
the visit and often has little to no participation in communication.   
Consumerism, in the lower left corner of Table 1, represents the opposite of 
paternalism.   Patients have primary responsibility for goal setting, negotiating, and decision-
making in the consumerism relationship model.   In medical visits characterized by 
consumerism, patients make demands for information and services that are obliged by the 
physician.   This view is often thought of in economic marketplace terms where consumers 
demand goods and services, physicians supply care, and transactions are conducted 
accordingly. 
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In the lower right quadrant of Table 1, mutuality represents the middle ground 
between paternalism and consumerism.  In this relationship model, both patient and 
physician exercise high control over the interactions.  Insofar as is possible, the power is 
balanced between patient and physician and agenda setting happens jointly, both 
participate in negotiation, and decision-making happens jointly.   Joint decision-making and 
negotiating happen through meaningful dialogue between patient and physician in 
relationships characterized by mutuality.   Patients explicitly communicate about their 
condition, values, and preferences.  Physicians respond by exploring those views with 
patients, providing thorough information, and actively involving them in treatment decisions.  
Through these exchanges, the experiences and inherent expertise of both participants are 
validated. 
Mutuality relationships have important implications for decision-making about 
medications because it is under conditions of mutuality that concordance is likely to be 
achieved (Elwyn, Edwards, & Britten, 2003).  Concordance has been defined as, “an 
agreement reached after negotiation between a patient and health care professional that 
respects the beliefs and wishes of the patient in determining whether, when and how 
medicines are to be taken.  Although reciprocal, this is an alliance in which the health care 
professional recognizes the primacy of the patient’s decisions about taking the 
recommended medications (Royal Pharmaceutical Society of Great Britain, 1997).”  
Exchanges about medications in which patients provide information on their feelings and 
preferences about taking medications, physicians ask questions, they provide patients with 
the pros and cons of taking and not taking medicine, and both parties agree on a decision 
meet the criteria for both concordance and mutuality. 
When the relationship is difficult to negotiate, both parties are functionally absent in 
decision-making, and neither participant in the medical visit exercises high levels of control 
the relationship is default, which is shown in the upper-left quadrant of Table 1.  The 
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relationship is considered default because it assumes a practical dysfunction as neither 
party exercises control to move interactions or the relationship forward.  Patients in default 
relationships may become angry and frustrated and make time and service demands that 
are impossible for the physician to meet.  Patients may subsequently discontinue care with 
the physician because of failed expectations for interactions and treatment (D. Roter & Hall, 
2006).  
To a certain extent these typologies of the patient-physician relationship may 
represent separate poles within which actual relationships and communication exist.  
However, understanding the foundations and boundaries within which the patient-physician 
relationship exists facilitates understanding the continuum of communication.  In addition, 
these typologies provide a framework for analyzing interactions between patients and 
physicians.   Also important to recognize, patient-physician relationships are influenced by 
numerous factors beyond communication.  Characteristics of the patient and the physician 
may alter their relationship preferences, as well as their communication and its outcomes 
(Lewis, DeVellis, & Sleath, 2002). 
Figure 1 outlines the conceptual framework for this application, which draws on 
typologies of patient-physician interaction and the mutual influence of the interacting 
partners in the patient-physician dyad (Lewis et al., 2002; Parsons, 1951; D. Roter & Hall, 
1992).  In addition, the medical communication literature has shown that particular physician 
and patient demographic factors, patient disease status, and medication characteristics 
influence patient-physician communication and, therefore, may influence communication 
about medication cost and management (Chewning & Sleath, 1996; Cooper-Patrick et al., 
1999; Sleath, Roter, Chewning, & Svarstad, 1999; Sleath & Rubin, 2002).  Each of these 
factors, in turn, has the ability to affect patient-reported satisfaction with medications. The 
following sections examine each of the components of the conceptual framework.
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Figure 1: Conceptual framework for understanding the impact of physician-patient 
communication about medication cost and medication management on medication 
satisfaction 
 
 
 
 According to the model, predisposing patient, physician, and medication factors 
directly influence patient-physician communication.  Patient-physician communication then 
influences patient satisfaction with medications.  In addition, patient and medication factors 
also exercise a direct influence on medication satisfaction.   
 
Patient Characteristics  
 Patient age, income, and education level have all been found to characterize more 
active physician-patient relationships (Lewis et al., 2002). Studies investigating the influence 
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of patient gender on communication in the medical visit show that female patients generally 
receive more information, ask more questions, and have more collaborative relationships 
with physicians than male patients (Cooper-Patrick et al., 1999). Further, several studies 
suggest that younger patients prefer to be more involved in medical decision-making as do 
patients with higher incomes, higher educational levels, and higher occupational levels 
(Chewning & Sleath, 1996). Disease severity also has the potential to influence 
communication because patients with more severe disease may be more likely to discuss 
medications and ask questions than patients with less severe disease (Chewning & Sleath, 
1996). Self-rated pain, as a measure of disease activity, is likely to influence communication 
about medication regimens and cost; patients experiencing higher levels of pain are less 
likely to be satisfied with their current medications and, therefore, may be more likely to 
communicate about their medication regimens and subsequent medication costs with their 
physicians than patients with lower pain levels (Jackson et al., 2001; Kjeken et al., 2006).  
Prescription drug coverage is also likely to influence communication about medication cost 
in regimen discussions.  Patients with very generous prescription drug coverage may not be 
as motivated to discuss medication costs as patients with less generous coverage. 
Physicians who are aware that patients have generous insurance coverage are also likely to 
be unmotivated to discuss medication costs. Research has shown distinct differences in the 
frequency of communication about medication costs at practice sites with different dominant 
prescription drug plans (Tarn et al., 2006). Taken together, these determinants suggest that 
communication about medication cost and medication management are likely to be affected 
by patient gender, age, race, ethnicity, education, income, disease severity, self-rated pain, 
and prescription drug coverage. 
 Patient characteristics also are expected to have a direct effect on patient reported 
satisfaction with medications. Research literature has demonstrated that older patients and 
those who report better health status are more satisfied with their health care and specific 
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aspects of care than younger patients or those reporting their health status as poor (Jackson 
et al., 2001; Kane et al., 1997).  It can be expected that patients with more severe RA and 
those experiencing more pain are less likely to be satisfied with their medications. Study 
results have indicated associations between satisfaction and female gender, social class, 
and race; however, the existence of contradictory and inconsistent findings make it difficult 
to make a clear determination of direction of association (Jackson et al., 2001).  With 
prescription drug coverage playing a role in access to certain medications, it is expected that 
prescription drug coverage type may affect patient assessment of medication satisfaction 
since access has been shown to be an important element in determinations of satisfaction 
(Cleary & McNeil, 1988).   
 
Physician Characteristics 
 The medical communication literature has shown that female physician gender is 
associated with more patient and physician talking during visits including more discussion of 
social issues, and more active enlistment of patient input (Cooper-Patrick et al., 1999; D. L. 
Roter, 2003). Beyond the impact of physician gender on interaction in medical visits, the 
literature has found that physician race and ethnicity matter, especially when patients and 
physicians are of the same race and ethnicity (Saha, Komaromy, Koepsell, & Bindman, 
1999).  Some research has suggested that physician age may affect communication style 
with patients, with older physicians less likely to use participatory decision-making styles 
than younger physicians (Epstein, Alper, & Quill, 2004).  This literature suggests that 
physician age, gender, race, and ethnicity may all affect the likelihood that medication 
management and medication costs are or are not discussed in medical visits. 
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Medication Characteristics 
 The characteristics of the medications under consideration and discussion in the 
medical visit may play a role in whether medication cost or medication management is 
brought up.  The research literature has shown that patients are more cost sensitive to 
symptom relieving medications than disease modifying medications.  A recent analysis of 
medical communication in primary care demonstrated different rates of cost communication 
by medication type (Piette, Heisler, Horne et al., 2006; Tarn et al., 2006).  Therefore, the 
relative cost of the RA medications being prescribed is likely to influence discussion.  In 
addition, the cost of medication is likely to influence patient ratings of medication 
satisfaction.  Studies that have examined costs of medical products and services have found 
that the higher the cost, the lower the satisfaction (Cleary & McNeil, 1988). Given the 
potential impact on reported medication satisfaction, knowing the types of medications 
discussed in the visit and their relative cost will be important variables to control for in the 
analyses.   
 
Communication between Physicians and Patients 
 A recent examination of visit communication between patients and physicians about 
the cost of newly prescribed medicines found that among a sample of family physicians, 
internists, and cardiologists medication cost was only discussed for 12% of newly prescribed 
medications (Tarn et al., 2006). Alexander et al. (2004) found that 11% of patients and 20% 
of physicians were able to recall a time they wanted to talk about cost but did not. Both 
patients and physicians report numerous barriers to discussing medication costs during 
medical visits (Alexander et al., 2005; Alexander et al., 2004; Piette et al., 2004b; 
Schafheutle et al., 2002).  Despite reported barriers to communication of medication cost 
between patients and physicians, patients who talk with their physicians about medication 
costs have rated these conversations ‘helpful’ (Piette et al., 2004b). Physicians have 
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reported employing a number of strategies to address issues of medication cost-related 
restriction when they are aware that it is an issue for patients (Alexander et al., 2005; Piette 
et al., 2004b). 
 Discussions of medication cost can be viewed in the larger context of medication 
management. Specifically, medication management refers to the set of decisions and 
behaviors patients engage in to evaluate and revise, at their discretion, their medication 
regimens (Chewning & Sleath, 1996).  Patients have been shown to be active in managing 
their medication regimens and, yet, this has been an often-overlooked element in patient-
physician communication about medications (Chewning & Sleath, 1996).   
 For chronic conditions like RA, patient medication management has a potentially 
large impact on the disease experience. RA medications have the potential to reduce pain, 
prevent joint damage, and preserve joint integrity and function. Medication therapy is 
prescribed to change the disease process, and should be used continuously.  However, the 
medications used to treat RA can potentially be harmful to patients and may only be partially 
effective (Neame & Hammond, 2005).  Because of variability in the side effects and 
effectiveness of medications, as well as the painful and highly somatic nature of RA, there is 
a need for constant medication calibration (Chewning et al., 2001).  RA patients must make 
decisions about the amount, timing, and quantity of medication to take based on a number 
of personal factors, including the cost of their medications.  Once patients leave physicians’ 
offices they must make decisions about the medicines they have been prescribed.  Patients 
may choose not to have a prescription filled because of the cost of the medication, may 
substitute less expensive over-the-counter (OTC) medicines for prescription medications, or 
they may alter the timing or dosing of medication to make it last longer between prescription 
fills.  In this way, medication cost is a feature of medication management, and medication 
management is something that may or may not be discussed in medical visits.  More 
remains to be learned about the frequency and content of patient disclosures to physicians 
 20 
about their self-initiated medication regimen changes.  The presence or absence of 
discussion about patient-initiated medication regimen management may have several 
implications. Without discussion and understanding of how patients monitor or conceptualize 
their RA, physicians are at a disadvantage for understanding patients’ judgments and 
medication decisions (Chewning & Sleath, 1996).  If physicians and patients discuss 
medication management strategies during the medical visit, they may agree on a regimen 
that is tailored on the basis of patients’ financial status.  For example, insurance coverage 
might be discussed and physicians might select preferred medications with lower co-
payments.  If such discussions do not take place, patients may be less satisfied with their 
medications and may modify their regimens without the input of the physician.   
In the proposed study, discussions of medication cost, patient-initiated medication 
regimen changes, and discussion of modifying the medication regimen are variables of 
interest in assessing the impact of physician, patient, and medication characteristics on 
physician-patient communication.  Patient initiated-medication regimen change 
communication and medical visit discussion of modifying the medication regimen can be 
conceived of as aspects of medication management communication in medical visits.  Both 
variables will be measured to confirm that they represent distinct constructs and to assess 
the relationship of medication cost communication with each.   
In addition, patient and physician questions about cost and the cost discussion 
initiator are viewed as important variables.  In general, physicians asking about medications 
is important because it allows physicians to assess patients’ educational needs and 
understanding of the treatment rationale, how treatment should be used, treatment goals 
and preferences, side effects, contraindications, and barriers to adherence (Sleath, Rubin, & 
Huston, 2003).  Question-asking can also be a sign of a more collaborative communication 
style because, by its very nature, physician question-asking engages the patient in 
conversation through required response (D. Roter & Hall, 1992).  However, physicians often 
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fail to ask their patients questions and there may be differential characteristics of physicians 
who do and do not ask questions of their patients (Sleath et al., 2003). Previous studies 
have found patients are reluctant to ask questions about medications during medical visits 
(Sleath et al., 2003). There are patient characteristics in question-asking that may be 
important: research has shown older patients were significantly more likely to ask about their 
medications.  Additionally, patients were significantly more likely to ask questions of younger 
physicians (Sleath et al., 1999).  
In addition to question-asking, assessing who initiates discussions about medication 
cost and medication management is important because it provides information about the 
nature of such communication and also it may have an impact on patient rated medication 
satisfaction.  In a primary care and cardiology setting in California, physicians overwhelming 
initiated medication cost and insurance coverage conversations (Tarn et al., 2006).  
However, it is unknown whether this varies by medical specialty or geographic area.  
Knowing more about patient and physician characteristics associated with question asking 
about medications costs and the initiator of conversations about cost can help inform 
interventions that improve communication about medication costs. 
 
Medication Satisfaction 
 Satisfaction is an increasingly important health outcome and can be used to evaluate 
the quality of care as well as identify particular factors of care, such as medications, that 
need to be changed to improve satisfaction (Jackson et al., 2001).  Medication satisfaction 
can be conceptualized as patients’ attitudes and judgments about the medications they are 
taking or are supposed to take (Kane et al., 1997).  Assessing satisfaction with medication 
as an outcome of communication about medication cost and management is especially 
pertinent since satisfaction has been shown to be associated with the nature of patient-
physician communication and with medication adherence (Bultman & Svarstad, 2000).  A 
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meta-analysis of 41 studies examining objectively measured patient-physician behaviors in 
medical encounters and satisfaction indicated that greater satisfaction had statistically 
significant associations with physician provision of more information, greater conversation 
about topics not directly medical, and more physician engagement of patients in decision 
making (Hall et al., 1988).  Looking specifically at RA, a study of 1,041 patients with RA 
found that patients who reported greater involvement in medical decision-making were 
significantly more satisfied with their treatment than patients who reported being less 
involved in decision-making (Kjeken et al., 2006).  Therefore, patients who communicate 
with their physicians about medication cost and medication management may be more likely 
to perceive their physicians as providing more information and engaging them more in 
medical decision making and are more likely to be satisfied with the medications they are 
prescribed. 
 Assessing satisfaction has been a recommended outcome measurement for medical 
visit communication about medication cost between patients and physicians (Alexander et 
al., 2003). With discussions about medication cost and management in medical visits 
centering on medications, assessment of patient-rated medication satisfaction is the most 
specific outcome and measurement match to the communication under study (Shikiar & 
Rentz, 2004).  Patient ratings of medication satisfaction are likely to be affected by 
communication with the physician and by properties of the medication (Shikiar & Rentz, 
2004). Physicians who discuss medication costs and ask patients how they manage their 
RA medications may be more likely to prescribe medications that fit within the budget and 
lifestyle of patients.  This would likely positively impact patient medication satisfaction 
ratings.  Conversely, in medical visits where physicians and patients do not discuss 
medication costs, patients may be less satisfied with their medications due to cost factors or 
reactions to the perceived omission of such information by the physician.  Because 
medication satisfaction has demonstrated association with the nature of patient-provider 
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communication, monitoring satisfaction may help identify situations in which communication 
is not optimal (Bultman & Svarstad, 2000; Cleary & McNeil, 1988). 
 
  
 
 
 
 
CHAPTER FOUR:  METHODS 
 
Overview 
  This study is a cross-sectional secondary analysis of data that were collected as part 
of an ongoing National Institute of Aging funded study examining patient-physician 
communication about quality of life and medication concerns in rheumatology visits. The 
data were collected from March 2003 to December 2005.  The study sample includes 200 
patients and eight rheumatologists from North Carolina.  Study data include clinic visit 
audiotapes, patient interviews, medical records, and questionnaires.  The University of North 
Carolina Institutional Review Board approved this study. 
 
Study Setting 
  The study includes eight rheumatologists practicing in academic and non-academic 
clinic settings in North Carolina.  Data were collected from four rheumatology practices, 
three academic affiliated clinics and one non-academic. Physicians were chosen based on 
whether they were rheumatologists who saw patients who were age 45 and older with RA. 
Written consent was obtained from each participating physician.  The physician sample was 
a convenience sample.  Eleven rheumatologists were approached to participate and eight 
(72.7%) agreed to participate.  Of the three physicians who refused to participate in the 
study, two were female, two were White/Caucasian, and one was Black/African American. 
 Examining medication cost and medication management communication among 
patients seeing rheumatologists rather than primary care physicians is advantageous 
because such patients are likely to have more complex RA disease than would be found 
among patients seeing primary care physicians.  These patients, therefore, are likely to be 
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taking more medications, which may be more expensive than patients with less severe RA 
(Neame & Hammond, 2005). Given this, examining data from rheumatologists and their 
patients is especially appropriate because they are particularly likely to be affected by the 
medication cost issues discussed above. 
 
Patient Eligibility 
  Patients were eligible for the study if they were 45 years of age and older, had a 
physician-confirmed diagnosis of RA, did not have a terminal illness, were able to speak 
English, and were mentally competent to participate.  Potentially eligible patients were 
identified by rheumatology clinic staff and were asked about their willingness to be 
contacted by study research assistants.  Research assistants administered the Mental 
Status Questionnaire to determine whether patients were mentally competent to participate 
(Fillenbaum, Heyman, Williams, Prosnitz, & Burchett, 1990).  Of the pool of 290 potentially 
eligible research subjects identified by clinic staff, 38 were excluded from study participation 
prior to the informed consent process. Reasons for exclusion from study participation were 
diverse and are in included in Table 2.  The mean age of excluded patients was 59.3 years 
(SD = 7.94 years), 25 (65.8%) were female, and 20 (52.6%) were White/Caucasian.  
Examination of participants and excluded patients revealed no statistically significant 
differences in age, gender, or race.   
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Table 2. Reasons for patient exclusion from study participation, frequency, and 
percent. 
 
Reason for exclusion Frequency Percent 
Patient not mentally capable of participating 9 23.7 
Physician felt patient not a good candidate 8 21.1 
Patient enrolled in another study  6 15.8 
RA diagnosis not definitive 5 13.2 
Patient did not speak English 3 7.9 
Patient too sick to be enrolled 3 7.9 
Patient unable to read 1 2.6 
Patient not returning to clinic 1 2.6 
Patient can not hear 1 2.6 
Patient too distressed 1 2.6 
Total 38 100.0 
 
After exclusions, 252 patients were eligible for study enrollment and were willing to be 
contacted by study research assistants at their routine medical visits.  Research assistants 
obtained written consent from each patient at the time of the clinic visit.  For each physician, 
eligible consenting patients were enrolled sequentially at baseline. Of the 252 potential 
participants that were approached, 52 of them refused leaving a total of 200 enrolled for 
baseline and a participation rate of 79.4%.  Of the 52 participants that refused to participate 
in the study, the mean patient age was 60.8 (SD = 10.13 years), 39 (75.0%) were female, 
and 34 (65.4%) were White/Caucasian.  Comparison of means and cross tabulations of 
patients that refused to participate and study participants revealed no statistically significant 
differences in patient age, gender, race, or ethnicity. 
  While potentially eligible patients were identified and enrolled based on whether they 
were seeing a study physician, patient enrollment across physicians was not even.  Table 3 
provides the frequency and percent of patients enrolled by participating study 
rheumatologists.  Differences in enrollment can be attributed to several possible sources. 
First, not all study physicians were enrolled at the outset of the study and not all physicians 
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remained in the study for the full duration.  Second, some physicians had limited clinic 
schedules so they saw fewer patients overall or had clinic hours that made it difficult to 
enroll patients.  Third, some physicians saw more patients with confirmed diagnoses of RA 
while others tended to see more patients with other types of rheumatic diseases.  Beyond 
differences in patient diagnoses, the patient case-mix of physicians differed by age, 
language spoken and other factors that affected enrollment.  In the study analyses, methods 
were used to try to account for differences in enrollment by physician as well as differences 
in the patient case-mix by physician. 
 
Table 3.  Patient enrollment by study rheumatologist. 
 
Physician  Number of Patients Enrolled Percent 
1 3 1.5 
2 5 2.5 
3 8 4.0 
4 11 5.5 
5 42 21.0 
6 42 21.0 
7 42 21.0 
8 47 23.5 
Total 200 100.0 
 
 
Data Overview  
  The data come from five primary data sources: (1) patient medical records, (2) clinic 
visit audiotapes, (3) patient interviews, (4) self-report questionnaires, and (5) physician 
report.  To audiotape, a research assistant set up a digital tape recorder and microphone in 
the exam room as patients entered, started the recorder as the physician entered, exited the 
exam room, and collected the recorder at the end of the consultation. Following the audio 
taped visit, patients were interviewed either in the exam room or in the clinic waiting room 
about their self-rated pain and medication satisfaction.  Patients then completed brief 
questionnaires reporting their: gender, age, education, income, race, and ethnicity.  Patients 
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independently completed the majority of questionnaires at the conclusion of the research 
assistant-led interview, but in a few cases patients were given questionnaires with self-
addressed, stamped envelopes to complete and return by mail.  Patients who did not 
complete and return the demographic information in the study questionnaire were contacted 
at follow-up visits to complete that information.  At study enrollment, physicians completed 
demographic self-report questionnaires that asked them to report: gender, age, race, and 
ethnicity. At the end of each patient’s medical visit, the physician was asked to record 
his/her perception of the patient’s RA disease severity.  
 
Medical Record Data 
To complement the existing data and obtain important information on patient 
prescription drug coverage and prescribed medications, patient medical records were 
abstracted in the course of this research.  Medical record data collection was approved by 
the Institutional Review Board and all patients in the study consented to have information 
abstracted from their medical records.  Medication and insurance information was 
successfully abstracted from rheumatology records for all 200 patients.  A medical record 
abstraction form was developed to facilitate the retrieval of information from the records 
(Appendix 1).  The purpose of the abstraction form was to obtain detailed information on the 
medications that patients were supposed to be taking at the time of their recorded medical 
visit, the number of prior visits with the physician in the study, patient weight, and patient 
health insurance information.   
Using the 2002 American College of Rheumatology Guidelines for the Management 
of Rheumatoid Arthritis as a foundation, the first page of the abstraction form listed the 
major medications used to treat RA within each medication category (i.e. NSAIDs, DMARDs, 
Glucocorticoids) with check boxes next to the medications to ease the recording burden of 
abstractors (American College of Rheumatology Subcommittee on Rheumatoid Arthritis 
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Guidelines, 2002). In addition to checking off the RA medication that patients were 
supposed to be taking before seeing the physician on the day of the recorded medical visit, 
the form instructed abstractors to record the medication dose, frequency of administration, 
and dates of medication start and, if applicable, stop.   
Further, for each medication the form contained spaces to record chart-noted 
changes in the medication regimen, notes on adherence, and notes related to medication 
costs.  Chart-noted changes in the medication regimen were recorded if they occurred 
during the recorded medical visit through one year of follow-up medical visits.  For chart 
notes on adherence, abstractors were instructed to record any notes that referred to patient 
adherence or non-adherence to medications that were recorded on the date of the recorded 
medical visit.  Abstractors were also instructed to record any notes from the chart that 
referred to medication cost or issues with insurance or medication assistance programs that 
would affect cost.  Abstractors were instructed to record verbatim any physician notes on 
adherence and medication cost.  In addition to the medication information contained on the 
first page, abstractors were instructed to record the number of prior visits the patient had 
with the physician who saw them on the date of the recorded medical visit, as well as chart 
noted patient weight in pounds or kilograms from the recorded medical visit. 
The second page of the abstraction form contained a table for abstractors to record 
information about the other medications patients were supposed to be taking that were not 
covered in the listing of RA medications on page one.  Abstractors were instructed to record 
all medications, regardless of whether they were used to treat RA.  In the table abstractors 
were supposed to record:  (a) medication name, (b) dose, (c) route of administration, (d) 
frequency of administration, (e) start and, if applicable, stop date, and (f) reason for stopping 
if noted in the record.  There was variability in the depth of information in each record, 
especially regarding non-RA medications, and abstractors were instructed to record as 
much of the applicable information as possible on each medication.  Below the table on 
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other medications, was a box for abstractors to circle the type of health insurance noted in 
the medical record from the date of the audio-recorded medical visit.  Further details on the 
categories of health insurance and conceptualization of this variable are provided in the 
measurement section of this chapter.  Abstractors were instructed that if they had any 
trouble discerning the appropriate type of health insurance that they should record verbatim 
what was in the record.  Further, medical record abstractors were instructed to write down 
any information provided about the patients’ prescription drug plan or prescription drug 
assistance programs included in the record. 
Once the medical record abstraction form was created, it was iteratively tested using 
a random sample of 5% of the medical records.  Through the iterations, the abstraction form 
was revised to facilitate completion.  The principal investigator and a clinical pharmacist who 
specializes in medication management for older adults reviewed the form and 10 initial 
abstractions jointly.  The clinical pharmacist provided instruction and background detail to 
the principal investigator about information contained in the abstractions as well as ways to 
improve the reliability and validity of future abstractions.   
To improve the quality of data abstracted from patient medical records the principal 
investigator and a pharmacy student familiar with medications for treating RA double-
abstracted 30 (15%) of the 200 medical records.  The information from the abstractions was 
compared and revealed that abstractors were in full agreement on all medication information 
and mostly agreed on the relevant notes from the records.  Discrepancies on the abstracted 
notes, although minor, were discussed and the abstraction instructions were adjusted 
accordingly.  Following final review of the form by fellow investigators, the principal 
investigator completed the medical record abstractions.  At sites that had both electronic 
and paper medical record information the paper records were checked against electronic 
data for consistency and to complete information that might have been missing from one of 
the sources. 
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Medical Visit Audiotape Data 
In the larger research project upon which this study was based, the researchers 
developed a coding tool to capture information on discussion of medications, issues such as 
side effects, and quality of life.  The coding tool was developed in conjunction with detailed 
coding rules and tapes were reviewed and coded by trained research assistants.   
Calculated inter-rater correlations and percent agreement among 6 coders based on the 
same 41 tapes was 0.71 or greater for the 45 items on the main coding tool.  While 
information on medications and changes to the medication regimen were captured in the 
main coding tool, important information for this study on communication about medication 
costs and management were not collected.  
To facilitate audiotape review and to measure the specific features of patient-
physician communication of interest in this study, a detailed coding instrument was designed 
to measure patient-physician communication about medication management and medication 
cost.  The tapes were coded for: (a) whether medication cost is brought up during the 
medical visit (e.g. prescription insurance coverage or OOP medication costs), (b) the 
number of patient questions about medication cost, (c) the number of physician questions 
about medication cost, (d) cost discussion initiator, (e) times of medication cost discussions, 
(f) patient initiated changes to the medication regimen, (g) description of the patient initiated 
changes to the regimen, and (h) times of discussion of patient initiated regimen changes.  
The details of the coding tool are discussed more fully in the measurement section of this 
chapter and the actual coding tool can be found in Appendix 2.  Explicit rules were 
developed to guide the coding of each item. The coding rules can be found in Appendix 3.  
The coding tool and rules were developed drawing on principles used previously in coding 
patient-physician medical visit interactions for specific content areas (Sleath et al., 2008; 
Sleath, Svarstad, & Roter, 1998).  
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The coding instrument and rules were pre-tested and revised several times using 
randomly selected audiotapes.  To further test the robustness of the coding tool, the 
instrument was used to code a random selection of medical visit audiotapes from 
rheumatologists and patients with RA drawn from a different patient sample. The principal 
investigator and a second, experienced coder participated in pre-testing and actual coding 
of the audiotapes.  The second coder was blinded to study hypotheses.  The principal 
investigator and second researcher coded a 10% random sample of the tapes throughout 
the coding period and met biweekly to discuss discrepancies.  In the initial coding and 
testing phase, all disagreements between coders were resolved by consensus and the 
coding rules were subsequently modified until coders and study investigators agreed upon 
the final coding rules.   
When the coding instrument and rules had been finalized, the principal investigator 
coded all of the actual study audiotapes and a new group of 35 randomly selected tapes 
were double-coded by the second researcher.  After the 35 tapes were double-coded, the 
inter-rater reliability was calculated using Pearson correlation coefficients for continuous 
variables and percent agreement for dichotomous variables, as well as, Cohen’s kappa to 
correct for chance in assessing agreement between the raters (DeVellis, 2005).  Results of 
inter-rater reliability indicated a Pearson correlation range from 0.42 to 1.00 for 35 tapes 
coded by two independent coders.  On categorical items, Cohen’s kappa ranged from 0.62 
to 1.00.  Pearson correlation coefficients and kappa statistics of 0.61 to 0.80 are considered 
good and those that are between 0.81 and 1.00 are considered very good.  The two items 
that had the lowest correlation were the counts of patient questions about cost (r = 0.48) and 
physician questions about cost (r = 0.42).  Examination of the data revealed that coders did 
not differ on whether questions were asked in a particular visit but on how many questions 
were asked.  Analysis of any versus no questions asked for patients revealed a Pearson 
correlation of 0.82 and a kappa of 0.80 and for any versus no questions asked for 
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physicians there was perfect agreement.  Since the question asking variables were 
transformed into ‘any’ versus ‘no’ cost questions asked for patients and physicians for the 
analysis and coders had high agreement on these variables, the low correlations on the 
original variables were not seen as an analysis issue. 
 
Measurement 
This section defines and describes all of the variables used in the analysis.  It follows 
Figure 1 moving from outcomes to predictors in the conceptual model with the major 
categories: satisfaction with medications, characteristics of communication between 
physicians and patients, patient characteristics, physician characteristics, and medication 
characteristics. Table 4 contains a listing of each of the variables within each category, the 
measure, source, and type or range.  The following sections provide detailed information on 
each of the variables.  
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Table 4.  Measures, sources, and types of variables 
Variable Measure Source Type/Range 
Satisfaction with 
Medications    
Medication Satisfaction Self-report  Patient 
interview 
1 = not at all 
2 = a little 
3 = somewhat 
4 = very 
5 = totally  
Communication 
Characteristics    
Presence of discussion 
about medication cost 
1 = yes 
0 = no 
Number of physician 
questions about cost 
Ratio 
Number of patient 
questions about cost 
Ratio 
Cost discussion initiator 1 = physician 0 = patient 
Patient-initiated regimen 
change communication 
Coding tool Medical visit 
audiotape 
1 = yes 
0 = no 
Discussion of modifying 
regimen 
Main-study coding 
tool 
Medical visit 
audiotape 
1 = yes 
0 = no 
Patient Characteristics    
Gender 1 = female 
0 = male 
Age Continuous 
Education 1 = 8th grade or less 
2 = some high school 
3 = high school graduate 
4 = some college 
5 = college graduate 
6 = any post-graduate work 
Income 1 = less than $20,000 
2 = $20,000 - $39,999 
3 = $40,000 - $59,999 
4 = $60,000 - $79,999 
5 = $80,000 or more 
Race 1 = Black/African American 
2 = White/Caucasian 
3 = Asian/Oriental or Pacific 
 Islander 
4 = American Indian/Alaskan 
 Native 
5 = Other 
Spanish/Hispanic 1 = yes 
0 = no 
Marital status 
Self-report Patient 
questionnaire 
1 = married 
2 = widowed 
3 = separated 
4 = divorced 
5 = never married 
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Variable Measure Source Type/Range 
RA severity American College 
of Rheumatology 
Classification of 
Global Functional 
Status 
Physician 
report 
1 (low) to 4 (high) 
Self-rated pain Visual analog scale Patient 
interview 
0 (no pain) to 10 (worst pain 
ever) 
Prescription drug coverage  Medical 
records 
1 = no coverage 
2 = partial drug coverage 
3 = generous drug coverage 
Physician 
Characteristics    
Gender 1 = female 
0 = male 
Race 1 = Black/African American 
2 = White/Caucasian 
3 = Asian/Oriental or Pacific 
 Islander 
4 = American Indian/Alaskan 
 Native 
5 = Other 
Spanish/Hispanic 1 = yes 
0 = no 
Age 
Self-report Physician 
questionnaire 
Continuous 
Medication 
Characteristics    
Cost of RA medications  Medical 
records 
Continuous 
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Satisfaction with Medications 
Medication satisfaction: A single-item assessing patient satisfaction with 
medications was asked of all patients in the patient interview immediately following the 
medical visit.  Patients were asked to respond to the item, “How satisfied are you with the 
medications you are supposed to take until your next visit?” by selecting one of the following 
five response categories: ‘Not at all’, ‘A little’, ‘Somewhat’, ‘Very’, or ‘Totally’.  Previous 
research has demonstrated that asking about overall medication satisfaction is associated 
with patient-physician communication and subsequent medication adherence (Bultman & 
Svarstad, 2000). 
 
Characteristics of Communication between Physicians and Patients 
Presence of discussion about medication cost:  This dichotomous variable was 
measured from the coding tool that was created to accompany the audiotape.  Presence of 
discussion about cost was coded as ‘yes’ if during the visit either the patient or physician 
discussed direct medication costs (e.g. OOP costs incurred by patients) or indirect 
medication costs (e.g. prescription drug assistance programs or prescription drug insurance 
coverage).  While multiple discussions of medication costs may have occurred during a 
single visit, one conversation was sufficient for the item to be coded ‘yes’. 
Number of physician questions about medication cost:  The number of 
questions the physician asks about medication costs was measured using the created 
audiotape-coding tool.  A count was recorded for each distinct question the physician asks 
about direct or indirect medication costs. These questions may have been open or closed-
ended but all were related to the medication cost discussion.  Questions that were framed 
as statements or semi-questions where it was still clear that the physician was inquiring 
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about medication costs were also counted.  As mentioned in the medical visit audiotape 
data section, this variable was transformed into a dichotomous ‘any’ versus ‘no’ questions 
asked variable for analysis. 
Number of patient questions about medication cost:  This variable was assessed 
using the same methods as physician question asking except it counted distinct medication 
cost questions asked by patients.  This variable was also transformed into a dichotomous 
‘any’ versus ‘no’ questions asked variable for analysis. 
Cost discussion initiator: This dichotomous variable was measured from the 
created audiotape-coding tool. Initiation of medication cost discussion was coded as 
‘physician initiated medication cost discussion’ if the physician brought up a medication cost 
topic, either direct or indirect, before the patient in the medical visit (i.e. if the physician asks 
a question about prescription drug insurance coverage or gives details about a medication 
cost before the patient asks a question or makes a statement about it then the item was 
marked as ‘physician initiated medication cost discussion’).  Alternately, the initiation of 
medication cost discussion was coded as ‘patient initiated medication cost discussion’ if the 
patient brought up a medication cost topic before the physician in the medical visit.  This 
means that if a patient asked the physician about obtaining a medication from a prescription 
drug assistance program or made a statement about the cost of a prescription prior to the 
physician asking the patient a question about medication costs or making a statement about 
medication costs then the item was marked ‘patient initiated medication cost discussion’.  As 
has been written previously, multiple discussions of cost may occur in each visit.  However, 
for the purposes of coding this item, we were interested only in who first brings up the topic 
since multiple discussions are likely to flow from first initiation of the topic.  Measuring which 
participant initiates the medication cost discussion permits the assessment of potential 
differences in the types and number of discussions started by patients or physicians. 
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Patient-initiated medication regimen change communication: This dichotomous 
variable was measured from the coding tool that accompanies the audiotape.  Presence of 
discussion of a patient initiated change to the medication regimen will be coded as ‘yes’ if 
during the visit the patient or the physician discuss a change to the regimen made by the 
patient independent of medical advice.  Patient-initiated changes to the medication regimen 
can be considered a facet of medication management.  For our purposes, medication 
management is defined as a patient’s ability to manage symptoms through medications and 
deal with physical and psychosocial consequences of their medication-taking (Barlow, 
Wright, Sheasby, Turner, & Hainsworth, 2002).  Effective management involves a 
continuous feedback loop of monitoring one’s condition, taking medications, and managing 
medication effects.  RA patients must make decisions about the amount, timing, and 
quantity of medication to take based on a number of personal factors, including the cost of 
their medications. Using this concept of medication management as a base, coders marked 
this item as ‘yes’ when patients and physicians discussed patient-initiated changes to the 
medication regimen that require a behavior change.  Patients may choose to take less or 
more medication than prescribed, split-pills to stretch out the time between prescription fills, 
alter their dosing schedule to accommodate their lifestyle, add or drop medications from 
their regimens, or substitute one medication for another. These examples do not make up 
the entire universe of possible conversations about patient-initiated changes in the regimen 
but are examples of some of the types of discussions.  In the context of this study, we were 
primarily interested in the discussions between patients and physicians about patients’ 
independent, purposeful actions to manage their medications. Physicians may actively 
participate in these discussions but the changes to the regimen should be patient initiated 
and directed. 
Discussion of modifying the regimen: This dichotomous variable was measured 
from the coding tool used in the larger study upon which this analysis is based.  In the main 
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audiotape coding tool coders responded to the item “Was the medication regimen changed 
at all during this visit?”  Presence of discussion of modifying the regimen was coded as ‘yes’ 
if during the visit the patient and the physician agreed to make a change to the current 
regimen. Medication regimen change was defined as any single or combination of the five 
following actions: (1) adding one or more medication(s), (2) stopping or holding one or more 
medication(s), (3) changing dose of one or more medication(s), (4) changing the schedule or 
frequency of one or more medication(s), or (5) switching from brand to generic(s).  From the 
main coding tool, this item had an inter-rater correlation of 0.95 among 6 coders, coding 41 
(21.2%) tapes.  This variable is being included in the study to facilitate sensitivity analysis of 
the patient-initiated medication regimen change communication variable. The measurement 
of both discussions of patient-initiated changes to the medication regimen and patient-
physician agreed upon changes to the regimen, permits the assessment of the relationship 
of each to medication cost communication and medication satisfaction.  The purpose of 
incorporating a measure of discussion of modifying the medication regimen is to compare 
and contrast the results obtained using this variable with those found using patient-initiated 
medication regimen change communication.  Patient-initiated medication regimen change 
communication should be a distinct construct from discussions of modifying the regimen.  
Assessing the differences in the predictors of the two variables and should help validate the 
differences in the constructs and permits examination of the ways in which the sample 
discussing regimen changes overall differed from the sample disclosing self-initiated 
regimen changes to physicians. 
 
Patient Characteristics 
Gender:  Two-category variable measured at baseline indicating male or female. 
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Age: Continuous variable measured in baseline patient questionnaire indicating 
patient age in years at the time of the baseline visit. 
Education: Six-category variable indicating highest grade completed in school with 
the following categories: ‘8th grade or less’, ‘Some high school’, ‘High school graduate’, 
‘Some college’, ‘College graduate’, or ‘Any post-graduate work’.  To assess suspected 
meaningful differences with this variable in analysis, education was dichotomized into ‘High 
school graduate or less’ and ‘More than high school education’. 
Income: Five-category variable indicating household’s total income from all sources 
with the following categories: ‘less than $20,000’, ‘$20,000 - $39,999’, ‘$40,000 - $59,999’, 
‘$60,000 - $79,999’, or ‘$80,000 or more’. To assess suspected meaningful difference in 
thresholds of income, in some analyses this variable was dichotomized into ‘$39,999 and 
less’ and ‘$40,000 and more’. 
Race: Five-category variable indicating category that best described patient’s racial 
background. Categories were as follows: ‘Black/African American’, ‘White/Caucasian’, 
‘Asian/Oriental or Pacific Islander’, ‘American Indian/Alaskan Native’, or ‘Other’.  Based on 
the population, in some analyses this variable was collapsed into ‘White’ and ‘Non-white’. 
Spanish/Hispanic Ethnicity: Dichotomous variable indicating whether patients were 
of Spanish or Hispanic origin or ancestry. 
Marital status:  Five-category self-report variable asking participants to choose the 
category that best describes their current marital status.  Categories were as follows: 
‘Married’, ‘Widowed’, ‘Separated’, ‘Divorced’, or ‘Never married’.  Based on the distribution 
of the variable for analysis marital status was dichotomized into ‘Married’ and ‘Not married’. 
RA severity: Rating of patient RA severity was measured using the American 
College of Rheumatology (ACR) Classification of Global Functional Status (Hochberg et al., 
1992). This four-category rating is completed by the physician at the end of the medical visit 
and places patients in the following categories based on their RA: (I) no restriction of ability 
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to perform normal activities, (II) moderate restriction but adequate for normal activities, (III) 
marked restriction, inability to perform most duties of the patient’s usual occupation or self-
care, or (IV) incapacitation or confinement to a bed or wheelchair, permitting little or no self-
care.  This measure has been shown to be able to discriminate between patients with 
different levels of RA severity (Hochberg et al., 1992).   
Self-rated pain: At the interview immediately following the medical visit patients 
were asked to rate their level of pain in the past 24 hours as measured by a horizontal visual 
analog scale (VAS) from 0 to 10 where 0 indicated ‘no pain’ and 10 indicated the ‘worst pain 
ever’.  Self-rated pain as measured by VAS is a recommended measure of RA disease 
activity by the American College of Rheumatology because it has demonstrated criterion, 
discriminant, and face validity as well as high test-retest reliability (Felson et al., 1993). 
Prescription drug coverage:  Prescription drug coverage is a three-category 
variable based on patient health insurance plan type, which comes from patient medical 
records.  The depth and quality of recorded health insurance information was variable.  For 
patients at particular clinics, great detail was recorded about the health insurance carrier, 
associated prescription drug plan, and medication co-payment amounts. For those same 
patients there was generally an extensive listing of the initiation and discontinuation dates of 
health insurance coverage by insurance carrier.  Alternately, for patients seen at other 
clinics, the information was more abbreviated and while health insurance carriers were 
listed, little to no information was provided about the associated prescription drug plan or 
medication co-payment amounts.  Research assistants abstracting health insurance 
information from the medical records were instructed to record all information available.  
When both electronic and paper medical records were available, both were consulted to 
confirm the recorded health insurance information.  Based on the information recorded on 
the medical record abstraction form, health insurance was then coded as one of six 
categories.  The six categories and their definitions are as follows:  
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(1) ‘Private or employer sponsored insurance’ – these are programs provided by companies 
such as Blue Cross and Blue Shield of North Carolina, the state employees health plan, 
Aetna, Cigna, etc.  This category contains all the insurance types that are not directly 
funded and maintained as either a state or federal entitlement program. 
(2) ‘Medicare with supplemental insurance’ – this category includes patients who have 
Medicare listed as their primary insurance and then have a secondary private or 
employer sponsored insurance program listed in the record.   
(3) ‘Medicare only’ – this category includes patients who only have Medicare listed as their 
health insurance provider 
(4) ‘Medicaid only’ – this category includes patients who only have Medicaid listed as their 
health insurance provider 
(5) ‘Medicare + Medicaid’ – this category includes patients who have both Medicare and 
Medicaid listed as health insurance providers. 
(6) ‘Self-pay’ – this category includes patients who have a note that they are self-pay 
customers and/or have a note that they have no known health insurance provider. 
Based on the health insurance category selected and the written notes on insurance from 
the medical record abstraction form, categories of prescription drug coverage were created.  
Categories are as follows: ‘no coverage’, ‘partial coverage’ (e.g. Medicare HMO, self-
purchased Medicare supplement with drug coverage, or state-sponsored low-income plans), 
and ‘generous drug coverage’ (e.g. employer-sponsored coverage or Medicaid drug 
coverage). Previous researchers conducting medication cost research have employed these 
categories.  Plans classified as partial coverage have been consistently found to offer more 
limited benefits, including higher cost sharing and lower spending allowances, compared 
with Medicaid and employer-sponsored plans (Soumerai et al., 2006).  Further, employer-
sponsored plans and Medicaid have been shown to be fairly similar in their coverage 
generosity and breadth (Soumerai et al., 2006).  An analysis of insurance plans and 
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generosity using OOP and total medication cost data further supports the generosity 
category definitions (Artz, Hadsall, & Schondelmeyer, 2002).  Further, prescription drug 
coverage generosity has been shown to predict prescription drug use and expenditures 
(Artz et al., 2002). 
 
Physician Characteristics 
The physician demographic variables: gender, age, race, and ethnicity were 
measured using the same questions as those administered to patients. 
 
Medication Characteristics 
Cost of RA medications: The listing of patient medications, taken from the medical 
records, was used to derive the continuous cost of RA medications variable.  Calculation of 
RA medication costs was selected because the costs of these medications are the most 
salient since patients and physicians negotiate the prescribing of RA medications in 
rheumatology medical visits. To determine the appropriate RA medications to include in cost 
calculation, the principal investigator again consulted with a clinical pharmacist specializing 
in medication management for older adults.   Jointly, the two researchers reviewed the 
medical record abstractions.  Drawing upon the 2002 ACR “Guidelines for the management 
of rheumatoid arthritis” and current standards of practice, a listing of RA medications and 
adjuvant therapies prescribed to balance the effects of RA medications was generated.  
Table 4 showing the medication costs details the RA medications that appeared in the 
medical records and were included on the generated RA medication list. 
Medication cost figures were derived using Average Wholesale Price (AWP) 
according to Red Book: Pharmacy’s Fundamental Reference (Thomson Corporation., 2004) 
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from 2004.  Since study data were collected from 2003-2005, AWPs from 2004 were 
abstracted to represent the most common medication cost figures for the period under 
study.  To test the sensitivity of medication cost information taken from Red Book, price 
information was also taken from the online medication retailer www.drugstore.com. While 
prices from Drugstore.com were slightly higher than AWPs, the differences were consistent 
across medications.  The presence of similar cost figures reinforced the medication cost 
trends present in AWPs.   While there has been considerable controversy over the accuracy 
and use of AWP in the past, the use of AWP in generating cost estimates still remains an 
accepted standard (Drummond, 1997).  Further, calculation of an accurate, actual OOP 
medication cost variable or cost-to-patient variable is incredibly difficult.  Multi-tier 
formularies are now standard and they offer discounts for purchases through mail order or in 
network pharmacies. Deductibles, OOP maximums, and benefit caps also complicate these 
calculations.  This means that the cost of a medication depends not only on its location on 
the tier system but also the means through which people obtain the medication and how 
much they have already spent on medications in the benefit year (Goldman, Joyce, Lawless, 
Crown, & Willey, 2006).  For the biologic medication Infliximab (Remicade®), the problem is 
confounded by the fact that it is usually administered in a clinic by a health care professional 
and paid for as part of medical services.   
Given the restrictions, calculation of RA medication costs using published AWPs and 
use of a measure of total medication cost as opposed to OOP medication cost was chosen.  
Table 5 contains a listing of the 2004 AWPs from Red Book for the RA medications used in 
this study. 
 45 
Table 5. Average wholesale prices for RA medications from Red Book: Pharmacy’s 
Fundamental Reference, 2004 (Thompson Corporation). 
 
Category/Medication  Strength   Per Pill  
 (U.S. Brand Name) (mg) Quantity AWP  Price/Unit 
Non-steroidal anti-inflammatory drugs 
(NSAIDs)     
Valdecoxib (Bextra®)           10 30 $94.22 $3.14 
 20 30 $94.22 $3.14 
Celecoxib (Celebrex®)      100 30 $54.25 $1.81 
 200 30 $88.98 $2.97 
 400 60 $269.06 $4.48 
Ibuprofen 400 30 $7.05 $0.24 
 600 30 $8.72 $0.29 
 800 30 $11.22 $0.37 
Meloxicam (Mobic®)          7.5 30 $86.23 $2.87 
 15 30 $111.37 $3.71 
Rofecoxib (Vioxx®)              12.5 30 $90.41 $3.01 
 25 30 $90.41 $3.01 
 50 30 $132.00 $4.40 
Naprosyn 500 30 $52.06 $1.74 
Naproxen  250 30 $23.30 $0.78 
Naproxen Sodium OTC 220 30 $3.34 $0.11 
Nabumetone (Relafen®)   500 30 $50.57 $1.69 
 750 30 $59.71 $1.99 
Sulindac (Clinoril®) 200 30 $36.55 $1.22 
Diclofenac (Cataflam®; Voltaren®) 50 15 $25.01 $1.67 
 75 180 $198.68 $1.10 
Ketoprofen (Orudis® KT; Oruvail®) 50 30 $36.86 $1.23 
Disease-modifying antirheumatic 
drugs (DMARDs)     
Adalimumab (Humira®) 40 2 $1,315.81 $657.91 
Azathioprine  (Imuran®) 50 30 $75.84 $2.53 
Etanercept (Enbrel®) 25 1 $164.47 $164.47 
Infliximab (Remicade®) 100 1 $691.61 $691.61 
Hydroxychloroquine [HCQ – generic] 200 60 $70.85 $1.18 
Plaquenil [HCQ – brand] 200 100 $189.20 $1.89 
Gold Sodium Thiomalate  
(Myochrysine®) 100 1 $76.22 $76.22 
Myochrysine SOL IM 50mg/ml 50 6 $102.42 $17.07 
Leflunomide (Arava®) 10 30 $372.32 $12.41 
 20 30 $372.32 $12.41 
Methotrexate [MTX] Tablets 2.5 32 $114.05 $3.56 
MTX Solution, Injection 25 mg/ml in 
10 ml  25 10 $20.49 $2.05 
Trexall (MTX Sodium) 5 30 $225.23 $7.51 
Sulfasalazine (Azulfidine®) 500 30 $7.59 $0.25 
Glucocorticoids     
Prednisone 5 30 $2.47 $0.08 
 10 30 $2.42 $0.08 
 20 30 $4.34 $0.14 
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Category/Medication  Strength   Per Pill  
 (U.S. Brand Name) (mg) Quantity AWP  Price/Unit 
Vitamin supplementation for DMARDs     
Folic Acid  1 30 $2.46 $0.08 
Leucovorin 5 30 $70.81 $2.36 
Folic Acid OTC 0.8 100 $2.48 $0.02 
Analgesics     
Opioid     
Methadone 10 60 $32.17 $0.54 
Morphine Sulfate 15 60 $26.77 $0.45 
Oxycodone hydrochloride 
(OxyContin®) 10 30 $52.35 $1.75 
 20 30 $97.90 $3.26 
 40 30 $162.41 $5.41 
Non-opioid 
    
Acetaminophen(Tylenol® OTC) 325 100 $7.15 $0.07 
Acetaminophen(Tylenol Extra 
Strength®) 500 50 $5.47 $0.11 
Acetaminophen(Tylenol Arthritis®) 650 50 $5.88 $0.12 
Tramadol (Ultram®) 50 30 $37.20 $1.24 
Lidocaine Patch (Lidoderm®) 5% 30 $152.90 $5.10 
Aspirin 325 20 $0.48 $0.02 
Analgesic Combinations 
    
Acetaminophen + codeine (Tylenol® 
With Codeine) 300/30 100 $52.49 $0.52 
Acetaminophen + hydrocodone 
[generic] 500/5 100 $11.53 $0.12 
Acetaminophen + hydrocodone 
(Vicodin®)  500/5 100 $69.72 $0.70 
Acetaminophen + hydrocodone 
(Lortab®) 500/10 40 $41.87 $1.05 
Acetaminophen + hydrocodone 
(Lorcet®)  650/7.5 30 $36.99 $1.23 
Acetaminophen + propoxyphene 
(Darvocet-N®) 650/100 30 $35.80 $1.19 
Acetaminophen + oxycodone 
(Percocet®) 325/7.5 60 $107.35 $1.79 
Acetaminophen + tramadol 
(Ultracet™) 325/37.5 30 $30.75 $1.03 
Osteoporosis Prevention     
Alendronate Sodium (Fosamax®) 70 4 $73.31 $18.33 
Risedronate (Actonel®) 35 4 $70.49 $17.62 
Raloxifene (Evista®) 60 30 $81.52 $2.72 
Calcitonin (Miacalcin®) nasal spray 200 iu 4 $90.99 $22.75 
Caltrate®  600 60 $7.82 $0.13 
Caltrate® 600 + D 600 60 $5.78 $0.10 
Os-Cal®  500 60 $6.18 $0.10 
Os-Cal® 500 + D 500/125iu 75 $6.88 $0.09 
Calcium + Vitamin D 300/100 100 $3.10 $0.03 
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Costing has two elements: measurement of the quantities of the resource and the 
assignment of unit costs or prices (Drummond, 1997).  To calculate the quantities of 
medication per patient, medication information was taken from the medical record 
abstraction form.  The medication, dose, and frequency of administration information for 
each RA medication listed in the record were used to calculate the amount of each 
medication prescribed over the course of 30 days.  As an example, a medication of a 
particular strength to be taken once daily should be 30 pills over 30 days.  Estimating the 
quantity of a medication prescribed over a 30-day period created standardized values so 
that amounts of medication were directly comparable.  The process was repeated for each 
RA medication on the medical record abstraction form.   
Complete information on dose and frequency of administration was available for the 
majority of RA medications.  For any given RA medication less than 2.5% of the dose or 
frequency information was missing and in no cases were both dose and frequency missing.  
In cases where dose or frequency was missing, the information was imputed using the usual 
or standard recommended dose or frequency for a given RA medication as outlined in 
clinical literature and consistent with recorded dose and frequency in the existing data 
(Wailoo et al., 2008).  For example, in three cases the dosing information on Infliximab was 
not recorded or incompletely recorded, since the amount administered is dependent on 
patient weight.  In the cases where a milligram per kilogram dose amount was provided for 
Infliximab, it was possible to calculate the total dose prescribed by using the patient’s 
recorded weight in kilograms (or by converting patient weight in pounds to kilograms) from 
the medical record abstraction form.  In the cases where dose information was not provided 
for Infliximab, the value was imputed.  A study indicated that in 2001 and 2002, years 
adjacent to the ones under study here, the mean Infliximab dose for a population of 150 RA 
patients was 3.98 mg/kg (Michaud et al., 2003).  Further, this dose was consistent with the 
mean dose of patients in the study for whom the Infliximab dose was recorded. 
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Pairing quantity with cost information, the price per pill/unit was multiplied by the 30-
day quantity prescribed to generate a cost for the medication (Drummond, 1997).  The 
individual medication costs were summed to create a single per-month medication cost 
variable for each patient. 
 
Analyses by Aim 
Aim 1 
To qualitatively examine the content of discussions regarding medication cost and 
medication management between RA patients and rheumatologists in routine clinic 
visits. 
  The purpose of the qualitative analysis of the content of communication between RA 
patients and rheumatologists was to advance understanding of what actually happens in 
conversations about medication cost and management.  As argued in previous chapters, 
little is known about the content of communication about medication costs and management 
and further understanding is important to drive conceptual thinking and theory development 
in this area.  Achievement of this aim required an investigation of the contextual and holistic 
nature of medical visit communication so a grounded theory approach was chosen.  
Specifics of the methods used follows.  A brief description of grounded theory is provided, 
details on audiotape transcription, and details on methods of textual analysis are presented.  
Details are provided so that readers may understand the methods undertaken and have the 
opportunity to assess for themselves the truth and quality of the inquiry (Chenail, 1995). 
Grounded theory was developed as a way to conceptualize and conduct qualitative 
analyses.  Specifically set apart from quantitative analysis, the use of grounded theory in 
qualitative analysis is not the quantifying of qualitative data but rather a nonmathematical 
process of interpretation, undertaken for the purpose of discovering concepts and 
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relationships in raw data and then organizing these into a explanatory scheme to advance 
theory development (Strauss & Corbin, 1998).  Taking these ideas into practice, grounded 
theorists propose that researchers analyze qualitative data using joint coding and analysis 
following systematic guidelines.  Codes should be allowed to emerge from the data rather 
than from predetermined categories.  To ensure the rigor of established codes, constant 
comparison should be employed to ensure consistency within and between codes.  Data 
should be sought to further theory development rather than for purposes of attaining a 
statistically representative sample.  There is a constant interplay between the researcher 
and the research act.   In short, using grounded theory researchers are supposed to remain 
close to, or “grounded” in, the data throughout the entire analysis process.  By staying 
grounded in the data, researchers can exercise the objectivity necessary to arrive at 
impartial and accurate assessments of events while also being sensitive to the nuances and 
meanings in the data that permit the connection between concepts.   As this is an 
exploratory look into medication cost and management communication in rheumatology 
visits, grounded theory is well suited to facilitate the elucidation of themes and concepts that 
may serve as building blocks of theory development. 
In this study, to complete the qualitative analysis of discussions of medication cost 
and medication management among rheumatologists and patients with RA, all audiotapes 
were first reviewed to determine the presence of communication about medication cost and 
management.  The tape review was accomplished through coding the audiotapes using the 
created coding tool described earlier.  As the independent coders reviewed the tapes, those 
tapes containing communication about medication cost and management were then 
transcribed.  Having transcripts of the physician-patient interactions was necessary for 
qualitative analysis but it also made coding more reliable.  Transcribing rules were used that 
follow those of previous researchers in the area of physician-patient communication 
(Mishler, 1984; Waitzkin, 1990).  The transcribing rules can be found in Appendix 4.  In 
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general, tapes were transcribed verbatim with the exception of proper names and any other 
information that could potentially lead to the identification of the participants.  Speakers were 
identified by their role (e.g. physician or patient), a line was started each time there was a 
new speaker, and interruptions and audible nonverbal behaviors (e.g. laughing or crying) 
were explicitly transcribed.  When the tapes contained portions that were difficult to hear or 
hard for the transcriptionist to understand they were marked with a time-stamp.  The 
transcripts were stored under the arbitrary patient identification number to further protect the 
identity of the participants.  The principal investigator personally transcribed four of the 
audiotapes and a professional transcriptionist completed the rest.  The transcriptionist went 
through a training period of rule review, examination of a sample transcript, and transcription 
of a tape not for use in the analysis to make sure the transcribing rules and procedures were 
clear.  The transcriptionist was blinded to the study purpose. 
The principal investigator reviewed the transcripts against the tapes to correct 
inaccuracies and fill in information that the transcriptionist was not able to hear or 
understand.  Having a better understanding of the context of communication and the 
regional dialects of participants, the principal investigator was able to complete much of the 
information that had originally been transcribed with a time-stamp. Common errors corrected 
included misspellings, incorrect punctuation, and mistaken wording.   Review of transcripts 
and error correction was important to maintain the participants’ true voices in the 
exchanges. 
Grounded theory suggests iterative data collection and analysis, so as transcripts 
were completed they were reviewed to facilitate becoming familiar with the data.  Once the 
transcriptions were completed, they were loaded into ATLAS.ti 5.2 (Atlas.ti Scientific 
Software Development GmbH, 2008).  ATLAS.ti 5.2, a qualitative data analysis program, 
was used to store the data, create codes, and build a coding scheme.  Patient 
demographics were also loaded into ATLAS.ti to analyze the data by patient characteristics. 
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Content analysis of the transcripts was performed using four linked processes: 
processing the raw data, data reduction, data display, and conclusion drawing/verification 
(Miles & Huberman, 1994; Morse & Field, 1995). As a general description, this process 
involved the following: (a) reading and examining the transcripts to identify units of analysis, 
which are defined as paragraphs, sentences, verb phrases, or single words that conveyed a 
single meaning, idea, or concept; (b) grouping together and labeling units corresponding to 
themes; (c) grouping together units that do not correspond to a theme but are deemed 
significant based on repetition and emphasis throughout the data; and (d) validating themes 
and data organization.   
Codes were generated to describe discovered concepts and the development of 
these codes loosely followed open coding and axial coding, suggested by Strauss and 
Corbin (Strauss & Corbin, 1998).  Open coding has a descriptive focus and is often a first 
step since the purpose is to, “open up the text and expose the thoughts, ideas, and 
meanings contained therein (Strauss & Corbin, 1998).”  Open coding uses line-by-line 
textual analysis to examine the data and break it into discrete parts by comparing similarities 
and differences.  Words, phrases, actions, styles of communication, and subject matter that 
are found to be similar are grouped into categories and subcategories.  In this analysis, 
categories generally described communication phenomenon and subject matter, such as 
“physician initiates discussion” and “medication cost”.  It is important to note that while codes 
were allowed to emerge from the data, there was special emphasis on categories of 
medication cost and management communication.  As categories were created a process of 
constant comparison was employed in assigning new codes, whereby text and subject 
matter that were considered the same were assigned the same code (Strauss & Corbin, 
1998).   The process of comparison continued throughout the coding process and as codes 
began to accumulate that shared similar meanings they were grouped under increasingly 
abstract category definitions.  Grouping data was important because it reduced the number 
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of concepts into more meaningful units and it added to the explanatory power of the analysis 
by adding depth.  For example, through grouping it became clear that medication cost 
communication was subtler than discussion of dollars and cents, containing talk about 
insurance coverage and assistance programs.  Effort was made to apply the most concise, 
representative codes to the text.  This meant that there was little to no overlap in the 
application of subcategory codes but subcategories were sometimes nested within category 
codes. 
Through category refinement the data ceased to be flat and took on a tree-like 
structure as relationships among them began to appear.   The assignment of relationships 
among codes is characteristic of axial coding.   In axial coding the analysis moves from the 
descriptive to the conceptual looking at how codes crosscut and link.  The examination is 
driven by the basic questions who, what, when, where, why and how with the goal of linking 
structure with process through code relationships. The basic tasks of axial coding include: 
(1) laying out the properties of a category, (2) identifying the conditions, interactions, and 
consequences associated with phenomenon, (3) relating a category to its subcategories 
through statements denoting how they are related, and (4) looking for cues in the data about 
the relationships among major categories (Strauss, 1987).   As an example of the axial 
coding employed in this analysis, please see Figure 2 below which shows the major 
category “Medication Cost Communication”, the associated category “General Strategies to 
Reduce OOP costs”, and the subcategories “Importing Medications” and “Medication 
Samples.”  Details about the codes and the linkages will be presented in the chapter that 
follows.  
 
 53 
Figure 2.  Coding relationships among the major category “Medication Cost 
Communication”, associated code “General Strategies to Reduce out-of-pocket 
(OOP) Costs”, and the subcategories “Importing Medications” and “Medication 
Samples”. 
 
 
is part of is part of
is associated with
Medication Cost Communication
General Strategies to Reduce OOP Costs
Importing MedicationMedication Samples
 
  
Through cyclical iterations of open coding and axial coding, the definition and 
conceptualization of the important themes of medication cost and management emerged 
from the transcripts.  The structure of medication cost and management communication 
became clear in the form of relevant dimensions such as “insurance coverage impacting 
OOP costs” and “medication assistance programs.”  Further, communication processes 
became clear, such as the differences in patient versus physician initiation of conversation 
about certain dimensions.  The ability to link structure with process as well as the repetition 
of themes throughout the transcripts indicated that they were grounded in the data and the 
analysis was reaching a point of saturation (Strauss & Corbin, 1998). 
Several sequential data steps were undertaken to improve coding reliability and 
validate the themes discovered in the analysis.  First, as has been mentioned above a 
process of constant comparison was employed so that each new assignment of a code 
initiated a brief review of previous uses of the same code to ensure that the content of the 
code was addressing the same concept.  Second, a system of double coding was 
employed.  Double coding involved going through the transcripts and assigning codes to the 
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text an initial time and then repeating the process.  As the transcripts were coded for the 
second time the codes were compared to the initial coding to make sure that the same 
sections of text and phrases were consistently coded.  Double coding revealed a high 
degree of consistency between the initial and second coding, although refinements to the 
coding scheme were made.   Third, negative cases were sought out and used to strengthen 
existing codes.  Negative cases are those that do not fit within the existing code structure.  
For example, in a medical visit where a patient discussed importing medications from 
Mexico to save money it seemed to fit into the category of general strategies to reduce OOP 
costs.  However, when a second patient discussed importing medication from outside the 
United States it seemed that this was not best defined as reducing OOP and a new code, 
“importing medication”, was created.  Hence, the coding scheme was revised to better 
represent the underlying concept.  Finally, an experienced qualitative-oriented researcher 
was consulted about the selection of particular codes and the process of coding to help 
ensure that codes had clear definition and appropriate application.  While none of these 
actions guarantee valid results, it is believed that, taken together, they indicate a rigorous 
approach to the conduct of the qualitative analysis and improve the validity of the findings.   
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Aim 2 
To describe relationships among patient characteristics, physician characteristics, 
and patient-physician communication about medication cost and medication 
management among RA patients and rheumatologists during routine clinic visits. 
H1: Discussions of medication cost and medication management are more likely to 
occur among physicians who are female and younger. 
H2: Discussions of medication cost and medication management are more likely to 
occur when patients are female, younger, more educated, have higher income, and 
have more severe RA.  
H3: Discussions of medication cost and medication management are more likely to 
occur when physicians and patients are in race concordant relationships.   
H4: Older patients are more likely to ask physicians questions about medication 
costs than younger patients. 
 
Analysis Overview 
 
 All study data were entered into SPSS 15.0 (SPSS Inc., 2007) and converted to 
STATA 9.2 (StataCorp LP, 2007) for analysis.  In addition, codes generated from the 
qualitative analysis in ATLAS.ti were also converted to STATA 9.2 and all variables were 
combined into a single analysis dataset.  Data analysis was broken into three distinct 
stages.  First, descriptive data analysis was undertaken to describe in detail the 
characteristics of the sample and the medical visit communication measured in the study.  
Second, the data were examined to assess the impact of missing data, as well as the 
influence of the study design with patients nested within physicians.   Using information 
gained from the data examination, methods for addressing missing and nested data were 
employed in subsequent analyses.  The third stage of data analysis focused on hypothesis 
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testing by assessing bivariate relationships between measured variables and using multiple 
logistic regression to examine how patient, physician, and medication characteristics 
influenced whether: (1) medication cost was brought up during the medical visit and (2) 
patient-initiated medication regimen changes were discussed.  Examining communication 
about medication costs in more depth, bivariate relationships and multiple logistic regression 
were used to examine the influence of measured variables on whether: (1) physicians asked 
questions about medication costs, (2) patients asked questions about medication costs, and 
(3) patients or physicians initiate cost discussions.  
Further, to compare and contrast with the predictors of patient-initiated medication 
regimen change communication, multiple logistic regression was also used to examine how 
patient, physician, and medication characteristics influenced whether the medication 
regimen was changed during the medical visit.  Assessing predictors of both patient-initiated 
medication regimen change communication and overall discussion of medication regimen 
changes in the medical visit provided a more complete picture of medication management 
communication.  Each of these stages of data analysis will be discussed in detail below. 
 
Descriptive Data Analysis 
First, descriptive statistics were calculated for all physician, patient, medication, and 
medical visit communication characteristics.  Frequencies and percents were used to 
describe categorical and dichotomous measures (e.g. medication satisfaction, discussion of 
medication cost, discussion of modifying regimen, patient initiated changes to the regimen, 
cost discussion initiator, physician gender, physician race, physician Hispanic, functional 
class, health insurance, patient gender, patient race, patient Hispanic, patient marital status, 
patient highest grade completed, and patient income).  Means and standard deviations were 
used to describe continuous and count variables (e.g. patient age, physician age, patient-
reported pain, number of RA medications, total RA medication cost, patient cost questions, 
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and physician cost questions).  For all continuous and count variables, the data were plotted 
to examine the structure and deviation from normal.  Variables that were skewed or 
unevenly distributed were transformed.  For example, the question asking about medication 
cost variables were left-skewed because of numerous zero values so they were transformed 
into dichotomous variables for any question asking.  The total RA medication cost variable 
had a positive skew with the mean exceeding the median as a number of patients had very 
high total RA medication costs.  Both the Box-Cox transformation and natural logarithm of 
the total RA medication cost variable were computed to adjust the distribution of the variable 
for analysis.  However, neither correction completely adjusted the distribution of the variable 
as confirmed the Shapiro-Wilk test where the null hypothesis that the sample was drawn 
from a normally distributed population was rejected for both transformations.  As a result, the 
original total RA medication cost variable was used in the analyses and non-parametric tests 
were conducted. 
In addition, frequencies, percents, means, and standard deviations of key patient and 
visit variables were also calculated by physician.  Chi-square tests were used to assess 
differences among physicians regarding categorical variables.  Analysis of variance was 
used to test which continuous variables varied among physicians.  Examination of patient 
and communication variables by study physician allowed for the assessment of differences 
among physicians in patient case-mix as well as medical visit characteristics.   
 
Data Examination 
Intra-Physician Correlations 
In this study, physicians were initially recruited and then patients were recruited 
based on whether they saw a participating study physician.  Given this arrangement, 
patients were nested within physicians and there was a need to account for the potential 
correlation among patients seeing the same study physician.  While it would have been 
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beneficial to utilize statistical techniques such as generalized estimating equations (GEE), 
which adjusts the standard errors of the regression coefficients to account for the fact that 
patients are nested within physicians, the number of physicians in the sample is not large 
enough to utilize these methods (Burton, Gurrin, & Sly, 1998).  Since there were only eight 
study physicians and all of the patient outcome variables were categorical or dichotomous, 
the methods for assessing intra-physician correlations were somewhat limited.   
Cross-tabulations of the outcome variables by physician were generated along with 
summary statistics, including means.  The presence of diversity within physicians on 
patients’ responses and means in the middle of the range of outcome values indicated low 
intra-physician correlation on the outcome values.  In contrast, if there had been a large 
number of patients within physicians answering ’yes’ or ‘no’ to a dichotomous outcome 
variable, essentially responses overwhelmingly clustering on a particular value, with a mean 
close to 0 or 1 it would have indicated a stronger correlation within physicians.   For most, 
but not all variables, analyses revealed variation in outcomes within physicians likely 
indicating a low intraclass correlation, meaning physicians communicated independently 
with patients and did not say the same things for each patient.  Previous research supports 
this finding, indicating that physician interaction style is not highly correlated with clinic site 
or physician (Sleath, Rubin, Campbell, Gwyther, & Clark, 2001; Sleath et al., 2003).  
However, given that means of assessing the intra-physician correlation were rudimentary, 
some variables appeared intracorrelated, and patients were selected into the study by 
physician, physician was used as a stratification variable in analyses. 
 
Missing Data 
The data were next examined for the presence and patterns of missing data.  Some 
respondents had missing data on one or more variables.  Table 6 below provides a listing of 
the variables and the frequency and percent missing. 
 59 
 
Table 6.  Analysis variables and the frequency and percent missing data (N=200). 
 
Variable # Missing (%) 
Satisfaction with Medications  
 Medication Satisfaction  1  (0.5) 
Characteristics of Communication 
 
 Presence of discussion about medication cost  7  (3.5) 
 Number of physician questions about cost  7  (3.5) 
 Number of patient questions about cost  7  (3.5) 
 Cost discussion initiator  7  (3.5) 
 Discussion of modifying regimen  7  (3.5) 
 Discussion of patient initiated changes to the medication regimen  7  (3.5) 
Patient Characteristics  
 Gender  0 (0.0) 
 Age  0 (0.0)  
 Education  10  (5.0) 
 Income  18  (9.0) 
 Marital Status  10  (5.0) 
 Race  0 (0.0) 
 Hispanic  7  (3.5) 
 RA severity  27  (13.5) 
 Self-rated pain  1  (0.5) 
 Number of Prior Visits with Doctor  0 (0.0) 
 Prescription drug coverage  0 (0.0) 
Physician Characteristics 
 
 Gender  0 (0.0) 
 Race/ethnicity  0 (0.0) 
 Age  0 (0.0) 
Medication Characteristics 
 
 Cost of medications  0 (0.0) 
 Number of RA medications prescribed  0 (0.0) 
 
 As Table 6 shows, data were missing on both outcome variables (medication 
satisfaction and characteristics of communication) and predictor variables (patient 
characteristics).  The one patient missing data on medication satisfaction was due to a lost 
patient interview and the communication data characteristics were missing because the 
medical visit recordings did not exist, generally due to a recording malfunction.  In both 
cases these data can be conservatively considered missing at random (MAR) since the 
missing data values were unrelated to why the data were missing.   
For the predictor variables, data were missing on education, income, marital status, 
Hispanic ethnicity, and RA severity.  The variable with the most missing data, RA severity, 
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was derived through physician assessment of patients’ functional status and required 
physicians to complete a form containing the ACR functional classification at the conclusion 
of the medical visit.  Many physicians forgot to complete the forms at the conclusion of the 
visit or took the form to complete later and never returned it to the research staff.   While 
certain physicians were more likely to not provide the data than others, the level of missing 
data appeared unrelated to the patients’ RA severity.   For the missing data on patients’ 
education, income, marital status, and Hispanic ethnicity, the level of missing data can be 
attributed to at least three causes: (1) the placement of these items at the end of the patient 
survey, (2) patients’ improper following of skip patterns, and (3) patients’ willful incompletion 
of the items.   For these variables, it is possible that the data are not missing at random 
(NMAR).  As an example, patients of a particular income category may be more or less likely 
to not answer the item.  Unfortunately, there was no way to formally evaluate whether the 
data was missing at random or not, since it would require knowledge of the missing values.  
However, simulation studies and scholars working on multiple imputation methods have 
shown that with a rich multivariate data set and multiple imputation methods, missing data 
can be successfully imputed even if the data are not strictly MAR (Faris et al., 2002; 
Schafer, 1997; Van Buuren, 2006). 
 For this study, multiple imputation methods were utilized to address the missing data 
in the predictor variables.  A conservative approach was chosen, and outcome variables 
were not imputed. This decision was made because a small percentage of data were 
missing on the outcomes and there is debate over the appropriateness of imputing outcome 
variables (P. D. Allison, 2002).  Listwise deletion of patients’ missing data on outcome 
variables left a sample of 192.   
Multiple imputation has several advantages: it can be applied very generally and is 
not problem specific, it preserves the correct conditional framework when there are 
incomplete covariates, and it can be used to construct comparatively simple sensitivity 
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analyses (Kenward & Carpenter, 2007).  The two major approaches for imputing multivariate 
data are joint modeling and fully conditional specification (FCS).  To best match the analysis 
models used in the present study, FCS methods were chosen to impute the missing 
predictor variables and joint modeling was employed as a sensitivity analysis on the FCS 
imputation methods. 
 FCS does not start from an explicit multivariate density, as does joint modeling, but 
instead assumes that the data have an underlying multivariate distribution that can be used 
to derive underlying conditional distributions for each covariate (Faris et al., 2002). 
Imputation under FCS is done by iterating over all conditionally specified imputation models, 
each iteration consisting of one cycle through all incomplete variables (Van Buuren, 2006). 
 FCS has practical advantages over joint modeling (Van Buuren, 2006). First, FCS 
allows for the creation of flexible multivariate models so that each variable with missing data 
has its own separate, specified imputation regression model.  One can easily specify models 
that are outside of the standard normal multivariate density.  For this analysis, this is 
especially powerful because the majority of variables are dichotomous or categorical, clearly 
not fitting the multivariate normal used in joint distribution modeling.  Second, it is easy to 
model interactions terms with FCS.  Third, generalization to models where the data are not 
missing at random might be easier.   
 Of course FCS is not without disadvantages.  Disadvantages of FCS include: (1) 
each conditional density has to be specified separately, so substantial modeling effort can 
be needed for datasets with many variables, (2) it is often computationally more intensive 
than joint modeling, and (3) relatively little is known about the quality of the resulting 
imputations because the implied joint distributions may not exist theoretically (Van Buuren, 
2006).  However, this theoretical weakness is often difficult to verify in practice and FCS 
appears robust against incompatibility.  To test the robustness and convergence of the 
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imputations in this analysis, imputation models were run with five and with ten iterations.  
The results of the logistic regressions did not change with additional iterations.   
 As a further check on the imputations and the quality of imputed data, a second 
multiply imputed data set was created using joint modeling in SAS 9.1 (SAS Institute Inc., 
2003).  Regressions run using this data produced similar results to those generated using 
FCS although the exact regression techniques could not be replicated to account for 
stratification on physician.  Associations with the imputed predictor variables and the 
outcome variables were assessed through combining chi-square statistics from analysis of 
the data sets created by the multiple imputations using methods described by Schafer and 
employed by Allison (P. Allison, 2000; Schafer, 1997).  Results indicated that the imputed 
variables education, income, marital status, Hispanic ethnicity, and RA severity were not 
significantly related to any of the outcome variables.  These results matched those 
generated using the complete case dataset. 
 Logistic regression models testing the stated hypotheses were run using the imputed 
datasets and a complete case dataset using listwise deletion to eliminate patients from the 
sample that had missing data on any of the modeled variables.  Overall, there were few 
differences in the coefficients, statistical significance, or confidence intervals of the 
regressions run using the imputed data and those generated using the complete cases.  
Results from the complete cases are presented since it was through complete case analysis 
that models could be appropriately stratified on physician. 
 
Hypothesis Testing 
 The focus of the hypotheses of aim two centered on describing the relationships 
among patient-physician communication about medication costs and management and 
patient, physician, and medication characteristics.  The specific communication variables 
under study included: presence of discussion of medication cost, number of physician 
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questions about cost, number of patient questions about cost, whether the patient or 
physician initiated the medication cost discussion, discussion of modifying the medication 
regimen, and discussion of patient initiated changes to the medication regimen.  All were 
dichotomous except for the questions asked about cost variables.  Plots revealed that 
question asking was highly left skewed with many patients and physicians asking zero 
questions about medication costs.  For analyses the variable was transformed for both 
patients and physicians into the dichotomous (‘yes’/’no’) variable ‘any questions asked about 
medication costs.’   
 For each of the communication outcome variables, bivariate analyses between 
characteristics of communication and patient, physician, and medication characteristics were 
conducted.  Variables were created to indicate gender concordance and racial concordance, 
indicating that patients and physicians in the medical visits were of the same gender or were 
of the same race.  Chi-square statistics were calculated to test the association between 
each of the communication outcome variables and categorical characteristic variables.  Two-
tailed t-tests were calculated to test the association between communication outcome 
variables and continuous variables.  A correlation matrix was also generated to assess the 
interrelationships among the other variables used in the analysis.  
 Since all of the communication outcome variables of interest were dichotomous, 
logistic regression models were constructed to test the impact of patient, physician, and 
medication characteristics on the outcomes, after controlling for other characteristics.  As an 
exploratory analysis, the goal was to begin to identify which characteristics together are 
most strongly associated with the communication variables of interest. 
 An important factor considered in model building was the size of the categories of the 
dichotomous outcome variables.   Some outcomes had relatively few cases per category so 
care had to be taken to build the most parsimonious models possible in order to achieve 
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stable estimates from logistic regression equations.  Only predictor variables that were 
statistically significant in the bivariate analyses were modeled in the multivariable analysis.  
 As mentioned previously, since patients were nested within physicians all 
regressions were stratified on physician.  To address the unequal patient sample sizes 
within physicians, low-enrolling physicians were combined into a single stratum.  While not 
ideal, establishing strata this way was another means of improving the efficiency and 
stability of the regression estimates.  Physicians in the combined stratum shared several 
characteristics: all were white, most were younger, and most had been in practice fewer 
years.  Sensitivity analyses were conducted by running the regression models with different 
strata and control variables to assess the robustness of the main findings. 
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Aim 3  
To examine how discussions of medication cost and medication management in 
routine clinic visits between rheumatologists and patients with RA affect patient-
reported medication satisfaction.  
H5: Patients who discuss medication costs with physicians during clinic visits are 
more likely to report being satisfied with their medications than patients who do not 
discuss medication costs. 
H6: Patients who discuss medication management with physicians are more likely to 
report being satisfied with their medications than patients who do not discuss 
medication management.  
 
To address this aim a single item assessing the degree of patient satisfaction with 
prescribed medications was asked of patients immediately following the audiotape recorded 
medical visit.  A plot of the five-category variable revealed that the data was skewed with 
zero patients reporting that they were ‘Not at all’ satisfied with their medications.  For 
analyses, the variable collapsed into a dichotomous variable with the medication satisfaction 
categories ‘A little or somewhat satisfied’ and ‘Very or totally satisfied.’  
 Bivariate analyses between medication satisfaction and patient, physician, 
medication, and communication characteristics were conducted.  Chi-square tests were 
conducted for high versus low medication satisfaction and categorical characteristic 
variables.  Two-tailed t-tests were calculated for high versus low medication satisfaction and 
continuous variables.   Bivariate associations between discussions of medication cost, 
discussion of regimen modification, patient initiated regimen changes and high versus low 
medication satisfaction were calculated using Mantel Haenszel tests, stratified on physician.   
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 The goal had been to use multivariable logistic regressions to separately examine 
the influence of discussions of medication costs and discussions of patient-initiated 
medication regimen changes on patient medication satisfaction taking into account patient, 
physician, and medication characteristic variables.  In addition, multiple logistic regression 
was going to be used to measure the influence of the interaction between medication cost 
discussion and regimen modification discussion on medication satisfaction while controlling 
for patient and physician variables.  However, the relatively few respondents (n=24) 
reporting low medication satisfaction presented a challenge to multivariable modeling.   This 
constraint meant that only a couple of predictors could be entered into each logistic 
regression model if it was expected to produce stable estimates from the regression 
equations.  To address this issue, only predictor variables that were statistically significant in 
the bivariate analyses were used in the multivariable analysis.  However, issues of model 
building were largely avoided since bivariate analyses revealed few significant relationships 
between medication satisfaction and patient, physician, medication, and communication 
characteristics.  Limited multiple logistic regression models stratified on physician were 
conducted to assess the predictors of high versus low satisfaction.  Again, sensitivity 
analyses were conducted by running the regression models with different strata and control 
variables to test the robustness of the findings. 
 
  
 
 
 
 
 
CHAPTER FIVE:  RESULTS 
 
 
Patient and Physician Characteristics 
Patient characteristics for the full sample of 200 patients are presented in Table 7.  
The mean patient age was 62.3 (SD=9.0), 74% were women, 22.5% Black/African 
American, and 1% identified as being of Spanish or Hispanic origin.  The majority, 112 
(59%), of patients were married and the majority, 65 (35.7%), reported a yearly total 
household of income of less than $20,000. Sixty patients (31.6%) reported being a high 
school graduate as their highest grade completed in school.  In terms of patient functional 
status, physicians rated the majority of patients, 90 (52.0%), as having moderate restriction 
but adequate for normal activities.  However, most patients were also experiencing some 
pain at the time of their visit.  The mean patient score on the zero to ten pain scale where 
zero was “no pain at all” and ten was the “worst pain ever” was 4.35 (SD=2.8).  Twenty-six 
patients (13.5%) had family or friends present for the visit.  Of the eight physicians in the 
study, their mean age was 46.2 years (range 32 – 59), six were White/Caucasian, one was 
Black/African-American, four were women, two identified as being of Spanish or Hispanic 
origin, and mean duration at the clinic under study was 9.1 years (range 1-15). 
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Table 7. Characteristics of RA patients in total sample (N=200).  
 Total Sample 
Characteristics Number of Patients (%)a 
Age, mean (range)  62.3 (45.2-88.5) 
Women  148 (74.0) 
Race  
 Black/African American    45   (22.5) 
 White/Caucasian  143  (71.5) 
 American Indian/Alaskan Native      7    (3.5) 
 Other      5   (2.5) 
Spanish or Hispanic Origin      2   (1.0) 
Marital Status  
 Married  112 (59.0) 
 Widowed    33 (17.3) 
 Separated    11   (5.8) 
 Divorced    28 (14.7) 
 Never Married      6   (3.2) 
Highest Grade Completed in School  
 8th Grade or Less    12   (6.3) 
 Some High School    28 (14.7) 
 High School Graduate    60 (31.6) 
 Some College    46 (24.2) 
 College Graduate    27 (14.2) 
 Any Post-Graduate Work    17   (9.0) 
Income  
 Less than $20,000     65 (35.7) 
 $20,000 - $39,999    47 (25.8) 
 $40,000 - $59,999    28 (15.4) 
 $60,000 - $79,999    18   (9.9) 
 Greater than $80,000    24 (13.2) 
American College of Rheumatology (ACR) 
Classification of Global Functional Status 
 
(I)   No restriction of ability to perform normal 
activities 
   50 (28.9) 
(II)   Moderate restriction     90 (52.0) 
(III)  Marked restriction    29 (16.8) 
(IV) Incapacitation or confinement to a bed   or 
wheelchair 
     4   (2.3) 
Patient-rated pain, mean (SD)  4.4 (2.8) 
Medical Insurance   
 Private or employer purchased    57 (28.5) 
 Medicare with supplemental    83 (41.5) 
 Medicare without supplemental    24 (12.0) 
 Medicaid  6 (3.0) 
 Medicare with Medicaid    15   (7.5) 
 None    15   (7.5) 
a. Totals may be less than 200 due to missing data 
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Patient Characteristics by Physician 
Analysis of the full sample of 200 patients and eight physicians revealed statistically 
significant differences in patient, medication, and medical visit characteristics by physician.  
Significant differences in patient characteristics by physician included: patient race, RA 
severity, prescription drug coverage, and number of prior physician visits.  Looking at each 
of these in more detail, two physicians saw more patients that identified as Black/African 
American than the other physicians (χ2 (21, 200)=54.8, p<0.001); one physician saw more 
patients in poor health with more severe RA according to ACR functional classification (χ2 
(21, 173)=33.8, p=0.04); two physicians saw more patients lacking prescription drug 
coverage (χ2 (7, 200)=17.1, p=0.02); and two physicians had seen almost all their patients in 
the sample five or more times prior to the study medical visit (χ2 (35, 200)=75.7, p<0.001).  
There were also significant differences in the number of RA medications patients were 
prescribed by physician (F=2.69, p=0.01).  Patients were prescribed an average of 
approximately four RA medications, but two physicians averaged nearly five medications per 
patient.  Finally, physicians differed on how much time they spent with patients as measured 
by medical visit length in minutes.  Two of the eight physicians in the study spent more time 
with patients, on average, than the other physicians (F= 7.19, p<0.001). 
 Taken together these can be thought of as case-mix and style differences among the 
physicians in the sample.  Differences in characteristics and outcomes by physician will be 
considered in more detail in subsequent sections and attempts were made to control for 
patient differences by physician in analyses.
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Medication Characteristics 
 Of the 200 patients enrolled in the study, 199 were prescribed at least one RA 
medication at the time of their audio recorded medical visit.  The mean number of RA 
medications per patient was 4.3 (SD=1.6) with a range of zero to nine.  The overwhelming 
majority, 183 (91.5%), were prescribed a disease-modifying antirheumatic drug (DMARD), 
including 62 patients (31%) who were prescribed a tumor necrosis factor(TNF)-α inhibitor.  
In addition to DMARDs, patients were also prescribed non-steroidal anti-inflammatory drugs 
(NSAIDs), analgesics, bisphosphonates, and vitamins.  Examining these categories, 41 
patients (20.5%) were prescribed non-selective NSAIDS and 51 (25.5%) were prescribed 
COX-2 selective NSAIDs.  Forty percent of patients were prescribed opioid analgesics or 
opioid analgesic combinations.  Twenty-nine percent of patients were prescribed 
bisphosphonates and 51.5% overall were prescribed some form of calcium supplementation 
for osteoporosis prevention.  Table 8 below shows the specific medications patients were 
taking by category. 
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Table 8. Medical record indicated RA medications for patients at the time of the audio-
recorded medical visit in total sample (N=200).  
 Total Sample 
Category/Medication (U.S. Brand Name) Number of Patients (%) 
Disease-modifying antirheumatic drugs (DMARDs)  
 Adalimumab (Humira®)  12 (6.0) 
 Etanercept (Enbrel®)  21 (10.5) 
 Infliximab (Remicade®)  29 (14.5) 
 Leflunomide (Arava®)  21 (10.5) 
 Methotrexate (Trexall™)  119 (59.5) 
 Hydroxychloroquine (Plaquenil®)  46 (23.0) 
 Sulfasalazine (Azulfidine®)  11 (5.5) 
Azathioprine  (Imuran®)  5 (2.5) 
 Gold Sodium Thiomalate  (Myochrysine®)  2 (1.0) 
Vitamin supplementation for DMARD  
Folic Acid  14 (57.0) 
Leucovorin  2 (1.0) 
Glucocorticoids  
 Prednisone  98 (49.0) 
Non-steroidal anti-inflammatory drugs (NSAIDs)  
 Valdecoxib (Bextra®)            7 (3.5) 
 Celecoxib (Celebrex®)       28 (14.0) 
 Rofecoxib (Vioxx®)               16 (8.0) 
 Meloxicam (Mobic®)           15 (7.5) 
 Naproxen (Naprosyn®)           9 (4.5) 
 Nabumetone (Relafen®)         3 (1.5) 
 Sulindac (Clinoril®)  1 (0.5) 
 Diclofenac (Cataflam®; Voltaren®)  3 (1.5) 
 Ketoprofen (Orudis® KT; Oruvail®)  2 (2.0) 
 Ibuprofen  8 (4.0) 
Analgesics  
Acetaminophen + codeine (Tylenol® With Codeine)  2 (1.0) 
Acetaminophen + hydrocodone (Lorcet®; Lortab®; Norco®; 
Vicodin®)  17 (8.5)  
Acetaminophen + propoxyphene (Darvocet-N® 100; Darvocet-N® 
50)  39 (19.5) 
Acetaminophen + oxycodone (Percocet®; Tylox®)  17 (8.5) 
Acetaminophen + tramadol (Ultracet™)  6 (3.0) 
 Methadone  3 (1.5) 
 Morphine sulfate  1 (0.5)  
 Oxycodone hydrochloride (OxyContin®)  3 (1.5) 
 Acetaminophen (Tylenol®)  19 (9.5) 
Tramadol (Ultram®)  10 (5.0) 
 Lidocaine Patch (Lidoderm®)  1 (0.5) 
Calcium supplementation and agents for osteoporosis prevention  
Alendronate Sodium (Fosamax®)  45 (22.5) 
Risedronate (Actonel®)  13 (6.5) 
Raloxifene (Evista®)  5 (2.5) 
Calcitonin (Miacalcin®)  4 (2.0) 
Calcium with or without Vitamin D (Caltrate®; Os-Cal® Caltrate® 
600+D; Os-Cal® 500)  103 (51.5) 
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 The total per month cost of RA medications prescribed to patients ranged from 
$0.00, for the patient not taking any medications, to $4,860.01. The values were non-
normally distributed with a positive skew.  Patients at the median had per-month medication 
costs of $246.91, while patients at the 25th and 75th percentiles had per-month medication 
costs of $145.10 and $1,314.86, respectively.  Patients prescribed TNF-α inhibitors had 
much higher per-month total medication costs than those who were not prescribed biologic 
agents.  Patients whose regimens included TNF-α inhibitors had median monthly total 
medication costs of $1,483.32 with a range of $843.88 to $4,860.01.  Patients whose RA 
medication regimens did not include TNF-α inhibitors had median monthly total medication 
costs of $177.35 with a range of $0.00 to $679.47.  Comparing mean per-month total RA 
medication costs, patients prescribed a TNF-α inhibitor had approximately eight times the 
medication costs than patients not prescribed such medications.  A histogram plot of per-
month total RA medication costs (Figure 3) shows the gap in between patients not 
prescribed TNF-α inhibitors and those that were. 
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Figure 3. Histogram of patient total per-month RA medication costs (N=200) 
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Medical Visit Audio Analysis  
Descriptive Data about Medication Cost and Management Communication 
Out of the total 200 medical visits, 193 were successfully recorded.  Reasons for 
missing audio data included: digital recorder malfunction, failure to start the recorder for the 
visit, and failure to power on the microphone.  Characteristics of the patients and physicians 
where the tape data were missing were generally similar to the characteristics when the 
tape data were not missing.  The mean age of patients with missing tape data was 60.5 
years-old, 85% were women, 43% were married, 71.4% were White/Caucasian, 71.4% had 
total annual incomes under $40,000, 14% had a high school education or less, and 57% had 
generous drug coverage.  The mean age of physicians when the audiotape data were 
missing was 43 years-old and approximately even numbers of data were missing by 
physician gender and race.   
Results of medical visit audio analysis are based on the available sample of 193 
audio recordings.  The mean visit length was 14.21 minutes (range 3.20 to 33.32 minutes).  
For most recorded medical visits, 158 (81.9%) the only people in the exam room were the 
rheumatologist and patient with RA.  Another medical professional was present for 11 
(5.7%) of the medical visits.  The other medical professional present was a medical student 
or resident for eight of the eleven visits, a nurse was present in the exam room in two visits, 
and a representative from a pharmaceutical manufacturer was present for one visit.  Study 
participants had family members or friends present for 26 (13.5%) of medical visits.  For 24 
of those visits, patients were accompanied by an immediate family member or members, 
generally partners/spouses and adult children.  In the other two cases, the identity of the 
person accompanying the study participant in the medical visit was unknown.  For two of the 
193 recorded visits both an additional health professional and family member were present.   
Sixty-five of the recorded visits (33.7%) included discussions of medication-related 
cost issues, 47.7%% of which were initiated by the patient.  The mean length of time spent 
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discussing medication costs for the 65 visits where cost was discussed was 1 minute 27 
seconds with a range of 3 seconds to 6 minutes 11 seconds.  During medication cost 
discussions the majority of patients (51%) did not ask any questions, representing the range 
minimum, while one patient asked four questions related to cost, representing the range 
maximum.  In contrast, physicians asked a mean of nearly 3 medication cost related 
questions during each visit where cost was discussed with a range of zero to eleven 
questions. 
Discussion of medication management and modifications to the medication regimen 
occurred in 99 of the 193 (51.3%) recorded medical visits.  In 40 of the recorded medical 
visits (20.7%), patients and physicians discussed patient-initiated changes to the medication 
regimen.  The mean length of time spent discussing patient-initiated changes to the 
medication regimen for the 40 visits where such changes were discussed was 38 seconds 
with a range of 7 seconds to 2 minutes 3 seconds.   
Table 8 shows the demographic characteristics of patients who discussed 
medication costs or patient-initiated changes to their medication regimens during medical 
visits.  Overall, the demographics of patients who discuss medication cost and patient-
initiated changes to the medication regimen are similar to each other and the overall 
population.  The sections that follow provide information on the content of communication 
about patient mediation management and medication costs, as well as specific differences 
in patient demographics within communication content areas. 
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Table 9.  Characteristics of patients discussing medication costs (N=65) or patient-
initiated medication regimen changes (N=40) during routine medical visits. 
 
 
Discussed Medication Costs 
Discussed patient-initiated 
regimen changes 
Characteristics Number of Patients (%)a Number of Patients (%)b 
Age, mean (range)  61.5 (45.3-84.2)  61.1 (45.2-79.8) 
Women  45 (69.2)  31 (77.5) 
Race   
 Black/African American   9 (13.9)  5 (12.5) 
 White/Caucasian  53 (81.5)  32 (80.0) 
 American Indian/Alaskan 
Native 
  0 (0.0)  0 (0.0) 
 Other  3 (4.6)  3 (7.5) 
Spanish or Hispanic Origin  1 (1.6)  1 (2.7) 
Marital Status    
 Married  34 (57.6)  21 (56.8) 
 Widowed  10 (17.0)  5 (13.5) 
 Separated  1 (1.7)  1 (2.7) 
 Divorced  11 (18.6)  8 (21.6) 
 Never Married  3 (5.1)  2 (5.4) 
Highest Grade Completed    
 8th Grade or Less  3 (5.1)  0 (0.00) 
 Some High School  9 (15.2)  10 (27.03) 
 High School Graduate  20 (33.9)  7 (18.92) 
 Some College  18 (30.5)  10 (27.03) 
 College Graduate  4 (6.8)  7 (18.92) 
 Any Post-Graduate Work  5 (8.5)  3 (8.11) 
Income   
 Less than $20,000  19 (33.3)  12 (33.33) 
 $20,000 - $39,999  17 (29.8)  9 (25.00) 
 $40,000 - $59,999  11 (19.3)  8 (22.22) 
 $60,000 - $79,999  6 (10.5)  4 (11.11) 
 Greater than $80,000  4 (7.1)  3 (8.33) 
ACR Classification of Global 
Functional Status 
  
(I)   No restriction of ability 
to perform normal 
activities 
 12 (21.4)  10 (28.6) 
(II)   Moderate restriction   33 (58.9)  20 (57.1) 
(III)  Marked restriction  9 (16.1)  4 (11.4) 
(IV) Incapacitation or 
confinement to a bed 
  or wheelchair 
 2 (3.6)  1 (2.9) 
Patient-rated pain, mean (SD)  4.6 (2.8)  4.8 (2.7) 
Medical Insurance    
 Private or employer 
purchased 
 20 (30.8)  12 (30.0) 
 Medicare with supplemental  21 (32.3)  18 (45.0) 
 Medicare without 
supplemental 
 12 (18.4)  4 (10.0) 
 Medicaid  2 (3.1)  2 (5.0) 
 Medicare with Medicaid  3 (4.6)  0 (0.0) 
 None  7 (10.8)  4 (10.0) 
 
 a. Totals may be less than 65 due to missing data. 
b. Totals may be less than 40 due to missing data. 
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Results of Aim 1 – Qualitative Examination of Medication Cost and Management 
Communication  
 
Medication Cost Discussion Content 
This section describes the results of the analysis of the content of communication 
about medication costs in the 65 medical visits where cost was discussed.  Under the major 
category medication cost, two themes emerged from the content analysis of the medical visit 
communication.  The first theme was insurance coverage and the impact that coverage had 
on prescription decision-making.  The second theme was strategies to reduce patients’ OOP 
medication costs.  Under the insurance coverage category was the subcategory insurance 
coverage affecting OOP costs, which was conceptualized as part of communication about 
insurance coverage but represented a distinct area of insurance coverage communication.  
Under the theme of general strategies to reduce OOP medication costs, there were three 
subcategories that were conceptualized as being part of strategies to reduce OOP 
medication cost since that was their intention but they were specific strategies to reduce 
OOP costs.  The subcategories were special programs offered by pharmaceutical 
companies to defray medication costs, importing medications from outside the United 
States, and receiving medication samples.  Attempts were made to apply the most 
representative code to the corresponding text resulting in little to no overlap in the 
subcategory codes.  However, subcategory codes were sometimes nested within category 
codes.  Figure 4 contains a graphical representation of the categories of medication cost 
and relationships among categories.  The sections below describe the categories in detail 
and provide illustrative excerpts from the transcripts. Actual transcript data and direct 
participant quotes are used as much as possible in an attempt to let the data speak for itself 
(Strauss & Corbin, 1998).  To preserve confidentiality, all direct quotations from the 
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transcripts are presented without identifying the speaker other than noting whether it is a 
patient, physician, or accompanying family member speaking.  Further, all proper names of 
people and places are omitted.  The generic “Dr. X” was used to replace any mention of a 
specific doctor’s name.  Ellipses indicate other omissions and square brackets replace other 
identifying features or provide clarifying information. 
 
Figure 4. The categories and subcategories of communication related to medication 
cost in medical visits. 
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Insurance Coverage 
 In the context of medication cost communication, discussion of patients’ health 
insurance coverage particularly prescription drug coverage was a significant, repeated 
theme.  Participants discussed insurance coverage in the context of medication cost 
communication in 48 medical visits.  Specifically, conversations about insurance coverage 
related either to insurance coverage as a barrier or facilitator to medication access or the 
influence of insurance coverage on prescription decision-making.  The impact of insurance 
coverage on access to medicine was the most frequently discussed of the two topics 
occurring in 28 medical visits.  In 13 (46%) of those conversations, patients and physicians 
were discussing insurance coverage as a barrier to accessing prescribed medications.  
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Patients were actively denied medications prescribed by their rheumatologist for their RA or 
were struggling to receive enough medication to remain adherent to their prescribed 
regimens.  Patients and physicians both initiated these conversations and physicians asking 
about access and patients disclosing insurance barriers to accessing medications often 
occurred in the context of communication about adherence.  The following exchange is 
illustrative of communication about insurance coverage as a barrier to accessing prescribed 
medications: 
Physician:  Are you taking the Arava regularly? 
 
Patient:  Not regularly, uh, uh. 
 
Physician:  And I saw a note from Dr. X that your insurance company was not 
covering the Arava? 
 
Patient:  Ah, they, I have a problem with the insurance company. 
 
Physician:  Tell me what’s going on because the last time we talked everything was 
a-okay.  Has something happened since then? 
 
Patient:  No, not at all they just, they sent a letter to me I don’t know why but – 
 
Physician:  They sent a letter to you and what did the letter say? 
 
Patient:  I can’t remember ((mumbles)) anyway it was something about they had 
refused. 
 
Physician:  Usually what, now you had been on the Remicade and they had refused 
that. 
 
Patient:  Yeah, they refused that one. 
 
Physician:  But they also sent you a letter about the Arava too? 
 
Patient:  Uh, huh. 
 
 
 Insurance coverage was discussed in the context of prescription decision-making in 
18 medical visits.  These conversations generally occurred as patients and physicians were 
trying to make decisions about adding new medications to patients’ regimens.  Generally, 
physicians initiated these discussions by asking patients about their insurance coverage or 
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talking about which medications were known to be covered by particular health plans.  
Patients and physicians would then engage in communication about what medications were 
likely to be covered by a patients’ insurance before settling on a treatment course of action.  
The following excerpt is typical of the communication about the impact of insurance 
coverage on prescription decision-making: 
Physician:  Okay, now in terms of looking at the TNF-alpha inhibitors um, one of the 
other concerns also becomes um, how you know getting coverage because they are 
 
Patient:  ((Interrupting)) Oh. 
 
Physician:  Extremely expensive.  
 
… 
 
Physician:  But um, a self-administered, a self injected drug is not covered by 
Medicare.  They do cover um, Infliximab, which is the TNF-alpha inhibitor that is 
administered as an IV.  In fact um, the other folks in the clinic today are 
predominantly getting that treatment.  Um, either because they have a GI disease 
um, inflammatory bowel disease or because they have um, rheumatoid um, and that 
usually has folks coming in for um, about two to three hours, actually more like three 
to four hours.  Two-hour infusion – 
 
Patient:  Whoa. 
 
Physician:  Um, and coming initially um, ah, starting at baseline -- two weeks, one 
month and then every two months.  Um, so it means sort of coming into the infusion 
clinic area every two months um, to get that. 
 
Patient:  For like all afternoon. 
 
Physician:  Yeah. 
 
… 
 
Physician:  So um, so it certainly um, then that certainly is covered.  We know that 
um, many of the private insurances cover both the um, Infliximab and also many of 
them will also cover the self-administered. 
 
Spouse:  Well [patient name] is covered by the state, which is really [name of 
insurance plan]. 
 
Patient:  It’s a good plan. 
 
Physician:  Yeah, and they should definitely cover the TNF-alpha inhibitors. 
 
Spouse:  Right. 
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Physician:  So if that looks like the way to go um, with the rheumatoid they’ll cover it 
so that shouldn’t be a problem for you. 
 
Not surprisingly, the majority of conversations about the impact of insurance coverage on 
prescribing centered on discussion of brand-name medications.  These medications have 
higher retail prices, often making them more difficult for patients to obtain without the 
assistance of prescription drug coverage.  
  
Insurance Coverage and OOP Medication Costs 
 Even for patients with prescription drug coverage for a particular medication, many 
health insurance plans pass portions of the medication cost onto patients.  This cost sharing 
is the direct charge to a patient at the time a prescription is filled and represents the price of 
the prescription medication to the insured patient, while insurance covers the remainder of 
the cost (Gibson, Ozminkowski, & Goetzel, 2005).  Typically, medication cost sharing takes 
the form of co-payments, a flat fee per prescription (e.g. $10), or coinsurance, a fixed 
fraction of each dollar of cost (e.g. 20%).   The coinsurance or co-payment amount a patient 
pays for his or her medication is their OOP medication cost. 
Insurance coverage determines patient OOP costs for a particular medication and, 
therefore, can be thought of as a part of insurance coverage communication.  Yet, 
communication about insurance coverage affecting OOP medication costs is more specific.  
Beyond the access to the medication granted by having insurance coverage there is the 
financial ability to access the medication based on the affordability of the co-payment or 
coinsurance.  In this way insurance coverage affecting OOP costs can be conceptualized as 
a second tier of communication about accessing medications or making decisions about 
new prescriptions.  Patients and physicians who conclude that a particular medication may 
be appropriate because it is covered on patients’ insurance plans often still have to grapple 
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with the impact of the costs to the patient.   There were 18 discussions of insurance 
coverage impacting patients’ OOP medication costs in 13 medical visits.  All of these 
conversations took place among patients who identified as White/Caucasian.  The transcript 
excerpt below illustrates communication about the impact of insurance coverage on OOP 
costs incurred by patients: 
Physician:  Ah, that’s actually the shot that you give. 
 
Patient:   ((Interrupting)) Oh, the shot. 
 
Physician:  Give, you know give yourself or get as an IV.  And then the other thing 
though becomes is that um, often times the state um, coverage is for eighty percent 
of the cost of the drug. 
 
Patient:  Oh, right.  So it could still be – 
 
Spouse:  ((Interrupting)) So is the twenty percent outrageous, it’s still outrageous? 
 
Physician:  Well, it’s about a thousand dollars a month. 
 
Spouse:  Oh. 
 
Patient:  Wow. 
 
Physician:  So the twenty percent of that actually - 
 
Spouse:  Two hundred dollars a month. 
 
Physician:  Yeah, um, becomes, so I think in terms of making the choice between the 
two you know I would clearly go for the TNF-alpha inhibitors if we didn’t have the 
setting of [infection] and that to my mind is a concern. 
 
Patient:  Yes, ah - 
 
Physician:  So um, I would, I would be much more comfortable to go forward with the 
Arava but you also have another… this sort of cost barrier which I think is important 
to also recognize. 
 
… 
 
Spouse:  Yeah, because our income is not great anymore.  Um, but I mean is this 
something that’s gonna be a lifetime thing or just until it comes under control? 
 
Physician:  Well, and that’s one of the difficulties too in that this is a newer therapy.  
Um, it looks like the folks who respond do need to keep dosing and at this point three 
to five years is what people have been followed and it looks like folks do need to 
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continue at least through that time. 
 
… 
 
Patient:  Right. 
 
Spouse:  What, I don’t see that we have too many choices anyway. 
 
Physician:  Uh, huh. 
 
Spouse:  Um, we’ll just go along with this Arava … because you have a stop-loss.  I 
mean eventually you max out on your per annual - 
 
Patient:  ((Interrupting)) Right. 
 
Spouse:  Payment anyway. 
 
General Strategies to Reduce OOP Medication Costs  
There were eleven conversations about general strategies to reduce OOP 
medication costs in nine medical visits.  Conversations qualifying as general strategies to 
reduce OOP medication costs were those led by patients or physicians about medication 
use or prescribing, without reference to a specific strategy, which would lessen patients’ 
OOP medication cost burden.  Two visits contained more than one conversation about 
reducing OOP medication costs.  Patients initiated these conversations in 4 of the visits.  
There were no clearly dominant characteristics among patients talking with physicians about 
reducing their OOP costs.  Of the nine patients talking about reducing costs, seven were 
married, six had no or only partial prescription drug coverage, five were under age 65, four 
had annual incomes of less than $40,000, and one was non-White.  
Conversations about reducing OOP medication expenses took two forms.  One focus 
was physicians discussing prescribing or medication use that would reduce patients’ OOP 
costs.  The following exchange is an example: 
Physician:  Um, does your insurance help you with your medications? 
Patient:  Yeah. 
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Physician:  Um, because I could give you a prescription for Aleve ah, in a little more 
potent form and then that way your insurance would help you ah, cover it if you’d like 
and, and you could take, I could give it to you in a three hundred and seventy five 
milligram tablet and you could take one at breakfast and then you could kind of use a 
second one during the day if you needed it.  You know if you didn’t feel like you 
needed it you don’t have to take it. 
 
Patient:  That would help a little more than the Aleve I’m taking now? 
 
Physician:  Yeah, it’s a little more potent than the one you’re on now. 
 
Patient:  Okay. 
 
Physician:  You want to do that? 
 
Patient:  Yeah. 
 
Physician:  Because that would, now that would save you some money. 
 
Patient:  Right.  Hopefully ah, alright. 
 
The other form conversations took was patient expression of trying to reduce OOP 
medication expenses by discussing the possibility of eliminating medicine or being 
prescribed alternate, less expensive medications.  Initiating a conversation about cost, one 
patient stated: 
This Arava is so expensive, is there anything else? It has gone up twice since I 
started taking it.  It is now $279 for 30 pills.  See I only have with my Medicare, I only 
have a supplement which pays an amount on my medicines. Plus, I’m taking 
Fosamax and the other things and our income has kind of taken a hit with things that 
have been going on with the economy. 
 
In response to patient questions about being prescribed alternate medications to 
reduce OOP costs, the physicians always engaged in the cost discussion with the patient by 
either bringing up alternate medications or dosing schedules to accommodate these patient 
concerns.  In response to the patient above, the physician responded with an alternate 
dosing schedule and a warning about the possibility a change would exacerbate the 
patient’s disease state:  
Physician:  I mean one of the things we can try if cost is an issue and I’ve done this 
with one patient is to cut the Arava back and take it every other day and see what 
happens. 
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Patient:  Uh, huh. 
 
Physician:  I mean you run the risk of this thing getting out of control and when that 
happens it really hard to get back in control.  So that really worries me a little bit.  But 
if you want to try that I’ve gotten away with that in some people and - 
 
Patient:  Okay. 
 
Physician:  You know certainly. 
 
Patient:  Well, that would certainly help me … 
 
Medication Assistance Programs 
As indicated in Figure 4, medication assistance programs are conceptualized as 
being part of strategies to reduce OOP medication expenses for patients since the intention 
of such programs is to reduce the financial burden medication costs place on patients.  
There was also a direct link between patient desire to reduce OOP costs and mention of 
medication assistance programs.  Continuing with the patient and physician exchange 
provided above, after discussing the possibility of the patient altering the Arava dosing, the 
physician mentions trying to find a medication assistance program for the patient:  
Physician: So I wish I could say there was something in my pocket that was going to 
do just as well for you but it took us so long to get you under control that I’d be really 
wary to rock the boat I will however say that there are companies and I’m not sure 
what Aventis, the company that makes Arava is doing right now in terms of helping 
people like you who are on a limited income, you may not even qualify... 
 
Patient:      I probably don’t qualify but... 
 
Physician: ...for any of these programs. 
 
Patient:      The only thing is I’m soon going to qualify if I’ve got to use everything I’ve 
got to... 
 
Physician:  I understand but I can look into that for you... 
 
As this quote also demonstrates, a patient’s eligibility for an assistance program was 
often brought up in tandem with notification about the assistance program.  Eligibility for a 
program was a concern for patients and physicians.  For one patient, frustration over 
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eligibility for assistance programs was part of a larger frustration about medication costs, as 
can be seen in the following exchange: 
Physician: I’m going to find out if there is any kind of program we can get you hooked 
up with and I will let you know, okay. 
 
Patient:     These drugs are great but when they’re so expensive... it’s the middle 
income people that lose out. 
 
Physician:  Right, because if you were really poor... 
 
Patient:      ((Interrupting)) really poor you’re going to get it all and if you’ve got 
oodles of money you can pay for it yourself.  There is no need to keep on 
researching if they’re going to have them [medications] priced to where people can’t 
use them. That’s what they say and they talk so much.  I’ve seen on television they 
are advertising Arava and Remicade on television ads that cost a fortune 
 
  
Discussions of prescription drug assistance programs to defray personal medication 
costs occurred in 14 of the 65 visits (21.5%) that contained cost discussions.  Patients 
initiated six of these conversations about prescription drug assistance programs.  All 
communication about medication assistance programs occurred with patients who had no or 
only partial prescription drug coverage and all but one reported annual income of less than 
$40,000.  Separate Pearson chi-square tests assessing the association between lacking 
prescription drug coverage (χ2 (1, 192)=16.8, p < 0.001) and low income (χ2 (1, 175)=8.39, p 
< 0.01) with discussing medication assistance programs confirmed the communication 
differences were statistically significant. 
There were three types of prescription drug assistance programs discussed.  The 
first and most common were prescription drug assistance programs run by pharmaceutical 
manufacturers to provide the medications they produce to patients experiencing financial 
difficulties.  Eligible patients generally have no healthcare coverage for the requested 
product and do not have access to alternative sources of coverage or funding.    Patients 
who are determined to be eligible will receive medications for little to no cost (Partnership for 
Prescription Assistance, 2008).   
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The second type of assistance program discussed was the publicly funded Medicare 
Replacement Drug Demonstration (Centers for Medicare & Medicaid Services, 2004).  The 
demonstration program, established by the Centers for Medicare and Medicaid services, ran 
from September 2004 to December 31, 2005 and provided select medications with the same 
beneficiary cost-sharing as would apply under standard Medicare Part D coverage.  Under 
the demonstration, Medicare Part B would pay for prescription or biological medications that 
were prescribed as replacements for medications already covered under Part B.  For 
patients with RA this meant that Medicare beneficiaries with Part B and no other prescription 
drug coverage could receive Adalimumab (Humira®) or Etanercept (Enbrel®) as a 
replacement for the already covered Infliximab (Remicade®). Prior to the demonstration 
Medicare Part B would only pay for treatments administered in a physician’s office, hence its 
coverage of the infused medication Infliximab (Remicade®).  During the demonstration, 
choice of treatment would not be limited by route of administration and eligible patients 
could receive and have covered the self-injectable medications Adalimumab (Humira®) or 
Etanercept (Enbrel®). 
The third type of assistance program discussed in the medical visits was one 
administered by the hospital system affiliated with some participating rheumatology clinics.  
Like the other programs, the purpose is to relieve the financial burden of patients in need 
through the provision of subsidized medications and services.  Also similar to other 
programs patients had to apply for the program and eligibility was determined by lack of 
other prescription medication coverage and ability to pay for medications. 
Regardless of the type of medication assistance program being discussed the 
conversations about the programs took on similar forms.  The conversations tended to focus 
on filling out paperwork or completing required processes to qualify for the programs, 
selecting a medication over another because it was likely to be covered by a program, or 
following up on patient eligibility and access to medication through a program.  The following 
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medical visit exchange highlights conversation about completing paperwork and selecting a 
medication based on the likelihood it would be covered by a program:  
Physician:  Yeah, but we were going to apply for the indigent program to see if - 
 
Patient:  ((Interrupting)) Oh, yeah. 
 
Physician:  They would donate it. 
 
Patient:  To see if I could get it, yeah. 
 
… 
 
Nurse:  Ah, I talked to a drug rep yesterday and she says no, Medicare is not 
covering but she said that if we would go ahead and send it in and I told her who you 
were and I just talked to her yesterday. She said she would work real hard on getting 
it covered. 
 
Patient:  Oh, okay. 
 
Nurse:  So see I’ve sent it in. 
 
Physician:  So for Humira - 
 
Nurse:  Uh, huh. 
 
Physician:  So she says to give her the prescription? 
 
Nurse:  No, she said just, just send it in and she’ll remember who she is and she’ll 
work it getting it covered. 
 
Physician:  Send it in to her? 
 
Nurse:  Uh, huh. 
 
Physician:  Okay, but they haven’t answered you from the last time? 
 
Nurse:  No, no they haven’t. 
 
Physician:  And Enbrel? 
 
Nurse:  Yeah, we’ve sent it in, now Enbrel I haven’t heard anything from Enbrel.  I 
can follow up on that one too. 
 
Physician:  Yeah. 
 
Nurse:  But it sounded, talking to her yesterday … Humira sounded like it would be, it 
would be the one that would approve it.  She sounded like that it was a pretty sure 
thing so. 
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Patient:  Uh, huh. 
 
Nurse:  I thought I’d just continue going through her since she gave me a pretty good 
promise on it yesterday. 
 
… 
 
Physician:  Well we’ll see if we can get you the Humira. 
 
Patient:  Yeah. 
 
Nurse:  I’ll work real hard on it.  She’s a new drug rep.  She said give her a week and 
then send the paperwork in. 
 
Physicians responded affirmatively to all patient requests to complete paperwork for 
assistance programs and followed up with other clinic staff on issues of eligibility.  Out of the 
14 visits where medication assistance programs were discussed, patients and physicians 
were talking about trying to get the patient on a program in four, talking about patients 
receiving medications from a program in three, and talking about a patient being denied 
program eligibility in one. 
Medication assistance programs were just one of the specific avenues discussed for 
reducing OOP costs.  The other two subcategories of strategies for reducing OOP costs 
were medications purchased outside the United States to reduce OOP medication costs and 
medication samples provided to patients to reduce medication costs.  Like medication 
assistance programs, they are viewed as specific components of communication about 
reducing OOP medication costs because they were conversations that occurred within the 
context of reducing costs but involved very specific strategies to decrease costs.  Each of 
these subcategories is discussed in detail below. 
 
Medications Purchased Outside the United States to Reduce Medication Costs 
There were two conversations in two medical visits about patients actively 
purchasing medications outside the United States to reduce their medication expenses.  The 
two patients were different on almost all demographic characteristics, sharing only two 
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commonalities: they were both female and had a high school education or less.  Both of the 
conversations about importing medication involved patients bringing to the medical visit or 
talking about bringing to the visit the medication they had purchased abroad.  As the 
exchange shows the patient brings the medication to the medical visit for the physician to 
examine: 
Patient:  Look at the medicine and make sure that um… 
 
Physician: Look at the new shape! 
 
Patient:  It’s exactly right? 
 
Physician:  How much did you pay for it? 
 
Patient:  $91 
  
Physician:  Well that’s one-third of the price… 
 
Patient:  I did want you to look at it. 
  
Physician:  I’m glad to know this but I’m sure it’s the exact same thing. You have to 
know Spanish to know how to take it, but you know how to take it, right? And you 
didn’t need a prescription to get this? 
 
Patient:  No 
 
Physician:  Unbelievable. And you think it’s working just as well? 
 
Patient:  Yes. 
 
Physician:  You haven’t noticed any difference? 
 
Patient:  I was particularly interested in that to make sure it wasn’t cut in any way. 
 
Physician: Right. That it wasn’t somehow less potent. In terms of your arthritis do you 
think you’re doing as well as you were on the other one? 
 
Patient: Yes 
 
 
Medication Samples 
 Samples are medications provided to physicians’ offices by pharmaceutical 
manufacturers.   A medication sample has been defined within the pharmaceutical industry 
as, “… a package containing a limited quantity of a pharmaceutical product sufficient to 
 91 
evaluate clinical response, distributed to authorized health care practitioners free of charge, 
for patient treatment (Groves, Sketris, & Tett, 2003).”  The provision of medication samples 
allows patients to try out a medication before paying for a prescription or acts as a 
supplement to whatever supply of medication patients already possess.  Either way, through 
the provision of free medication, samples offset patient costs incurred when prescriptions 
are filled.   The intention of providing samples for patients to try a medication is clearly 
different than providing patients with samples because they cannot access the medicine 
through other channels or because it would provide them a stock of medication that would 
offset their prescription medication costs.  In this study, communication about samples had 
to be clearly related to cost communication and the samples had to be provided to relieve a 
financial burden or permit access to a medication that was financially out of reach for 
patients. 
 Medication samples were discussed in 16 instances in 11 medical visits.  In eight of 
the visits the physician was offering or providing the patient with samples, in two visits the 
patient asks whether the physician has any samples of a particular medication, and in one 
the patient was informing the physician that she had received some samples of a medication 
from another physician. The following visit excerpt is a typical example of a physician 
offering a patient samples: 
Physician: Let’s see, we’ve got Fosamax, do you ah, I’ve got some in the cupboard 
you need some? 
 
Patient:  What? 
 
Physician:  Fosamax. 
 
Patient:  Yeah, sure. 
 
Physician:  Yeah, I’ve got some in the cupboard.  And, and we have Enbrel. 
 
Patient:  I told [nurse name] that I always feel bad doing that… 
 
Physician:  No, no, no, you kidding oh, yes, oh, please. 
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Patient:  Because other people probably need it more than I do. 
 
Physician:  Oh. [Whispering and can’t hear what is being said].  
 
Patient:  The way of the world…oh, yeah, yeah, oh, yeah. 
 
When patients asked for samples, in both cases the physicians agreed to follow-up.  As the 
following example shows: 
Patient:  However, I have ran out of Mobic but I knew I was coming in today so - 
 
Physician:  Yeah. 
 
Patient:  Do you have any? 
 
Physician:  Let me go look and see if I’ve got some samples.  I’ll give you some to 
hold you over until they can - 
 
Patient:  ((Interrupting)) Okay. 
 
Physician:  Re-supply you. Okay? 
 
Patient:  Alright, uh, huh. 
 
There was diversity in patients’ characteristics among those that had medication 
sample discussions with physicians, although the majority of patients discussing medication 
samples had no or only partial prescription drug coverage and annual incomes of less than 
$40,000.  There was, however, a clear physician effect among those discussing medication 
samples.  One physician generated the majority of discussion about providing patients with 
medication samples.  While it is unclear whether the effect was due to the physician or the 
clinic in which the physician practiced, this particular physician offered more samples as part 
of medication cost communication when compared to the other physicians in the study.  
 
Summary 
 The results of the qualitative examination of medication cost communication reveal 
that medication cost communication is not monolithic.  Communication about medication 
costs takes several different forms with the different types of discussions more likely to 
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happen among different patient populations.   Medication cost communication is comprised 
of the categories insurance coverage and strategies to reduce patient OOP medication 
expenses.  Associated with the category insurance coverage is the subcategory insurance 
coverage affecting patient OOP costs.  Associated with the category reducing patient OOP 
costs are the subcategories medication assistance programs, importing medication, and 
medication samples.  The constructs that emerged from the data and their associations with 
one another provide an initial foundation for theory development about medication cost 
communication.  The summary table (Table 10) below lists each code, the number of 
mentions, the number of medical visits where the code was discussed, and an exemplary 
quote highlighting the concept. 
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Table 10. Highlights of the codes and concepts of medication cost communication. 
 
Total Patient/Physician Statements 16,748 
Total Medical Visits 65 
    
Count of text-units by code  
Code 
# Mentions 
# Medical 
Visits Exemplary quote 
Insurance 
Coverage 
71 28 Physician: Once you know who your new insurance 
provider is going to be I think it would be a good idea 
to just let me know and then we can find out what their 
policy is about some of these medicines and that may 
make a huge difference for you and hopefully they’ll, 
they’ll go for this… 
 
Insurance 
OOP Costs  
18 13 Physician:  So you’re not paying out of pocket? 
Patient:  No, uh, uh, I’ve been paying a portion of it 
but still. 
Physician:  And can you afford that? 
Patient:  Yeah, right now I’m fine.  Yeah. 
 
General 
Strategies to 
Reduce OOP 
Costs 
 
11 9 Patient:  I mean the pills are okay it’s just I’m trying 
figure out how to decrease cost ((Laughing)). 
Physician:  And, and Fosamax is an expensive one. 
 
Medication 
Assistance 
Programs 
26 14 Physician:  There’s a program that we may be able to 
get it for you because you don’t have ah, prescription 
coverage … So they may, may qualify you for a 
program that’ll be able to get it for you which would be 
great.   
 
Importing 
Medication 
2 2 Patient: I’m going to bring it in to you because I get my 
[medication] from Canada …because it’s a whole lot 
cheaper. 
 
Medication 
Samples 
16 11 Physician:  We can … keep you stocked with samples 
because you’re here and around. 
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Patient Disclosure of Self-Initiated Medication Regimen Changes 
This section describes the results of the analysis of the content of communication 
about patient initiated changes to the medication regimen in the 40 medical visits where 
such changes were discussed.  Special emphasis is placed on the intersection of 
communication about medication costs and communication about patient medication 
management.  As mentioned in the previous chapter, in this study we were particularly 
interested in patient actions to manage their RA medications.  To qualify as communication 
about a patient initiated change to the regimen, it had to require a behavior change on the 
part of the patient (e.g. taking more or less medication than prescribed) and the change had 
to be patient initiated and directed.  The focus on patients’ purposeful, independent actions 
to manage their medications was chosen to be able to examine disclosure of patient 
regimen changes in the setting of medication cost communication.  Looking both at 
disclosure of changes in medical visits overall and within visits where medication costs were 
discussed provided insight into patient medication behaviors both in the presence and 
absence of likely cost pressures.   
 Examining the 40 medical visit transcripts where patient initiated regimen changes 
were disclosed, the regimen changes fell roughly into three categories.  The first category 
was patient communication about taking more medication than prescribed or adding an 
additional medication to their regimen.  Eighteen patients (45%) took more medication than 
had been prescribed or added an additional medication to their RA regimen.  Almost 
unanimously patients who took more medication than prescribed or added a medication to 
the regimen were doing it to relieve pain.  As the following exchange illustrates: 
Patient:  You was giving me Lorcet 10 but you dropped me down to Vicodin seven 
and a half’s last time. 
 
Physician:  Okay. 
 
Patient:  So and if it’s, if it’s any way possible I wish you could give me a few more 
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because them ninety don’t last me three months.  That ain’t but one a day. 
 
Physician:  Okay. 
 
Patient:  Some days doc, I have to take a couple -- two or three. 
 
Physician:  Okay. 
 
Patient:  I mean I’ve tried to make them last but I mean … 
 
The second category was discussion of patient substitution of one medication for 
another.  Five patients (12.5%) substituted one medication for another.  In three of these 
cases patients discontinued a prescription NSAID or analgesic for an OTC NSAID or 
analgesic and in two of these cases patients substituted prescription bisphosphonates with 
OTC calcium preparations.  The following is an exchange where a patient disclosed 
discontinuing a prescription analgesic for an OTC NSAID: 
Patient:  So I didn’t, I have been taking some - 
 
Physician: ((Interrupting)) Yeah. 
 
Patient:  Darvocet. It helped but I wanted to get off of it so I took the [unclear 
medication name].  That helped but still it wasn’t quite like I wanted so I went to  
Aleve - 
 
Physician:  Uh, huh. 
 
The third regimen change category discussed was patient disclosure of taking less 
medication than prescribed, discontinuing a medication, or never starting a prescribed 
medication.  Seventeen (42.5%) medical visits contained disclosure of patients taking less 
medication than prescribed, discontinuing, or never starting a medication.  There were no 
clear dominant medications or reasons for taking less medication than prescribed provided 
by patients.  Some patients stopped medications because of actual or perceived side-
effects, some the reasons are not stated or are not clear, and in some cases because of 
cost or life constraints.  In the following exchange the patient discloses having never started 
the medication that was prescribed at the last visit: 
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Patient:  I haven’t done what you told me. 
 
Physician:  ((Laughing)) So you’re gonna confess, huh? 
 
Patient:  Yes. 
 
Physician:  Oh, let’s see now last time … we were gonna go back on Methotrexate 
but you didn’t do that? 
 
Patient:  And I didn’t do that. 
 
Physician:  Okay. 
 
Patient:  It’s all because of work.  It’s like I told [the nurse], if I, I’m the only one there. 
 
Physician:  Yeah. 
 
Patient:  If I could do it by eight or eight fifteen in the morning I can do that but I can’t 
leave work because I have nobody to cover for me. 
 
Physician:  Okay, you mean to come here and get your shots? 
 
Patient:  Yes, yeah. 
 
Physician:  Okay. 
 
Patient:  But you know if I could do that I’ve got to have some help helping me. 
 
Physician:  Yeah. 
 
Patient:  Because I don’t want to give my job up. 
 
Physician:  Yeah, I understand that. 
 
Patient:  So that’s the reason for that. 
 
As a group, these regimen changes represent a threat to patients’ adherence with 
their medication regimen.  Adherence has generally been defined as, “the extent to which 
patients take medications as prescribed by their health care providers. (Osterberg & 
Blaschke, 2005).”  Through altering their regimens patients are deviating from taking 
medications as prescribed and exhibiting poor medication adherence to varying degrees.   
 Of the  40 patients disclosing self-initiated changes to their medication regimens, 23 
(57.5%) also discussed medication cost-related issues during their medical visits.  Fifteen 
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(65%)  of the 23 patients discussing medication cost issues and self-initiated changes to 
their medication regimens had no or only partial prescription drug coverage and twelve had 
annual incomes of $40,000 or less.  There was a strong physician effect in disclosures of 
patient-initiated medication regimen changes both overall and among patients also talking 
about medication costs.   Overall disclosure of patient-initiated regimen changes occurred in 
17 of 40 medical visits with patients seeing the same physician and in 10 of 23 visits where 
medication costs were also discussed.   
For patients and physicians in the 23 medical visits communicating about medication 
cost issues and patient-initiated regimen changes, 14 patients disclosed taking less 
medication than prescribed, 7 took more medication than prescribed, and 2 substituted 
prescription for OTC medications.  These findings contrast with the 17 medical visits where 
patient-initiated regimen changes were discussed but medication cost issues were not.  In 
those cases, 11 patients disclosed taking more medication than prescribed, while only 3 
took less medication than prescribed, and 3 substituted prescription for OTC medications.   
Not only were patients who discussed medication costs more likely to disclose taking less 
medication than prescribed by physicians, they also explicitly linked their medication 
restriction with cost pressures.  The following exchange is perhaps the best example of this 
communication: 
Patient:  Um, well, you know I had been on the hospital plan - 
 
Physician:  Uh, huh. 
 
Patient:  That paid for my medications well they refused to pay for it anymore. 
 
Physician:  Oh, really.  So you quit? 
 
… 
 
Patient:  So there was no, in my eyes there was no point in coming because I 
couldn’t get any medicine in - 
 
… 
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Patient:  And see since they cut my medicine I haven’t had medicine since June.  I - 
 
Physician:  Oh, you couldn’t get any…? 
 
Patient:  I have been off of Flexeril.  I’ve come off the estrogen, you name it I mean I 
have not had ah, the only thing I’m taking, thank God - 
 
Physician:  Uh, huh. 
 
Patient:  You had written me a prescription for the Prednisone. 
 
Physician:  Uh, huh. 
 
Patient:  That is so inexpensive - 
 
Physician:  Yeah, ah - 
 
Patient:  I could get that. 
 
Physician:  That’s cheap, yeah, oh, yeah. 
 
Patient:  So I kept getting the Prednisone.  I took my last one this morning.  Ah, I take 
my calcium and my vitamin D - 
 
Physician:  Uh, huh. 
 
Patient:  And that’s it. 
 
Looking closer at the patient-initiated regimen changes among patients who 
discussed medication cost issues, eight actively decreased the dose of a medication, five 
stopped a medication altogether, and the one patient mentioned above never started the 
prescribed medication.   In many, but not all, of these cases the decreased or discontinued 
medications were more expensive brand name medications.  For the 7 patients who 
discussed taking more medication than prescribed and also discussed medication cost 
issues in their visits, even though they were taking more medication, they were generally 
increasing use of medications that were fairly inexpensive.  Three of these patients were 
supplementing their pain medications with OTC analgesics; one was taking additional 
generic prescription analgesic; and three had increased the dose of their prednisone.  
Further, the two patients disclosing medication substitutions and discussing medication 
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costs were disclosing changes from brand-name prescription medications to OTC 
medications.  In all cases where patients disclosed to physicians that they made changes to 
their medication regimens and they had also communicated with their physicians about 
medication cost issues, patients were likely to have their overall medication costs stay the 
same or decrease.  
Table 11 provides a summary of the medical visit communication about patient-
initiated changes to their medication regimens.  The table highlights the categories of 
patient-initiated medication regimen change communication, the number of medical visits 
where it was discussed, the number of medical visits where medication cost was also 
discussed, and an exemplary quote from the category. 
 
Table 11. Highlights of the categories of communication about patient-initiated 
changes to the medication regimen. 
 
Total Patient/Physician Statements 10,865 
Total Medical Visits 40 
Medical Visits where Medication Costs and Patient-
Initiated Regimen Changes Discussed 23 
    
Count of visits by category  
Category 
# Medical 
Visits 
# Visits Where 
Medication Costs 
also Discussed Exemplary quote 
 
Taking more 
medication than 
prescribed  
 
18 
 
7 
 
Physician: You are taking for pain Percocet? 
And you stopped the Tylenol? 
Patient: No, I’m taking both of them. It 
seemed like I wasn’t getting enough relief at 
night. 
 
Substitution of one 
medication for 
another 
5 2 Physician:  Could you take … Actonel once 
a week? 
Patient:  I didn’t, I didn’t take it.  I’m taking 
ah, calcium. 
 
Taking less 
medication than 
prescribed 
17 14 Physician:  And so are you getting your 
Arava at all? 
Patient:  I’m getting it. 
Physician:  You’re paying for it out-of-
pocket?  And how many days a week are 
you, are you taking it? 
Patient:  I take it three days a week. 
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It is important to note that patients’ communication about their medication 
management was measured and, therefore, only represents the vocal fraction of patients 
who actively make decisions about their medications and alter their regimens.  However, 
looking at patients who talk about medication costs, it appears they are more likely to 
disclose restricting their medication use than any other type of regimen change.  This may 
be a form of mutual disclosure where patients who are comfortable talking about medication 
cost issues are also more comfortable revealing to physicians their medication adherence 
issues.  
 
Summary – Medication Cost and Management Communication Content  
 These sections provided descriptive details on the content of communication about 
medication cost, patient medication management, and the intersection between the two.  
The medical visit transcripts revealed that communication about medication costs was 
multifaceted and variable based on patient and physician characteristics.  The transcripts 
further revealed patients’ active disclosure of their alterations to their medication regimens.  
Patients appeared to actively manage their medication regimens and the types of regimen 
alterations disclosed varied by whether medication costs were also discussed.  Patients 
discussing medication cost issues with physicians more often restricted their medication use 
than patients not discussing medication cost issues.  Assessment of the content of 
communication about medication cost and management provides important context for 
understanding the two constructs and their relationship to each other.  Further, it serves as 
the building blocks for examination of the patient, physician, and medication characteristics 
associated with medication cost and patient medication management communication.  
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Results of Aim 2 – Examination of relationships among patient characteristics, 
physician characteristics, and patient-physician communication about medication 
cost and management. 
 This section describes the results of the examination of the patient, physician, and 
medication characteristics that are associated with communication about medication costs, 
patient-initiated medication regimen changes, and whether the medication regimen was 
changed during the visit.  Results in this section are based upon the sample of 192 patients 
for which complete data were available on the outcome variables.  The results build upon 
each other and are presented in the following sections.  First, the results of the bivariate 
associations between patient, physician, and medication characteristics and the 
communication variables are presented.  Second, the correlations among the independent 
analysis variables are presented.  Third, the results of the logistic regression models 
predicting medical visit communication about medication costs, patient-initiated regimen 
changes, and overall medication regimen changes are presented. 
 
Bivariate Results 
Communication about medication costs by patient, physician, medication, and other 
communication characteristics 
 Table 12 shows the differences in patient, physician, medication, and other 
communication characteristics when medication costs are and are not discussed.  Chi-
square statistics were calculated for the cross-tabulation of communication about medication 
costs by categorical variables.  T-tests were conducted to compare the mean values for 
continuous variables between visits with the presence and visits with the absence of 
communication about medication costs.  For total monthly RA medication costs, the non-
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parametric Wilcoxon rank-sum test was used to assess the relationship between this 
variable and the dependent communication variables of interest.   
Looking at communication variables, more patients who had their medication 
regimens changed during their medical visits communicated about medication costs (40%) 
than patients who did not have their regimen changed but talked about medication costs 
(27%).  While chi-square test revealed that there were not statistically significant differences 
in the groups using an alpha of 0.05, the results highlighted the difference with the p-value 
approaching 0.05. Supporting the findings from the qualitative analysis, patients who 
discussed medication costs during the visit were significantly more likely to also discuss self-
initiated changes to their medication regimens (p < 0.001).  Nearly sixty percent of patients 
who disclosed self-initiated medication regimen changes also discussed medication costs. 
 Examining patient characteristics, there were few differences between those who did 
and did not discuss medication costs.  The groups were similar with respect to gender, age, 
education, income, marital status, ethnicity, RA severity, pain, and the number of prior visits 
with the study physician.  The two notable differences were in patient race and prescription 
drug coverage.  Among White/Caucasian patients 38% discussed medication costs in their 
visits while among non-White patients only 22% discussed medication costs (p = 0.03).  
Also, 50% of patients lacking prescription drug coverage discussed medication costs in their 
medical visits while only 30% of patients who had partial or generous prescription drug 
coverage discussed medication costs (p = 0.02). 
 There were no significant differences in physician or medication characteristics 
between the presence or absence of visit communication about medication costs.   
Communication about medication costs occurred in relatively equal proportions with 
physicians of both genders and those who were White/Caucasian versus those identified as 
non-White/Caucasian.  Approximately 31% of patients seeing female physicians discussed 
medication costs and 35% of patients seeing male physicians discussed medication costs.  
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While more patients seeing White physicians discussed medication costs (38%) than 
patients seeing non-White physicians (27%), the difference was not statistically significant.  
For both patients talking and not talking about medication costs in the visit, the mean 
physician age was 46.3 years. 
While there were no statistically significant differences in the number of RA 
medications patients were prescribed or the total RA medication costs between those who 
did and did not discuss medication costs, it is notable that the median total monthly RA 
medication costs were slightly higher for patients who discussed medication costs.  In both 
groups patients were prescribed an average of 4 medications but the median total RA 
medication cost was $294.66 for patients talking about medication costs compared to 
$241.32 for patients not talking about costs.  Despite the expense of TNF-α inhibitors, 
patients prescribed those medications were no more likely to discuss medication costs than 
patients not prescribed those medications (χ2 (1, 192) = 0.01, p = 0.91). 
 Bivariate associations were also calculated for patient/physician gender and race 
concordance and medication cost communication.  Patients and physicians were in gender 
concordant relationships when both were female or male and were in race concordant 
relationships when both identified as being members of the same racial group.  Of the 192 
patients in the analysis sample, 103 (54%) were in gender concordant relationships with 
their physician and 121 (63%) were in race concordant relationships with their physician.  
Bivariate results indicated that neither gender nor race concordance had a statistically 
significant relationship with medication cost communication (results not shown).   This 
finding does not support hypothesis three of aim two which stipulated that conversations 
about medication costs were more likely to occur when patients and physicians were in race 
concordant relationships.  It is interesting that a significant bivariate relationship between 
patients identifying as White/Caucasian and discussing medication costs exists but there is 
no relationship between racial concordance in the medical visit and communicating about 
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medication costs.   This finding suggests that patient characteristics may matter more in 
communication about medication costs than characteristics of patients and physicians 
together. 
Table 12.  Medical visit communication about medication costs by other 
characteristics of communication, patient, physician, and medication characteristics 
(N=192). 
 Medication Cost Communication a  
Variable b 
Yes (n=64) 
 Frequency (%) 
No (n=128) 
Frequency (%) 
Characteristics of Communication 
  
 Discussion of modifying medication regimen   
  Yes  39 (39.8)  59 (60.2) 
  No  25 (26.6)  69 (73.4) 
 Discussion of patient initiated changes to the 
medication regimen     
   Yes  23 (57.5)  17 (42.5) 
   No  41 (27.0)  111 (73.0) *** 
Patient Characteristics   
 Gender   
  Female  45 (31.7)  97 (68.3) 
  Male  19 (38.0)  31 (62.0) 
 Age, mean (std dev)  61.7 (9.4)  62.9 (9.0) 
 Education    
  High school or less  31 (32.6)  64 (67.4) 
  More than high school  27 (30.7)  61 (69.3)  
 Income   
  Less than $40,000  35 (33.0)  71 (67.0) 
  $40,000 or more  21 (30.4)  48 (69.6) 
  Marital status   
  Married  33 (30.6)  75 (69.4) 
  Not married  25 (33.3)  50 (66.7) 
 Race   
  White  52 (38.0)  85 (62.0)  
  Non-White  12 (21.8)  43 (78.2) * 
 Ethnicity   
  Hispanic  1 (50.0)  1  (50.0) 
  Non-Hispanic  61 (66.7)  122 (33.3) 
ACR Classification of Global Functional Status 
  
(I)   No restriction of ability to perform 
normal activities  12 (24.5)  37 (75.5) 
(II)   Moderate restriction  
 32 (36.8)  55 (63.2) 
(III)  Marked restriction 
 9 (34.6)  17 (65.4) 
(IV) Incapacitation or confinement to a 
bed or wheelchair  2 (50.0)  2 (50.0) 
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 Medication Cost Communication a  
Variable b 
Yes (n=64) 
 Frequency (%) 
No (n=128) 
Frequency (%) 
 Self-rated pain, mean (std dev)  4.6 (2.8)  4.2 (2.9) 
 Prior visits with physician   
  Fewer than five  12 (30.8)  27 (69.2) 
  Five or more  52 (34.0) 101 (66.0) 
 Prescription drug coverage   
  No coverage  18  (50.0)  18  (50.0)  
  Partial or generous coverage  46 (29.5)  110 (70.5) * 
Physician Characteristics 
  
 Gender   
  Female  29 (31.2)  64 (68.8) 
  Male  35 (35.3)  64 (64.7)  
 Race   
  White  41 (38.0)  67 (62.0) 
  Non-White  23 (27.4)   61 (72.6) 
 Age, mean (std dev)  46.3 (8.8)  46.3 (7.9) 
Medication Characteristics 
  
 Cost of medications, median (range) 294.66(5.52-4860.01) 241.32(0-5087.57) 
Number of RA medications prescribed, mean 
(std dev)  4.3 (1.7)  4.2 (1.6) 
a Significance level of the chi-square statistic for categorical variables, two-tailed t-test for continuous 
variables, and Wilcoxon rank-sum for non-normally distributed continuous variables:  * p < 0.05,  ** p 
< 0.01, *** p < 0.001 
b Totals for individual variables may be less than 192 due to missing data.  
 
 
 In addition to examining communication about medication costs, bivariate 
associations of specific characteristics of medication cost communication were also 
calculated.  Associations among patient, physician, and medication characteristics and 
whether the patient or physician initiated the medication cost conversation were calculated.  
Chi-square statistics were calculated for discussion initiator and categorical variables and t-
tests were run for continuous variables.  Results revealed only two significant differences in 
whether patients or physicians initiated the medication cost conversation.  Patients were 
more likely to initiate medication cost conversations if they rated their pain lower on average 
(mean = 3.8, sd = 2.7), than if physicians initiated those conversations (mean = 5.3, sd = 
2.6).  The difference was statistically significant (t = 2.27, p = 0.03).  The only other 
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difference in whether patients or physicians initiated the medication cost communication in 
the medical visit was physician age.  Patients were more likely to initiate the medication cost 
conversation if the physician was younger on average.  When patients initiated the cost 
discussion, the physicians they saw had an average age of 43.9 years (sd = 8.2).  In 
contrast, when physicians initiated the cost discussion they had an average age of 48.5 
years (sd = 8.8), a difference that was statistically significant (t = 2.17, p = 0.03).  This 
finding is interesting and may have a couple of explanations.  It could be that older 
physicians are more likely to initiate medication cost communication or that patients feel 
more comfortable bringing up the topic of medication costs with younger physicians.  A 
logistic regression equation regressing pain and physician age on patient initiation of the 
medication cost discussion reinforced the results found in the bivariate analyses.  Both 
variables were significant predictors of patient initiation of the medication cost 
communication and the relationships remained in the same direction.  Patients were more 
likely to initiate cost conversations if they reported lower pain levels (OR = 0.80, 95% CI = 
0.70 -0.92) and patients were more likely to initiate cost conversations with younger 
physicians (OR = 0.94, 95% CI = 0.93-0.95). 
 The other characteristic of medication cost communication examined was patient 
and physician question asking about medication costs.  The count variables for number of 
questions about medication costs that patients and physicians asked were collapsed into 
dichotomous variables for any patient questions about cost and any physician questions 
about cost.  Chi-square statistics and t-tests were used to assess the differences in patient, 
physician, and medication characteristics between patients and physicians that asked no 
questions in medication cost communication and those that asked at least one question.  
Looking at patient question asking about medication costs, results revealed no statistically 
significant differences in any of the variables examined and whether patients asked any 
questions.  Thus, there was no evidence to support hypothesis four of aim two that older 
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patients would be more likely to ask questions than younger patients.  These findings are 
not surprising given that patients asked questions in fewer than half the visits where 
medication costs were discussed, limiting the power to detect differences in characteristics. 
Analysis of patient, physician, and medication characteristics with any physician 
questions asked about medication costs revealed only one significant association.  
Physicians were more likely to ask medication cost questions to patients with better 
functional status and less severe RA than they were of patients with more severe RA.  In 
visits where medication costs were discussed and physicians asked patients cost-related 
questions, physicians asked questions of 38 patients (88.4%) who had no or moderate 
functional restriction and only asked questions with 5 patients (11.6%) who had marked or 
severe functional restrictions (χ2 (3, 55)=8.75, Fisher’s exact = 0.023).  
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Communication about patient-initiated medication regimen changes by patient, 
physician, medication, and other communication characteristics 
Table 13 shows the differences between the presence and absence of 
communication about patient-initiated changes to the medication regimen and other 
communication, patient, physician, and medication characteristics.  Supporting the 
qualitative analysis finding of a possible relationship between communication about 
medication costs and patient-initiated regimen changes, the bivariate analysis revealed a 
significant association between the variables.  Approximately 36% of patients discussing 
medication costs in their visits also disclosed self-initiated changes to their medication 
regimens, more than the 13% discussing patient-initiated changes alone (p < 0.001). 
Perhaps not surprisingly, 26.5% of patients had their medication regimens changed during 
the visit when they disclosed to physicians self-initiated regimen changes, a significant 
difference from the 15% of patients who did not have their regimens changed and disclosed 
self-initiated medication regimen changes (p < 0.05). 
 Examination of the associations among patient characteristics and communication 
about patient-initiated regimen changes, revealed almost no significant relationships.  The 
only distinguishing patient characteristic between patients who did and did not disclose self-
initiated regimen changes was age over or under 55 years.   Younger patients (under 55 
years-old) were more likely to disclose changes to their regimen to physicians than older 
patients (p = 0.02).  While this provides some support for the hypothesis that younger 
patients are more likely to discuss medication management, it is notable that significant 
differences in disclosure of patient-initiated regimen changes did not exist when comparing 
mean patient ages between those who did (mean age = 61.1) and did not (mean age = 
62.8) discuss patient-initiated regimen changes. 
 There were significant differences in patient disclosure of medication regimen 
changes by physician characteristics.  Patients were more likely to disclose medication 
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regimen changes to male physicians (28%) than female physicians (13%) in the medical 
visit (p = 0.009).   Patients were also more likely to disclose self-initiated regimen changes to 
physicians who were, on average, older (p = 0.01).  The finding that patients were more 
likely to disclose self-initiated changes to their medication regimens to physicians who were 
male and older runs directly counter to the hypothesis that communication about medication 
management would be more likely to occur when physicians were female and younger.  
However, as discussed in a previous section, qualitative analysis of the communication 
about patient-initiated regimen changes revealed that the patients of one particular 
physician were far more likely to disclose regimen changes.   The significant differences in 
patient disclosure are likely due to this particular older, male physician.  A comparison of 
communication about patient-initiated regimen changes with this older, male physician and 
another older, male physician in the sample who had seen a similar number of patients 
revealed statistically significant differences in communication (χ2 (1, 86)=5.2, p=0.02).  It 
may be that the physician differences are due not to the age and gender of the physicians, 
but instead to something about the particular physician with whom more patients disclosed 
self-initiated regimen changes.  With only eight physicians in the sample, results regarding 
significant differences among patients seeing physicians with particular characteristics must 
be interpreted with caution.   
While there appeared to be significant communication differences by physician 
characteristics, the relationship did not extend to matching patient and physician 
characteristics.  Bivariate assessment of patient/physician gender and race concordance 
with communication about patient-initiated regimen changes revealed no significant 
relationships (results not shown).  Again, this finding counters hypothesis three of aim two 
which suggested that patients would be more likely to discuss their medication management 
when they were in race concordant relationships.  It is interesting that when examining 
patient disclosure of medication regimen changes, physician gender had such a significant 
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impact but not concordance.  Again, it may be the influence of the particular physician with 
whom the majority of patients disclosed their self-initiated regimen changes. 
 Patients communicating with physicians about self-initiated changes to their 
medication regimens were prescribed an average of four medications and had median total 
monthly RA medication costs of $209.58 while patients not talking about their regimen 
changes were prescribed the same average number of medications and had median costs 
of $253.29.   In summary, the differences in medication costs between patients disclosing 
and not disclosing regimen changes were small and there were no differences in the 
average number of medications prescribed.    
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Table 13. Medical visit communication about patient-initiated medication regimen 
changes by other characteristics of communication, patient, physician, and 
medication characteristics (N=192). 
 Communication about Patient-Initiated 
Medication Regimen Changes a 
Variable b 
Yes (n=40) 
 Frequency (%) 
No (n=152) 
Frequency (%) 
Characteristics of Communication 
  
 Discussion of medication costs   
  Yes  23 (35.9)  41 (64.1)  
  No  17 (13.3)  111 (86.7) *** 
 Discussion of modifying medication regimen   
   Yes  26 (26.5)  72 (73.5)  
   No  14 (14.9)   80 (85.1) * 
Patient Characteristics   
 Gender   
  Female  31 (21.8)  111 (78.2) 
  Male  9 (18.0)  41 (82.0) 
 Age, mean (std dev)  61.1(10.6)  62.8(8.7) 
  Over 55 years of age  27 (17.5)  127 (82.5) 
  Under 55 years of age  13 (34.2)  25 (65.8) * 
 Education    
  High school or less  17 (17.9)  78 (82.1) 
  More than high school  20 (22.7)  68 (77.3) 
 Income   
  Less than $40,000  21 (19.8)  85 (80.2) 
  $40,000 or more  15 (21.7)  54 (78.3) 
  Marital status   
  Married  21 (19.4)  87 (80.6) 
  Not married  16 (21.3)   59 (78.7) 
 Race   
  White  32 (23.4)  105 (76.6) 
  Non-White  8 (14.5)  47 (85.5) 
 Ethnicity   
  Hispanic  1 (50.0)  1 (50.0) 
  Non-Hispanic  36 (19.7)  147 (80.3) 
ACR Classification of Global Functional Status 
  
(I)   No restriction of ability to perform 
normal activities  10 (20.4)  39 (79.6) 
(II)   Moderate restriction  
 20 (23.0)  67 (77.0) 
(III)  Marked restriction 
 4 (15.4)  22 (84.6) 
(IV) Incapacitation or confinement to a 
bed or wheelchair  1 (25.0)  3 (75.0) 
 Self-rated pain, mean (std dev)  4.8 (2.7)  4.2 (2.9) 
 Prior visits with physician   
  Fewer than five  7 (17.9)  32 (82.1) 
  Five or more  33 (21.6)  120 (78.4) 
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 Communication about Patient-Initiated 
Medication Regimen Changes a 
Variable b 
Yes (n=40) 
 Frequency (%) 
No (n=152) 
Frequency (%) 
 Prescription drug coverage   
  No coverage  8 (22.2)  28 (77.8) 
  Partial or generous coverage  32 (20.5)  124 (79.5) 
Physician Characteristics 
  
 Gender   
  Female  12 (12.9)  81 (87.1) 
  Male  28 (28.3)  71 (71.7) ** 
 Race   
  White  27 (25.0)  81 (75.0) 
  Non-White  13 (15.5)   71 (84.5) 
 Age, mean (std dev)  49.1 (9.5)  45.6 (7.7) * 
Medication Characteristics 
  
 Cost of medications, median (range)  209.58 (0-4606.63)  253.29(3.1-5087.57) 
Number of RA medications prescribed, mean 
(std dev)  4.1 (1.8)  4.3 (1.6) 
a Significance level of the chi-square statistic for categorical variables, two-tailed t-test for continuous 
variables, and Wilcoxon rank-sum for non-normally distributed continuous variables:  * p < 0.05,  ** p 
< 0.01, *** p < 0.001 
b Totals for individual variables may be less than 192 due to missing data.  
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Communication about medication regimen changes by patient, physician, medication, 
and other communication characteristics 
 Table 14 shows the differences in patient, physician, medication, and other 
communication characteristics by whether or not the medication regimen was changed 
during the visit.  The purpose of assessing the relationships among these variables and 
whether or not the medication regimen was changed during the visit was to compare and 
contrast the results obtained when examining patient-initiated regimen change 
communication.  As mentioned in the methods chapter, medication regimen changes were 
those discussed by patients and physicians that resulted in a change to the medication 
regimen that represented a distinct departure from the previously prescribed regimen.  
These sensitivity analyses were conducted to help confirm that the two variables were 
measuring different latent constructs of medication management.   
 The association between communication about overall regimen changes during the 
visit and categorical variables were tested with a chi-square test.  T-tests were conducted for 
the association between regimen changes and the continuous variables.  Given the positive 
skew of the total monthly RA medication cost variable, a Wilcoxon rank-sum test was used 
to assess the relationship between medication costs and whether the regimen was changed 
during the visit.   
 As mentioned in the two previous sections, there were differences in whether 
patients who talked about medication costs or self-initiated regimen changes had their 
medications changed during the visit.  Patients discussing medication costs or self-initiated 
changes to their regimens tended to have their regimens modified during the visit.  
 Several patient characteristics were associated with visit medication regimen 
changes.   Patients under 55 years old were more likely to have their medication regimens 
changed during the visit than older patients (p = 0.02).  Fifty-six percent (n = 77) of patients 
who identified as White/Caucasian had their regimens changed during the visit, while 38% 
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(N = 21) of patients identifying as other than White/Caucasian had their regimens changed 
(p = 0.02).  Not unexpectedly, patients who had their medication regimens changed had 
higher mean pain levels (4.7) than patients who did not have their regimens changed (3.9) in 
the sample (p = 0.04).  Patients who had seen the study physician five or fewer prior times 
were more likely to have their regimen changed in the visit than patients who had seen the 
study physician more than five times (p < 0.001).  Patients were also more likely to have 
their medication regimens changed at the visit if they lacked prescription drug coverage 
compared with patients who had partial or generous prescription drug coverage (p = 0.04).   
 There were also differences in patient medication regimen changes by physician 
characteristics.  Patients seeing male physicians were more likely to have their medication 
regimen changed.  Sixty percent of patients seeing male physicians had their regimens 
changed while 42% of patients seeing female physicians had their regimens changed (p = 
0.01).  Physician age was also a significant factor.  Patients seeing younger physicians 
(mean = 45 years-old) were more likely to have their regimen changed than patients seeing 
older physicians (mean = 48 years-old) in the sample (p = 0.01).   
 There were no significant differences in total monthly medication costs or number of 
RA medications by whether or not the regimen was changed.  Both patients who had and 
patients who didn’t have their medication regimens changed at the visit were taking an 
average of four medications.  The median total monthly RA medication cost for patients who 
had their medication regimens changed at the visit was $217.38 while patients who did not 
have their regimens changed had median totally monthly RA medication costs of $296.41, a 
difference that was not statistically significant.  It is possible that patients not having their 
regimens changed at the visit may have already been switched over to medications that 
were potentially more effective, but expensive. 
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Table 14. Medication regimen changed during medical visit by other characteristics of 
communication, patient, physician, and medication characteristics (N=192). 
 Medication Regimen Changed During Visit a 
Variable b 
Yes (n=98) 
 Frequency (%) 
No (n=94) 
Frequency (%) 
Characteristics of Communication 
  
 Discussion of medication costs   
  Yes  39 (60.9)  25 (39.1) 
  No  59 (46.1)  69 (53.9) 
 Discussion of patient initiated changes to the 
medication regimen   
   Yes  26 (65.0)  14 (35.0) 
   No  72 (47.4)  80 (52.6)* 
Patient Characteristics   
 Gender   
  Female  71 (50.0)  71 (50.0) 
  Male  27 (54.0)  23 (46.0) 
 Age, mean (std dev)  62.4(10.1)  62.6 (8.1) 
  Over 55 years of age  72 (46.8)  82 (53.2) 
  Under 55 years of age  26 (68.4)  12 (31.6) * 
 Education    
  High school or less  46 (48.4)  49 (51.6) 
  More than high school  47 (53.4)  41 (46.6) 
 Income   
  Less than $40,000  54 (50.9)  52 (49.1) 
  $40,000 or more  38 (55.1)  31 (44.9) 
  Marital status   
  Married  55 (50.9)  53 (49.1) 
  Not married  38 (50.7)  37 (49.3) 
 Race   
  White  77 (56.2)  60 (43.8) 
  Non-White  21 (38.2)  34 (61.8) * 
 Ethnicity   
  Hispanic  0 (0.0)  2(100.0) 
  Non-Hispanic  93 (50.8)  90 (49.2) 
ACR Classification of Global Functional 
Status   
(I)   No restriction of ability to perform 
normal activities  22 (44.9)  27 (55.1) 
(II)   Moderate restriction  
 46 (52.9)   41 (47.1) 
(III)  Marked restriction 
 13 (50.0)  13 (50.0) 
(IV) Incapacitation or confinement to a 
bed or wheelchair  4(100.0)  0 (0.0) 
 Self-rated pain, mean (std dev)  4.7 (2.8)  3.9 (2.8) * 
 Prior visits with physician    
  Fewer than five  30 (76.9)  9 (23.1) 
  Five or more  68 (44.4)  85 (55.6) *** 
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 Medication Regimen Changed During Visit a 
Variable b 
Yes (n=98) 
 Frequency (%) 
No (n=94) 
Frequency (%) 
 Prescription drug coverage   
  No coverage  24 (66.7)  12 (33.3) 
  Partial or generous coverage  74 (47.4)  82 (52.6) * 
Physician Characteristics 
  
 Gender   
  Female  39 (41.9)  54 (58.1) 
  Male  59 (59.6)  40 (40.4) * 
 Race   
  White  49 (45.4)  59 (54.6) 
  Non-White  49 (58.3)  35 (41.7) 
 Age, mean (std dev)  44.8 (8.1)  47.8 (8.1) * 
Medication Characteristics 
  
 Cost of medications, median (range) 217.38(0-4860.01) 296.41(3.1-5087.57) 
Number of RA medications prescribed, mean 
(std dev)  4.2 (1.7)  4.2 (1.5) 
a Significance level of the chi-square statistic for categorical variables, two-tailed t-test for continuous 
variables, and Wilcoxon rank-sum for non-normally distributed continuous variables:  * p < 0.05,  ** p 
< 0.01, *** p < 0.001 
b Totals for individual variables may be less than 192 due to missing data.  
 
 A comparison of the bivariate results of patient, physician, and medication 
characteristics with patient-initiated regimen change communication and having the 
medication regimen changed in the medical visit shows several differences.  There were 
several variables that had statistically significant bivariate relationships with having the 
medication regimen changed during the visit that did not demonstrate statistically significant 
relationships with patient-initiated regimen change communication.  Patient race, prior visits 
with study physician, and prescription drug coverage were all variables that had a 
statistically significant relationship with medication regimen communication overall but not 
patient-initiated regimen change communication.  Further, the statistically significant 
relationship between physician age and having the medication regimen changed during the 
visit was opposite of the significant relationship between physician age and patient-initiated 
regimen change communication.  Patients seeing younger physicians were more likely to 
have their regimens changed while patients seeing older physicians were more likely to 
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communicate about patient-initiated medication regimen changes.  The differences in the 
significant bivariate relationships and the different directions of the relationships with 
physician age underscore the likely difference in the two constructs. While assessment of 
the differences in bivariates cannot conclusively demonstrate that the two variables are 
measuring different latent constructs, this evidence suggests that purposeful patient-initiated 
changes to the medication regimen disclosed to physicians are separate from general 
communication about medication regimen changes.  
 119 
Correlation matrix of patient and medication variables used in analyses 
 Table 15 presents the Pearson correlation coefficients and statistical significance of 
the other variables used in the analyses.  Thus far the bivariate relationships between 
predictor variables and communication about medication costs, patient-initiated regimen 
changes, and changes to the medication regimen as well as differences by physician have 
already been discussed.  Since those relationships have been described, this section 
focuses on the statistically significant interrelationships among the patient and medication 
variables used in the analyses.  The purpose of assessing these interrelationships is not to 
draw meaningful conclusions from the results themselves but to look at the potential impact 
the interrelationships among the variables could have on the multivariable logistic regression 
models.  Put another way, this information is provided as a quick look at the relationships to 
demonstrate there are no issues of multicollinearity and with this purpose in mind only 
correlations greater than 0.30 will be focused on in the subsequent text.  
 Low income patients were more likely to have a high school education or less (r = 
0.44, p < 0.001) and were less likely to be married (r = -0.47, p < 0.001).  Patients reporting 
higher levels of pain were more likely to have more severe RA (r = 0.33, p < 0.001).  Total 
monthly RA medication costs were related to the number or RA medications prescribed (r = 
0.39, p < 0.001) and were negatively related to lacking drug coverage (r = -0.20, p < 0.01).  
This finding makes common sense, the more RA medications a patient is prescribed the 
greater the total monthly RA medication costs will be.  Patients who lack prescription drug 
coverage will have lower total medication costs because they are less likely to be prescribed 
expensive medications for which they will have to pay the total cost. 
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Table 15. Correlation matrix assessing relationships among independent variables predicting communication about 
medication costs, medication management, and patient-reported medication satisfaction. a 
 Female Age HS or less 
education 
Low 
income 
Married White Hispanic RA 
severity 
Pain Prior 
visits 
No drug 
coverage 
Number 
RA 
drugs 
Total 
drug 
costs 
Female 1.000             
Age 0.011 1.000            
HS or 
less 
education 
0.009 0.109 1.000           
Low 
income 
0.103 0.214** 0.443*** 1.000          
Married -0.269*** -0.059 -0.157* -0.470*** 1.000         
White -0.087 0.099 -0.159* -0.286*** 0.201** 1.000        
Hispanic 0.060 0.065 0.102 0.087 -0.021 -0.054 1.000       
RA 
severity 
0.112 0.071 0.094 0.179* -0.139 -0.027 0.089 1.000      
Pain 0.220** -0.133 0.220** 0.163* -0.088 -0.196** -0.047 0.327*** 1.000     
Prior 
visits 
-0.084 -0.103 -0.060 -0.059 0.038 -0.024 -0.051 0.025 0.010 1.000    
No drug 
coverage 
-0.171* -0.143* 0.122 0.252*** -0.059 -0.109 -0.049 0.059 0.020 0.156* 1.000   
Number 
RA drugs 
0.172* 0.094 0.035 -0.092 0.021 0.090 0.080 0.222** 0.143* -0.232** -0.159* 1.000  
Total 
drug 
costs 
0.019 0.070 -0.002 -0.132 0.062 0.014 0.009 0.084 0.096 -0.128 -0.197** 0.393*** 1.000 
a
 Based on two-tailed tests: * p < 0.05,  ** p < 0.01, *** p < 0.001 
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Logistic Regression Results 
 In the next step of the analysis, logistic regression was used to assess predictors of 
medical visit communication about medication costs, patient-initiated regimen changes, and 
overall medication regimen changes.  As discussed in the methods chapter, the group sizes 
of the dependent communication variables limited the number of predictors that could be 
entered into the models and still produce reliable test statistics.   For the main models only 
significant patient, physician, and medication bivariate predictors were entered into the 
regression equations.  To test the robustness of the main models separate regressions were 
run including all significant bivariate predictors, as well as physician characteristics and 
patient and medication variables that were significantly different by physician.  The purpose 
of these multivariable logistic regression models was to test the impact of other significant 
variables on the main predictors of interest and they should be considered sensitivity 
analyses for the main regression models.  The results of these models should be interpreted 
with caution.  They are tempered by the inclusion of increasing numbers of variables, 
reducing the stability of the estimates, and will not be interpreted directly but only assessed 
for their impact on the magnitude and variability of the beta-coefficients of the significant 
variables from the main models.   
For each of the dependent communication variables of interest, the main 
multivariable logistic regression models are based on significant bivariate patient, physician, 
and medication predictors of communication and are always Regression 1.  For each of the 
models, Regression 1 is always based on the complete case sample of 192.  The additional 
regression models run as sensitivity analyses are Regressions 2-4.  Regression 2 presents 
the predictors of the communication variables of interest based on all statistically significant 
bivariate predictors.  All Regression 2 models are also based on a complete case sample of 
192.  Regression 3 presents the predictors of the communication variables of interest based 
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on all the significant bivariate predictors in combination with the variables that differed by 
physician. Regression 4 builds on Regression 3 by including physician variables when they 
were not already significant bivariate predictors of the communication variable of interest.  
Only for the medication cost communication outcome variable were there no significant 
bivariate associations with physicians characteristics so Regression 4 data including 
physician variables is only presented for medication cost communication.  Regressions 3 
and 4 are based on a complete case sample of 166.  The study samples did not differ 
substantially by patient, physician, or medication characteristics.  Also, as discussed in the 
section on missing data, the results of regression models run using the imputed dataset had 
few differences from those run using the complete cases.  Each regression equation was 
stratified on physician to account for the enrollment of patients within physician.  For each of 
the equations, there were five physician strata.  Further, for each model robust standard 
errors were calculated to account for unknown forms of heteroskedasticity in the models.  
 
Predictors of medication cost communication 
 Table 16 presents the logistic regression results obtained when testing the predictors 
of medication cost communication.  Examining the results of Regression 1, including 
significant patient, physician, and medication bivariate predictors of medication cost 
communication, revealed that patients who identified as White/Caucasian and those with no 
prescription drug coverage had significantly greater probability of communicating about 
medication costs in the medical visit.  Results indicated that for White patients the odds of 
communicating about medication costs are 2.5 times the odds of other patients (p < 0.05).   
This finding indicates that White patients were more likely to discuss medication costs and 
physicians were more likely to engage patients in medication cost discussions if they were 
White.   
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Perhaps as expected, results indicated that lacking prescription drug coverage was 
significantly related to communicating about medication costs (p < 0.05).   Patients lacking 
prescription drug coverage had over two and a half times the odds of discussing medication 
costs in the medical visits as patients who had partial or generous prescription drug 
coverage (OR 2.8, 95% CI 1.2 – 6.5). 
Regression 2, examining all the significant bivariate predictors of medication cost 
communication, revealed that all variables remained significant predictors of the probability 
of communicating about medication costs in the medical visit.  Patients who identified as 
White/Caucasian and those with no prescription drug coverage still had significantly greater 
odds of communicating about medication costs than patients who did not identify as White 
or who had partial or generous prescription drug coverage.  For patients who discussed self-
initiated regimen changes in their medical visit, their odds of communicating about 
medication costs were 3.3 times the odds of patients who did not discuss self-initiated 
regimen changes (p < 0.001).   The strength and statistical significance of this relationship is 
interesting and adds further evidence to support the idea that some form of mutual 
disclosure may be involved with talking about medication costs and disclosing patient-
initiated changes to the medication regimen.   
 Looking at Regression 3, with the inclusion of variables that differed significantly by 
physician, and Regression 4, with the inclusion of physician characteristics, results revealed 
that all three variables that were significant predictors of medication cost communication in 
Regression 2 remained significant.  In fact, in models 3 and 4 the strength of the 
significance of the relationship between patient-initiated regimen change discussions, 
White/Caucasian race, having no drug coverage, and communication about medication 
costs increases.  This finding means that even when controlling for the effect of additional 
variables in the regression models these variables are still significant predictors of 
communicating about medication costs in the medical visit.  Results indicate there is no 
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support for hypothesis two of aim two that discussions of medication cost would be more 
likely to occur when patients were female, younger, more educated, had higher income, and 
more severe RA.  In fact, there is no support that any of these variables are significantly 
related to communication about medication costs. 
 While it is interesting that the results in Regression 4 indicate that communication 
about medication costs is significantly more likely to occur with White/Caucasian physicians 
and younger physicians, these results must be interpreted with caution because of the 
inclusion of nine predictor variables in the model.  The results provide some support for 
hypothesis one of aim two, that discussions of medication cost would be more likely to occur 
among physicians who are younger.  However, this finding must be interpreted with caution. 
It may be that some characteristics of physicians do matter in communication about 
medication costs and these variables are picking up the effect but in the interest of not 
making inferences beyond what the data will support, the finding is briefly noted here. 
 
Predictors of patient-initiated regimen change communication 
 Table 17 shows the results when testing the predictors of communication about 
patient-initiated medication regimen changes.  Regression 1 shows the results of the model 
that included the patient, physician, and medication variables that were significant bivariate 
predictors of patient-initiated regimen change communication.  Results revealed that only 
the physician variables were significant predictors of communicating about patient-initiated 
medication regimen changes in the medical visit.  The physician variables female (OR 0.43, 
95% CI 0.24 – 0.79) and age (OR 1.04, 95% CI 1.02 – 1.10) were significant in Regression 
1, indicating that male and older physicians were more likely to communicate about patient-
initiated regimen changes than younger or female physicians. 
Regression 2 shows the results of the regression model that included all of the 
significant bivariate predictors of patient-initiated medication regimen change 
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communication.   In Regression 2, medication cost communication, physician gender, and 
physician age all significantly predicted disclosure of patient-initiated medication regimen 
changes in the medical visit.  Although discussion of overall medication regimen changes 
and patient age were significant bivariate predictors of patient-initiated regimen change 
communication, they were not significant in the multivariable model.  
Communicating about medication costs in the medical visit was associated with a 3.5 
times greater odds of also communicating about patient-initiated medication regimen 
changes in the visit (p < 0.001).  The finding indicates approximately the same increase in 
communication likelihood as found in the previous regression on communication about 
medication costs.  The relationship indicates that communication about medication costs or 
patient-initiated regimen changes increases the chance of communicating about the other 
topic by an approximately similar magnitude.  Communication about medication costs 
remained a significant predictor of communication about patient-initiated regimen changes 
after the addition of variables that differed significantly by physician in Regression 3 (p < 
0.001). 
The physician variables female (OR 0.5, 95% CI 0.27 – 0.87) and age (OR 1.1, 95% 
CI 1.02 – 1.10), which were significant in Regression 1, remained statistically significant 
predictors of patient-initiated regimen change communication in Regression 2. The inclusion 
of variables that differed significantly by physician in Regression 3 strengthened the 
significance of the findings on the physician variables and indicated that physician race was 
also a significant predictor of communication about patient-initiated regimen changes.  
White/Caucasian physicians were more likely to communicate about such regimen changes 
than physicians who did not identify as White/Caucasian (p < 0.01).  These findings run 
counter to hypothesis one of aim two which hypothesized that medication management 
communication would be more likely to occur with physicians who are female and younger.  
The finding here that older, male, White physicians are more likely to communicate about 
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patient-initiated regimen changes is not surprising since the physician who most patients 
disclosed their self-initiated regimen changes to was an older, White male.  As mentioned 
earlier, this physician was significantly different on this variable even when compared to 
another older, White male physician so it is entirely possible that this physician represents 
an outlier and he and his behavior matter more than any of his demographic characteristics.  
Examination of the medical visit transcripts revealed that this physician engaged in more 
social talk and had longer visits than most other physicians in the study. 
 
Predictors of having medication regimen changed during the medical visit 
 Table 18 presents the multivariable logistic regression equations predicting 
medication regimen changes.  As before, Regression 1 contains the patient, physician, and 
medication variables that were significant bivariate predictors of having the medication 
regimen changed, Regression 2 contains all variables that were significant bivariate 
predictors of having the medication regimen changed, and Regression 3 contains those 
variables plus ones that differed significantly by physician.  Results indicate that patient age, 
pain, and having no drug coverage were the most consistent predictors of having the 
medication regimen changed at the visit.  Patients under 55 years old had approximately 
two times the odds of having their regimen changed as patients 55 years old and older (OR 
2.04, 95% CI 1.22 – 3.43).  Patients reporting greater pain also had greater odds of having 
their medications changed than patients reporting less pain (OR 1.16, 95% CI 1.06 – 1.27).  
Patients lacking prescription drug coverage were 1.6 times more likely to have their regimen 
changed than patients with partial or generous prescription drug coverage (p < 0.01).   
 In Regression 1, physician gender was marginally significant (p = 0.05), indicating 
male physicians had greater odds of making regimen changes than female physicians.  
When additional variables were included in Regressions 2 and 3 this variable was no longer 
a significant predictor of regimen change communication.  Similarly, in Regression 2 model 
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results indicted that patients who had seen the study physician fewer than five prior times 
were more likely to have their regimens changed than patients who had seen the study 
physician five or more times (p = 0.05).  This finding was only marginally significant and 
when controlling for fewer variables in Regression 1 and additional variables in Regression 
3, the number of prior physician visits was no longer a significant predictor of having the 
medication regimen changed.  The other three predictors (patient age, pain, and lacking 
drug coverage) all remained significant predictors of having the medication regimen 
changed in Regression 3 when control variables that differed by physician were added to 
the model.   
It is interesting that neither communicating about medication costs nor discussing 
patient-initiated regimen changes are significant predictors of having the medication regimen 
changed.  This finding indicates that although changes are disclosed and discussions of 
cost issues are addressed, patients may not have subsequent changes made to their 
medication regimens.  The finding that talking about medication costs does not predict 
medication regimen changes is especially interesting given that lacking prescription drug 
coverage is a significant predictor of having the regimen changed.  The finding could 
indicate several possible scenarios: physicians may be aware of patient insurance status 
and make changes to the regimen without needing to talk about costs; conversations about 
cost may prohibit a regimen change if the discussion reveals patients cannot afford a 
medicine; or not having drug coverage means that patients and physicians must cycle 
through several sub-optimal therapies to select the one that works best for the price. 
These regression results also support the distinction between medication regimen 
change communication generally and patient-initiated medication regimen change 
communication.  The two communication variables had very little overlap in predictors.  For 
medication regimen changes overall, patient age, pain, and insurance coverage all impacted 
whether the regimen was changed during the visit. In contrast, physician characteristics 
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were the biggest predictors of whether patient-initiated regimen changes were discussed in 
the medical visit.  Further communication about patient-initiated regimen changes did not 
predict having the medication regimen changed.  Based on the results, these two variables 
appear to address different areas of medication management.  It is interesting that patient-
initiated regimen change communication is strongly related to medication cost 
communication but neither variable is related to having the medication regimen changed.  
The variable nature of the relationship of medication cost communication with medication 
regimen change communication and patient-initiated regimen change communication may 
highlight important differences in the relationship between medication cost communication 
and medication management.  
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Table 16. Multivariable logistic regression results for predictors of medication cost communication including: significant 
patient, physician, and medication bivariate predictors (Regression 1, N = 192), all significant bivariate predictors 
(Regression 2, N=192), significant bivariate predictors and characteristics that differed by physician (Regression 3, N = 
166), and significant bivariate predictors, characteristics that differed by physician, and physician characteristics 
(Regression 4, N = 166). 
 
 Medication Cost Communication a           
 Regression 1   Regression 2   Regression 3   Regression 4   
Variable 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
White 2.52 1.01 1.15 – 5.54 0.02 2.51 0.98 1.17 – 5.39 0.02 2.51 0.82  1.32 – 4.78 0.01 2.37 0.77  1.25 – 4.48 0.01 
No drug 
coverage 2.78 1.19 1.20 – 6.45 0.02 3.09 1.03 1.62 – 5.92 0.001 3.15 0.95  1.75 – 5.70 <0.001 3.1 1.19  1.46 – 6.57 <0.001
Patient-
initiated 
regimen 
change 
discussed 
    3.32 0.49  2.49 – 4.43 <0.001 3.37 0.45  2.59 – 4.38 <0.001 3.57 0.66  2.48 – 5.13 <0.001
RA severity           1.38 0.49  0.69 – 2.76 0.36 1.41 0.53  0.68 – 2.93 0.35 
Number RA 
medications 
    
     1.01 0.11  0.82 – 1.25 0.91 1.04 0.11  0.84 – 1.28 0.75 
Fewer than 
5 prior visits 
    
     0.85 0.26  0.47 – 1.53 0.58 0.78 0.23  0.43 – 1.40 0.40 
MD female 
    
          1.3 0.4  0.71 – 2.37 0.39 
MD White 
    
          1.48 0.26  1.04 – 2.09 0.03 
MD age 
    
      
 
      0.98 0.003  0.98 – 0.99 <0.001
a
 Standard errors adjusted for 5 physician strata.  
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Table 17. Multivariable logistic regression results regressing communication about patient-initiated medication regimen 
changes on significant patient, physician, and medication bivariate predictors (Regression 1, N = 192), all significant 
bivariate predictors (Regression 2, N=192), and significant bivariate predictors plus characteristics that differed by 
physician (Regression 3, N = 166). 
 
a
 Standard errors adjusted for 5 physician strata. 
 Communication about patient-initiated regimen changes a      
 
Regression 1   Regression 2   Regression 3   
Variable 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Age – Under 55 2.24 0.98 0.96 – 5.26 0.06 1.94 0.94  0.75 – 5.04 0.17 1.66 1.03  0.49 – 5.59 0.42 
MD female 0.43 0.13 0.24 – 0.79 <0.01 0.48 0.15  0.27 – 0.87 0.02 0.39 0.12  0.22 – 0.70 <0.01 
MD age 1.04 0.01 1.01 – 1.07 <0.01 1.06 0.02  1.02 – 1.10 0.01 1.03 0.11  1.01 – 1.05 <0.01 
Medication Cost 
Communication     3.52 0.45  2.74 – 4.53 <0.001 3.22 0.63  2.19 – 4.72 <0.001 
Medication Regimen 
Changed     1.89 0.86  0.78 – 4.59 0.16 2.33 1.06  0.96 – 5.69 0.06 
MD White        1.82 0.32  1.29 – 2.57 <0.01 
White 
    
      0.76 0.31   0.34 – 1.71 0.51 
RA severity 
    
      0.77 0.24   0.42 – 1.41 0.40 
No drug coverage 
    
      
 
 0.47  0.39   0.09 – 2.36 0.36 
Fewer than 5 prior 
visits 
    
   
 0.50 0.38  0.11 – 2.21 0.36 
Number RA 
medications 
    
   
 0.87 0.16  0.61 – 1.24 0.44 
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Table 18. Multivariable logistic regression results regressing medication regimen changes on significant patient, physician, 
and medication bivariate predictors (Regression 1, N = 192), all significant bivariate predictors (Regression 2, N = 192), and 
significant bivariate predictors plus characteristics that differed by physician (Regression 3, N = 166). 
 
a
 Standard errors adjusted for 5 physician strata. 
 
 
 Medication regimen changed during medical visit a       
 
Regression 1   Regression 2   Regression 3   
Variable 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Odds 
Ratio 
Robust 
SE 95% CI p 
Age – Under  55 2.04 0.54 1.22 – 3.43 <0.01 1.88 0.46  1.17 – 3.03 0.01 2.20 0.47  1.45 – 3.33 <0.001 
White 3.02 2.08 0.79 – 11.66 0.11 2.91 1.98  0.76 – 11.04 0.12 3.09 2.16  0.78 – 12.18 0.11 
Pain 1.16 0.06 1.06 – 1.27 <0.01 1.15 0.06  1.04 – 1.27 <0.01 1.13 0.04  1.04 – 1.21 <0.01 
Fewer than 5 prior 
visits 2.92 1.74 0.91 – 9.38 0.07 2.93 1.60  1.01 – 8.52 0.05 2.88 2.15  0.67 – 12.44 0.16 
No drug coverage 1.60 0.26 1.17 – 2.19 <0.01 1.62 0.27  1.16 – 2.25 <0.01 1.63 0.41  1.00 – 2.67 0.05 
MD female 0.52 0.17 0.27 – 0.99 0.05 0.56 0.21  0.27 – 1.16 0.12 0.63 0.31  0.24 – 1.65 0.35 
MD age 0.96 0.02 0.92 – 1.01 0.08 0.95 0.03  0.90 – 1.01 0.11 0.95 0.04  0.88 – 1.02 0.17 
Patient-initiated 
regimen changes 
discussed     
1.89 0.91  0.73 – 4.87 0.19 1.96 0.86  0.84 – 4.61 0.12 
RA severity         1.12 0.21  0.78 – 1.61 0.55 
Number RA  
medications         1.14 0.09  0.97 – 1.33 0.12 
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Results of Aim 3 – Examination of the impact of discussions of medication cost, 
patient-initiated regimen changes, and overall regimen changes on patient-reported 
medication satisfaction. 
 The purpose of this aim was to examine how discussions of medication cost and 
medication management in routine clinic visits between rheumatologists and patients with 
RA affect patient-reported medication satisfaction.  Results in this section are based upon 
the sample of 192 patients for which complete data were available on the outcome 
variables. First, descriptive information on patient-reported medication satisfaction is 
presented.  Second, bivariate associations  among communication, patient, physician, and 
medication characteristics and high versus low medication satisfaction are presented. 
Bivariate associations between discussions of medication cost, discussion of regimen 
modification, patient initiated regimen changes and high versus low medication satisfaction 
using a Mantel Haenszel test, stratified on physician, are also presented.  Third, multiple 
logistic regression results examining the influence of discussions of medication costs and 
patient-initiated regimen changes on patient medication satisfaction are presented. 
 
Descriptive Data  
Patient-reported Medication Satisfaction 
 As shown in Table 19, there were no patients who reported being not at all satisfied 
with the medications they were supposed to take until their next medical visit.   Overall, 
patients in the sample were satisfied with their medications and responses were right-
skewed toward the more positive response categories.  For the purposes of analysis, this 
variable was transformed into a dichotomous low versus high satisfaction variable.  Low 
satisfaction was comprised of the 24 patients (12.5%) reporting they were ‘a little’ or 
‘somewhat’ satisfied with their medications and high satisfaction was comprised of the 166 
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patients (87.5%) reporting they were ‘very’ or ‘totally’ satisfied with the medications they 
were supposed to take until their next visit. 
 
Table 19. Categories of patient-reported medication satisfaction (N = 192). 
 
Patient-reported medication satisfaction Number of Patients (%) 
Not at all satisfied with medications prescribed  0 (0.0) 
A little satisfied with medications prescribed    2 (1.04) 
Somewhat satisfied with medications prescribed  22 (11.46)        
Very satisfied with medications prescribed  52 (27.08)      
Totally satisfied with medications prescribed  116     (60.42) 
  
Bivariate Results 
Patient-reported medication satisfaction by communication, patient, physician, and 
medication, characteristics 
Table 20 shows the differences in communication, patient, physician, and medication 
characteristics by low and high patient medication satisfaction.  Chi-square statistics were 
calculated for the cross-tabulation of low versus high medication satisfaction and categorical 
variables.  T-tests were conducted to test the association between low versus high 
medication satisfaction and the continuous variables.  To take into account the positive skew 
in the total monthly RA medication cost variable, the non-parametric Wilcoxon rank-sum test 
was used to assess the relationship between this variable and patient-reported medication 
satisfaction.   
Of all the communication, patient, physician, and medication characteristics, only one 
had a statistically significant association with medication satisfaction.  Patients who talked 
about medication costs in the medical visit were more likely to report low satisfaction with 
their medications (p = 0.02).  Twenty percent of patients talking about medication costs in 
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their medical visit reported low medication satisfaction while only 9% of patients who did not 
talk about medication costs reported low satisfaction.  This finding runs counter to 
hypothesis five that patients who discuss medication costs would be more likely to report 
being satisfied with their medications.  There may be several potential reasons for the 
difference and it is notable that the presence of an association is not indicative of causality.  
It is possible that patients experiencing cost pressures discussed them in their visits but no 
solutions were found so patients were left feeling less satisfied with their medications.  It is 
also possible that patients’ assessment of satisfaction included medication costs and 
discussion of medication costs was a marker of low medication satisfaction.   
There were no significant relationships between discussion of patient initiated 
regimen changes or discussion of modifying the regimen and patient-reported medication 
satisfaction.  In fact, 12.5% of patients disclosing medication regimen changes reported low 
medication satisfaction and 12.5% reported high medication satisfaction, an even 
proportion.  The finding of no difference in satisfaction based on talking or not talking about 
patient-initiated regimen changes runs counter to the hypothesized relationship postulated in 
hypothesis six of aim three.  That hypothesis stated that patients discussing medication 
management in their medical visits would be more likely to report being satisfied with their 
medications.   Similarly, there were no differences in patient reported medication satisfaction 
based on whether the medication regimen was changed at the visit.  Fourteen percent of 
patients who had their medication regimens changed at the visit reported low satisfaction 
and 11% of patients who did not have their regimens changed at the visit reported low 
satisfaction. 
Similar proportions of patients reporting low satisfaction compared to high 
satisfaction were female, married, white, non-Hispanic, and lacked prescription drug 
coverage.  As may be expected, patients reporting low medication satisfaction reported 
higher mean levels of pain than patients reporting high medication satisfaction (5.2 versus 
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4.2).  While the differences were not significant, patients with a high school education or less 
were more likely to report high satisfaction (90.5%) than patients with more than a high 
school education  (84%) and patients with annual incomes under $40,000 were more likely 
to report low medication satisfaction (15%) than patients with annual incomes of $40,000 or 
more (9%). 
There were no significant differences in the percent of patients reporting low 
medication satisfaction by physician characteristics.   However, more patients reporting low 
medication satisfaction saw female physicians than male physicians and younger physicians 
than older physicians.   
There were also no significant differences in medication characteristics among 
patients reporting low versus high medication satisfaction.  However, it was interesting that 
patients reporting low medication satisfaction had higher median total monthly medication 
costs ($366.81) than patients reporting high medication satisfaction ($240.65).  Patients 
reporting low medication satisfaction also were taking more medications on average than 
patients reporting high medication satisfaction (4.5 versus 4.2 medications). 
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Table 20. Patient-reported medication satisfaction by communication, patient, 
physician, and medication characteristics (N=192).  
 
 Patient-Reported Medication Satisfaction a 
Variable b 
Low (n=24)  
 Frequency (%) 
High (n=168) 
Frequency (%) 
Characteristics of Communication 
  
 Discussion of medication costs   
  Yes  13 (20.3)  51 (79.7) 
  No  11 (8.6)  117 (91.4) * 
 Discussion of patient initiated changes to the 
medication regimen   
   Yes  5 (12.5)  35 (87.5) 
   No  19 (12.5)   133 (87.5) 
 Discussion of modifying medication regimen   
   Yes  14 (14.3)  84 (85.7) 
   No  10 (10.6)  84 (89.4) 
Patient Characteristics   
 Gender   
  Female  18 (12.7)  124 (87.3) 
  Male  6 (12.0)  44 (88.0) 
 Age, mean (std dev)  63.7 (9.8)  62.3 (9.1) 
 Education    
  High school or less  9 (9.5)  86 (90.5) 
  More than high school  14 (15.9)  74 (84.1) 
 Income   
  Less than $40,000  16 (15.1)  90 (84.9) 
  $40,000 or more  6 (8.7)  63 (91.3) 
  Marital status   
  Married  12 (11.1)   96 (88.9) 
  Not married  11 (14.7)  64 (85.3) 
 Race   
  White  17 (12.4)  120 (87.6) 
  Non-White  7 (12.7)  48 (87.3) 
 Ethnicity   
  Hispanic  0 (0.0)  2(100.0) 
  Non-Hispanic  23 (12.6)  160 (87.4) 
ACR Classification of Global Functional 
Status   
(I)   No restriction of ability to perform 
normal activities  4 (8.2)  45 (91.8) 
(II)   Moderate restriction  
 10 (11.5)   77 (88.5) 
(III)  Marked restriction 
 6 (23.1)   20 (76.9) 
(IV) Incapacitation or confinement to a 
bed or wheelchair  1 (25.0)   3 (75.0) 
  
Self-rated pain, mean (std dev) 
 
  
 5.2 (2.6) 
 
  
 4.2 (2.8) 
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 Patient-Reported Medication Satisfaction a 
Variable b 
Low (n=24)  
 Frequency (%) 
High (n=168) 
Frequency (%) 
 Prior visits with physician    
  Fewer than five  7 (17.9)   32 (82.1) 
  Five or more  17 (11.1)   136 (88.9) 
 Prescription drug coverage   
  No coverage  5 (13.9)   31 (86.1) 
  Partial or generous coverage  19 (12.2)   137 (87.8) 
Physician Characteristics 
  
 Gender   
  Female  14 (15.1)   79 (84.9) 
  Male  10 (10.1)   89 (89.9) 
 Race   
  White  13 (12.0)   95 (88.0) 
  Non-White  11 (13.1)   73 (86.9) 
 Age, mean (std dev)  44.2 (6.8)  46.6 (8.3) 
Medication Characteristics 
  
 Cost of medications, median (range) 366.81(61.84-5087.57) 240.65(0-4860.01) 
Number of RA medications prescribed, mean 
(std dev)  4.5 (1.4)  4.2 (1.6) 
a Significance level of the chi-square statistic for categorical variables, two-tailed t-test for continuous 
variables, and Wilcoxon rank-sum for non-normally distributed continuous variables:  * p < 0.05,  ** p 
< 0.01, *** p < 0.001 
b Totals for individual variables may be less than 192 due to missing data.  
 
 
 Looking further at the relationships between medication satisfaction and communication 
about medication costs, patient-initiated regimen changes, and visit changes to the 
medication regimen, the communication variables were stratified on physician and their 
relationship to high versus low medication satisfaction was calculated using the Mantel-
Haenszel chi-square statistic.  The null hypothesis of the test is that the odds ratios for the 
variables within physician are equal to one.  The odds ratios are equal to one when the 
proportions within physicians are the same, indicating no differences in variables when 
controlling for physician.  Looking at the relationship between medication satisfaction and 
communication about medication costs, stratifying on physician, the Mantel-Haenszel chi-
square statistic is 4.26 with an accompanying p-value of 0.04.  These results indicate that 
the null hypothesis can be rejected; the differences in medication satisfaction among those 
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who communicate about medication costs remain after controlling for physician.  As with the 
bivariate analyses, there were no significant differences in satisfaction by patient-initiated 
regimen change communication or medication regimen changes using the Mantel-Haenszel 
and stratifying on physician.  However, the results of the Mantel-Haenszel tests must be 
interpreted with caution due to the small number of patients reporting low medication 
satisfaction; these findings may or may not be suggestive of actual relationships. 
 
Logistic Regression Results 
 
 As mentioned in the methods section, the goal had been to use multivariable logistic 
regression to separately examine the influence of discussions of medication cost and 
discussion of regimen modification on patient medication satisfaction after taking into 
account patient, physician, and medication characteristic variables.  In addition, multiple 
logistic regression was going to be used to measure the influence of the interaction between 
medication cost discussion and regimen modification discussion on medication satisfaction 
while controlling for patient and physician variables.  However, the relatively few 
respondents (n=24) reporting low medication satisfaction presented a challenge to 
multivariable modeling.   This constraint meant that only a couple of predictors could be 
entered into logistic regression models and be expected to produce stable estimates from 
the regression equations.  To address this issue, only predictor variables that were 
statistically significant in the bivariate analyses were modeled in the multivariable analysis.  
However, issues of model building were largely avoided since bivariate analyses revealed 
few significant relationships between high versus low medication satisfaction and patient, 
physician, medication, and communication characteristics.  In fact, the only significant 
bivariate predictor of patient-reported medication satisfaction was medical visit 
communication about medication costs.   
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 As an exploratory analysis, three multivariable logistic regression models were run 
looking at predictors of low patient-reported medication satisfaction.  Table 20 shows the 
results of these regressions.  Regression 1, based on the complete case sample of 192, 
shows the regression of medication cost communication on low medication satisfaction.  
Regression 2 based on a sample of 166 contains the predictor medication cost 
communication and the variables that differed significantly by physician.  Regression 3 
builds on Regression 2 with the addition of physician characteristics.  The smaller complete 
case sample in Regressions 2 and 3 did not constitute a dramatically different sample based 
on comparisons of patient, physician, and medication characteristics.  Additionally, when the 
regression models were run using a multiply imputed dataset the model results did not 
change substantially from those generated with the complete case dataset.   Each 
regression equation was stratified on physician to account for the enrollment of patients 
within physician.  For each of the equations, there were five physician strata.  Further, for 
each model, robust standard errors were calculated to account for unknown forms of 
heteroskedasticity in the models. 
 Looking at the regression results, medication cost communication was not a 
significant predictor of medication satisfaction.  In fact, none of the variables were significant 
in Regression 1 or 2.  In Regression 3, being a female physician and younger physician age 
appeared to be significant predictors of low medication satisfaction but with so many 
variables in the model and so few patients reporting low satisfaction the stability of the 
estimates are in question.  In sum, none of the measured variables can be determined to be 
reliable predictors of patient-reported medication satisfaction in the sample.  With so few 
patients reporting low medication satisfaction, it is unclear whether any of the findings are 
detecting an actual relationship between variables or are simply an artifact of having so little 
diversity in patient-reported medication satisfaction. 
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Table 21.  Multivariable logistic regression results for regressing low medication satisfaction on significant bivariate 
predictors (Regression 1, N = 192), significant bivariate predictors and significant characteristics by physician (Regression 
2, N = 166), and significant bivariate predictors, significant characteristics by physician, and physician characteristics 
(Regression 3, N = 166) 
 
a
 Standard errors adjusted for 5 physician strata. 
 
 Low Medication Satisfaction a        
 Regression 1   Regression 2   Regression 3   
Variable 
Odds 
Ratio 
Robust 
Standa
rd 
Error 
95% 
Confidence 
Interval p 
Odds 
Ratio 
Robust 
Standard 
Error 
95% 
Confidence 
Interval p 
Odds 
Ratio 
Robust 
Standard 
Error 
95% 
Confidence 
Interval p 
Medication cost 
communication 2.71 1.47  0.94 – 7.86 0.07 2.48 1.53  0.74 – 8.31 0.14 2.54 1.69  0.69 – 9.34 0.16 
White     0.73 0.25  0.37 – 1.44 0.36 0.81 0.25  0.44 – 1.49 0.50 
RA severity     1.61 0.80  0.61 – 4.29 0.34 1.58 0.78  0.60 – 4.17 0.35 
No drug 
coverage    1.03 0.58  0.35 – 3.08 0.95 0.88 0.52  0.28 – 2.80 0.84 
Fewer than 5 
prior visits    1.62 0.46  0.93 – 2.82 0.09 1.20 0.17  0.90 – 1.59 0.21 
Number RA 
medications    1.07 0.18  0.78 – 1.48 0.67 1.12 0.20  0.79 – 1.60 0.51 
MD female       1.48 0.11  1.29 – 1.71 <0.001 
MD White       0.92 0.16  0.66 – 1.28 0.62 
MD age        0.94 0.01  0.93 – 0.95 <0.001 
  
 
 
 
 
 
CHAPTER SIX: DISCUSSION 
 
 
 The purpose of this dissertation was to better understand communication about 
medication cost and medication management between patients with RA and 
rheumatologists and its effect on patient-reported medication satisfaction.  This study helps 
address gaps in the literature regarding communication between physicians and patients 
about medication cost and medication management.  While the healthcare literature has 
stressed the importance of patient-physician communication about medication costs, this 
was one of the first studies to examine the content and predictors of actual discussions of 
medication cost in the context of medication management (Alexander et al., 2003; 
Alexander et al., 2004).  Both qualitative and quantitative methods were used to examine 
communication about medication costs, communication about patient medication 
management, and the impact that such communication has on patient medication 
satisfaction.  The following sections summarize the findings and discuss the implications of 
the qualitative and quantitative results, discuss the major limitations and strengths of the 
study, and present potential directions for future research. 
 
Summary of findings 
Medication cost communication 
Looking at the descriptive data, results indicated that patients in the sample had total 
monthly medication costs ranging from $3.10 to $4,860.01 for patients taking one or more 
RA medications.  Within the range of total medication costs, there was a gap in total costs 
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between patients prescribed biologic therapies and those not prescribed biologic therapies.  
Patients prescribed TNF-α inhibitors had median total monthly medication costs that were 
over eight times more than the median total monthly medication cost of a patient not 
prescribed a biologic therapy.  The finding of great differences in medication costs between 
patients prescribed and not prescribed biologic therapies is consistent with the work of other 
researchers looking both at total costs and patient OOP medication costs (Goldman et al., 
2006; Michaud et al., 2003).  This provides some support that use of a total RA medication 
cost variable derived from published average wholesale prices likely has the same trends as 
actual cost values.  Further, the similarity between the medication cost values derived in this 
study and actual total and OOP costs found by others lends credence to the idea that the 
values in this study likely performed in a similar manner in the analysis to actual costs or 
OOP costs, had they been available. 
Audiotape analysis results revealed that 34% of visits contained discussions of 
medication cost, a higher rate than has been reported in previous studies of patient-
physician communication about medication costs.  A recent examination of actual visit 
communication between patients and physicians about the cost of newly prescribed 
medicines found that among a sample of family physicians, internists, and cardiologists 
medication costs were only discussed for 12% of newly prescribed medications (Tarn et al., 
2006)  A number of factors could account for this discrepancy.  First, this analysis was not 
limited to medical visits in which new prescriptions occurred as in the prior study (Tarn et al., 
2006).  The approach undertaken in this study may more accurately reflect the prevalence 
of medication cost discussions since it takes into account communication about both new 
and continued medications.  Second, our sample was drawn from adults under the care of a 
specialist for a chronic condition which generally requires ongoing medication use.  The 
patient sample in Tarn et al. (2006) was slightly younger (mean age 55) without a specific 
chronic illness seeing family physicians, internists, or cardiologists.  Finally, participants in 
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our study all had a diagnosis of RA and new breakthroughs have led to the development of 
potentially more effective but more expensive RA medications (DeWitt et al., 2006).   
A recent study by Wilson and colleagues (2007) lends further support that 
communication about medication costs may be more likely in older patient populations with 
chronic conditions.  They conducted a survey of over 17,000 community dwelling Medicare 
beneficiaries 65 years and older living in low-income neighborhoods in all 50 states and 
found that 30.9% reported talking with their doctor about medication costs and 41.3% with 
three or more chronic conditions reported talking with their doctor about medication costs 
(Wilson et al., 2007).  Given that the population in the study reported here was older and 
had at least one chronic condition for which they were seeking care from a specialist it is 
perhaps not surprising that the prevalence of medication cost communication falls between 
the rates found by Wilson et al (2007). 
Interestingly there were no differences in whether patients or physicians discussed 
medications costs based on whether patients were prescribed biologic RA medications.  The 
finding is interesting because of the high total and out-of-pocket costs associated with these 
medications.  The finding could indicate that total medication cost burden or cost burden 
relative to income matters more than the cost of any singular medication. It is also possible 
that were not differences by biologic medication prescription because physicians simply did 
not offer and did not discuss those medications with patients they felt could not afford such 
medications.  More information is needed on the impact of patient and physician perceptions 
of cost burden to better understand the impact on communication about specific 
medications. 
It is also worth noting that cost pressures may still burden the 66% of patients not 
discussing medication costs.  This study measured communication about medication costs 
and not patient perception of medication cost burden; it is possible and even likely that a 
portion of the patients not discussing medication costs were burdened by them. While it is 
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encouraging that one-third of the sample discussed medication costs, it is important to 
remember that among the two-thirds of patients not discussing medication costs some may 
be significantly impacted by their RA medication costs and not addressing these issues with 
their rheumatologists. 
Study results indicated that the majority of patients did not ask questions during 
medication cost discussions.  Previous research has found that patients are reluctant to ask 
questions about medications during medical visits, a finding which appears to extend to 
medication costs as well (Sleath et al., 2003).  However, physicians did ask medication cost 
questions, often initiating medication cost communication with patients.  The presence of 
physician-question asking, especially at the outset of medication cost discussions is 
indicative of the beginning of a participatory dialogue as it requires active patient 
engagement in the conversation.  Further, physician question asking is important because it 
allows the physician to assess the patient point of view (Sleath et al., 2003).  These results 
provide some evidence that physicians are trying to engage patients in communication when 
medication costs are discussed in the medical visit.  The discovery that physicians were 
relatively active questioners in medication cost discussions was possible because of the 
analysis focus on the content of medical visit communication. 
In past research, communication about medication costs has been measured in large 
surveys often using a single question or couple of questions to assess whether patients can 
recall communicating with physicians about medication costs (Piette et al., 2004b; Wilson et 
al., 2007).  Such measures are subject to patient recall bias and, through limited questions, 
address medication cost communication as a single concept.  In this study, audiotape 
analysis permitted examination of actual communication about cost, avoiding the pitfalls of 
recall bias, thereby allowing a deeper examination of communication about medication 
costs.  Examining the specific content of medication cost communication permitted a 
comprehensive understanding of the cost topics that patients and physicians were covering 
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and the role that the each participant played in the communication.  Developing a deeper 
understanding of medication cost communication will help move toward more fully 
developed conceptions and theories of such communication and the impact it has on patient 
outcomes like medication adherence.  Prior scholarship examining conceptual models of 
patient responses to medication cost pressures have conceptualized communication about 
medication costs as solely in the purview of physicians (Piette, Heisler, Horne et al., 2006).  
However, the results of this study indicate that patients actively initiate medication cost 
discussions and that medication cost communication is not a monolithic concept but is 
comprised of several components.   
 In this study, medication cost communication was comprised of the categories 
insurance coverage and strategies to reduce patient OOP medication expenses.  
Associated with the category insurance coverage was the subcategory insurance coverage 
affecting patient OOP costs.  Associated with the category strategies to reduce patient OOP 
costs are the subcategories medication assistance programs, importing medications, and 
medication samples.   
By engaging patients in conversations about insurance coverage, physicians are 
increasing their own awareness of patients’ medication cost burdens (Alexander et al., 
2003).  Through discussion of insurance coverage and the impact on patients’ OOP costs, 
physicians have more information available for the prescription decision-making process.   In 
this study, when such discussions happened, physicians overwhelmingly selected 
medications for patients that were covered by their insurance.  
In the second major category, general strategies to reduce patient OOP medication 
costs the conversations generally took one of two forms.  The first was physicians 
discussing prescribing or medication use that would reduce OOP costs and the second was 
patients discussing their desire to reduce medication costs by being prescribed less 
expensive medicines or eliminating medicines from their regimens.  Patient discussion of 
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their desire to reduce OOP medication expenses is somewhat surprising given past 
literature indicating that patients rarely, if ever, disclose to physicians that they want to 
reduce or eliminate medications to lower costs (Donovan & Blake, 1992; Piette et al., 
2004b).  However, these discussions are critically important because they provide 
physicians with an opportunity to help patients differentiate between necessary and 
discretionary medications and doses when faced with cost pressures (Benedetti et al., 
2008). 
Under the major category of strategies to reduce patients’ OOP medication costs, 
three distinct subcategories of communication were discovered.  With the first, medication 
assistance programs, patients and physicians discussed several types of programs.  Not 
surprisingly, all communication about medication assistance programs happened with 
patients who had no or partial prescription drug coverage and all but one had an annual 
income below $40,000.  All conversations were aimed at providing patients access to 
medications they would not otherwise be able to afford or receive.  It is encouraging that 
communication about medication assistance programs is happening with the patients these 
programs are designed to help.  The literature on prescription drug assistance programs 
recommends that physicians and other health practitioners become aware of such programs 
and direct patients toward programs for which they are eligible (Chisholm & DiPiro, 2002).  
In this rheumatology setting, both patients and physicians had an awareness of medication 
assistance programs and results support that in many cases physicians were directing 
patients towards programs for which they were eligible.  Even with Medicare Part D, 
research indicates that pharmaceutical assistance programs represent an important cost 
savings avenue for low-income persons (Havrda, Omundsen, Bender, & Kirkpatrick, 2005).  
The second subcategory, importing medicines, was geographically interesting 
because the sample was drawn from North Carolina, a non-border state.  Further, while 
there were only two conversations about medication purchased outside the United States to 
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reduce medication costs, it represents an interesting and important policy issue.  Data from 
a 2003 large, nationwide survey of Medicare beneficiaries age sixty-five and older found that 
five percent of seniors said that they had purchased some of their prescription medications 
from Canada or Mexico (Safran et al., 2005).  Additional data indicated that the incidence of 
medications purchased outside the United States had been steadily increasing prior to 2003 
(Saatsoglou, 2004).  While the communication captured in this analysis was limited, it may 
be an indication of the increasing trend of purchasing medications abroad and demonstrates 
that at least some seniors are discussing their foreign-purchased medications with 
physicians.  Prescription drug counterfeiting and the potential for tampering are just some of 
the risks associated with foreign-purchased prescription drugs (Saatsoglou, 2004).  Patient-
physician communication about such purchases may place physicians in a difficult position 
because, while they want patients to be able to obtain the medications they prescribe, 
without chemical tests they have no way of validating that foreign-purchased medications 
are indeed the ones prescribed. 
 The third subcategory discussed under strategies to reduce OOP medication costs 
was medication samples.  In eleven medical visits the provision of medication samples was 
discussed.  There was diversity in patient characteristics in discussions of medication 
samples but a clear physician effect because one physician talked the most about sample 
provision.  The physician effect is perhaps not surprising.  One physician in the sample 
appeared to have greater access to and supplies of medication samples than the other 
physicians in the study.  The lack of difference in characteristics among patients receiving 
samples is counter to recent literature on the topic.   An analysis of medication sample 
receipt using data from the 2002 Medical Expenditure Panel Survey found that sample 
recipients were more likely to be White and female (Alexander, Zhang, & Basu, 2008).  
While the provision of medication samples has been suggested as one strategy to assist 
patients burdened by medication costs, the use of samples in the office setting has been 
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contested (Alexander & Tseng, 2004; Alexander et al., 2008).  Some argue that the 
provision of samples provides patients access to medications and helps physicians become 
familiar with new medications, while others argue that sample use encourages use of newer 
more expensive medications over older but as effective medicines.  Further, opponents of 
sample provision argue that the strategy is unsustainable and ultimately increases patient 
prescription costs (Alexander et al., 2008).  In this study, patients generally received 
samples of medicines for which there were no equivalent generic medications.  However, 
the issue of sustainability still remains since it was unclear whether patients could stay 
reliably stocked with samples. 
 The results of the qualitative analysis provided some clues about the relationships 
that were discovered in the quantitative analysis.  Qualitative examination of communication 
about medication costs revealed that all conversations about the impact of insurance 
coverage on OOP costs happened with patients who identified as White/Caucasian.  
Qualitative analysis also revealed that communication about medication assistance 
programs and general strategies to reduce OOP costs occurred more often with patients 
who had no or only partial prescription drug coverage.  Building on these findings, 
multivariable logistic regression results found lacking prescription drug coverage and 
White/Caucasian patient race to be significant predictors of medication cost communication.   
Patients lacking prescription drug coverage had nearly three times the odds of 
communicating about medication costs as patients who had partial or generous prescription 
drug coverage.  This finding is slightly higher than an earlier study of coverage and 
communication about costs.  A 2003 telephone survey of primary care patients in Los 
Angeles found that the variable that most powerfully predicted the likelihood patients and 
physicians would discuss OOP costs was patients’ pharmacy benefit design (Shrank et al., 
2006).  Patients without prescription drug coverage were 2.3 times more likely to discuss 
OOP costs with their physicians than patients paying no co-payments (p< 0.001).  In the 
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present study, my focus on patients with RA and the use of observational, as opposed to 
survey, methods may partially account for the increase in the magnitude of the relationship 
between lacking drug coverage and communication about medication costs.   
A surprising finding was that patients identifying as White/Caucasian were 
approximately 2.5 times more likely to communicate about medication costs in their medical 
visits than patients not identifying as White/Caucasian.  The racial differences in 
communication about medication costs may be due to several factors.  Recent research on 
RA medication costs found that drug costs for non-Hispanic, White patients were $443 
greater for a 6-month period than for non-White patients (Michaud et al., 2003). 
Put in the context of other research on racial differences in medical visit 
communication, this finding makes sense.  Cooper-Patrick and colleagues found that 
African-American patients had significantly less participatory medical visits with their 
physicians than White/Caucasian patients (Cooper-Patrick et al., 1999).  Perhaps due to 
non-White patients’ feelings of differential participatory engagement in the medical visit, they 
were less likely to bring up medication cost topics and physicians were less likely to address 
the issue as well.  The research literature has demonstrated that non-White patients often 
have less active communication behaviors in medical visits and physicians are less 
participatory and are less likely to engage non-White patients in communication (Gordon, 
Street, Kelly, Souchek, & Wray, 2005; R. L. Johnson, Roter, Powe, & Cooper, 2004). In a 
counter finding, Heisler and colleagues discovered in their survey study of over 4000 
patients that physicians were more likely to ask non-White patients about medication cost 
issues (Heisler, Wagner, & Piette, 2004). Regardless of the mechanism through with the 
difference in cost communication is operating, the finding that medication cost conversations 
were more likely to occur with White/Caucasian patients is troubling.  Several research 
studies have indicated that non-White patients may be more likely to be burdened by their 
medication costs and are more likely to restrict their medication use for cost-related reasons 
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(Piette, Heisler, Horne et al., 2006; Soumerai et al., 2006; Steinman, Sands, & Covinsky, 
2001).  In fact, Steinman and colleagues found that non-White Americans were almost three 
times as likely to report cutting back on medication use due to cost problems as 
Whites/Caucasians, even when controlling for OOP costs, overall health and drug coverage, 
income, and health status indicators (Steinman et al., 2001). 
If non-White patients are less likely to discuss medication costs but more likely to 
alter their medication taking because of cost reasons, then this is an important area to 
address in medical visit communication.  Pre-visit questionnaires can ask patients about 
medication cost issues but perhaps more importantly communication skills can be taught to 
both patients and physicians.   Patients can be coached on active participation and question 
asking in medical visits.  A prior randomized controlled trial showed that patients who were 
coached to ask questions and negotiate medical decisions were more active participants in 
medical visits than patients in the control condition who did not receive such training 
(Greenfield, Kaplan, & Ware, 1985).  Further, training physicians about racial disparities in 
medical visit communication may improve communication with patients from different 
cultural backgrounds (Carrillo, Green, & Betancourt, 1999; Culhane-Pera, Reif, Egli, Baker, 
& Kassekert, 1997).   
Communication about medication costs was significantly related to communicating 
about patient-initiated regimen changes.  Logistic regression results revealed that patients 
talking about one had at least 2.5 times the odds of talking about the other.  As has already 
been mentioned, these findings indicate mutual disclosure in this population, where 
discussion of one topic was more likely to generate discussion of the other.  The reasons for 
this may have something to do with the nature of disclosure in the medical visit and patients 
feeling comfortable sharing information with their physician.  Physicians using patient-
centered communication behaviors have been shown to be positively associated with 
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patient participation and expression of concern in the medical visit, regardless of the specific 
subject matter (Zandbelt, Smets, Oort, Godfried, & de Haes, 2007). 
 
Communication about patient-initiated changes to the medication regimen 
Looking at patient disclosure of self-initiated medication regimen changes, in 21% of 
the recorded medical visits patients and physicians discussed patient-initiated changes to 
the medication regimen.  Patient-initiated changes to the medication regimen were those 
that required a behavior change on the part of the patient and were entirely patient initiated 
and directed.  Just as examination of medication cost communication revealed multiple 
categories, examination of patients’ actions to manage their RA medications revealed 
several communication categories.  Communication about patient-initiated medication 
regimen changes, revealed three primary categories.  Of the 40 patients disclosing self-
initiated regimen changes in the medical visit, 18 discussed taking more medication than 
had been prescribed, five substituted one medication for another, and 17 discussed taking 
less medication or discontinuing prescribed medication.   A 1992 interview and medical visit 
observation study of patients with RA found patients engaged in similar medication 
modification behaviors (Donovan & Blake, 1992).  Out of their sample of 54 patients, 
interviews revealed 25 to be what they considered ‘non-compliers’, 10 no longer took their 
medications, 13 took fewer pills than prescribed, and two took more medication than 
prescribed (Donovan & Blake, 1992).  These results reveal that patients in both this sample 
and the prior RA sample were active managers of their medications, choosing to take more 
or less medication.  However, in this study patients were revealing these behaviors to 
physicians: something that Donovan and Blake did not discover in their patient sample.  In 
that study, none of the patients that altered their DMARD regimens disclosed that to 
physicians in the recorded medical visits (Donovan & Blake, 1992).  The discovery that 
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nearly a quarter of patients in this sample disclosed regimen changes is encouraging and 
important.  Patient revelations to physicians about self-initiated changes to the regimen are 
important because they offer a powerful opportunity for patients and physicians to reassess 
the medication regimen and explore other regimen issues, such as costs and medication 
administration. Almost unanimously, the patient changes to the regimen discussed in the 
sample reduced the patients’ total RA medication cost burden. 
Logistic regression results revealed that physician age and gender were significant 
predictors of communication about patient-initiated medication regimen changes.  However, 
as was mentioned in the results chapter, patients overwhelmingly disclosed self-initiated 
regimen changes with a particular physician in the sample.   Even when comparing this 
physician to another with similar demographic characteristics, there remained significant 
differences in patient disclosure of medication regimen changes.  Of special note, the 
physician that elicited more patient disclosure of self-initiated regimen changes had longer 
visits on average than most other physicians and engaged patients in more social talk than 
all other physicians.  Further, the same physician had seen all patients in the sample more 
than five times, some for many years.  The combined effect of longer ongoing relationships, 
longer visit times, and more social talk in the visit may have made it easier for patients to 
disclose their regimen changes.   
Regardless of the mechanism supporting the disclosure, the revelations provided 
valuable information.  Patients disclosed changes that represented potential drug safety 
issues as well as issues of effectiveness.  Some patients were adding medications to the 
regimen that could potentially result in overdose and some patients were substituting 
medications that were known to be less effective.  The disclosures provided an opportunity 
to reassess the regimen and discuss the appropriateness of the medicines patients were 
actually taking, as opposed to the ones they were supposed to be taking. A recent survey of 
420 patients who were prescribed DMARDs found that 34% of patients actively altered their 
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medications (Lim, Ellis, Brooksby, & Gaffney, 2007).  It is likely that the patients who 
revealed medication modifications were a fraction of the total number modifying their 
regimens.  Patients are active agents in medication taking whether they disclose their 
management issues to physicians or not.  Physicians may be well served to recognize the 
primacy of patients in medication taking and ask patients open-ended questions about how 
they are using their medications. 
 
Medication regimen changes 
Interestingly, analysis results revealed that neither talking about medication costs nor 
patient-initiated regimen change communication was predictive of having the medication 
regimen changed during the medical visit.  Overall medication regimen change 
communication resulting in a regimen change was distinct from patient-initiated regimen 
change communication.   The measure of medication regimen change was whether the 
physician actually made a change to the regimen during the visit, while patient-initiated 
regimen changes were patient focused and directed.  The results indicated there was no 
significant relationship between medication regimen change communication overall and 
patient-initiated regimen change communication.  This reinforces that the two variables are 
addressing different aspects of medication management.  Overall discussion of medication 
regimen changes in a medical visit may represent a shared decision-making opportunity or 
physician-directed process depending on the communication.  Patient-initiated regimen 
changes and disclosure of such changes are manifestations of patient autonomy and may 
represent intentional patient dissent (Elwyn et al., 2003).  On the communication and 
decision-making spectrum, these two concepts represent different ends.  Medication 
regimen changes are largely within the purview of physicians, while patient disclosures of 
self-initiated changes are largely in the patients’ domain, thus representing different areas of 
medication management communication. 
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The lack of clear association between medication regimen changes and 
communication about medication costs or patient-initiated regimen changes is neither 
positive nor negative.  Discussion of costs and patient regimen changes may provide 
physicians with information or assuage patient feelings and be useful without resulting in a 
regimen change.   
Looking at the multivariable logistic regression results, four factors significantly 
predicted having the regimen changed during the visit.  The variables patient age under 55 
years-old and fewer than five prior visits with the study physician were predictive of having 
the regimen changed, but not strongly so. These could be patients with more recent RA 
diagnoses for whom an effective RA medication regimen had yet to be found.  The strongest 
predictors of having the RA medication regimen changed were patient pain rating and 
lacking prescription drug coverage.  Patient pain may be a sign of uncontrolled RA; 
therefore, medication regimen changes to better control the disease make intuitive sense.  
The increased odds of a medication regimen change due to lack of prescription drug 
coverage is an interesting finding.  For patients lacking prescription drug coverage, 
expensive, but effective biologic medications may not be an option and they may have to 
cycle through other, less-expensive medications to address their RA.  
 
Patient medication satisfaction 
 In bivariate assessments, patients talking about medication costs appeared to be 
more likely to report low medication satisfaction.  However, the relationship did not remain 
when using logistic regression where no variables clearly predicted low medication 
satisfaction.  Assessments of factors significantly related to and predictive of medication 
satisfaction were limited in this study by the small variation in patient-reported medication 
satisfaction.  Just over 60% of the sample said they were totally satisfied with the 
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medications they were supposed to take until their next visit, the highest rating possible.  
Patients were asked the item on medication satisfaction by a research interviewer, which 
may have encouraged patients to respond more positively than had they responded to the 
item in a survey.  Alternately, it is possible that patients in the sample were genuinely very 
satisfied with their medications.  To better assess medication satisfaction, the study would 
have benefited from using multiple items to assess satisfaction.   Had multiple items been 
available all assessing the latent medication satisfaction construct, it is possible and 
perhaps likely that there would be greater variation in patient medication satisfaction.  
Current recommendations in the research literature suggest using multiple items to assess 
medication satisfaction (Shikiar & Rentz, 2004). 
 Prior research with patients with RA found that patient perception of a high-level of 
involvement in medical decisions was significantly associated with satisfaction (Kjeken et al., 
2006). Other research indicates that physician communication is related to medication 
satisfaction and adherence (Bultman & Svarstad, 2000).  Bultman and Svarstad argue that a 
collaborative physician approach where physicians respond to patients by acknowledging, 
reassuring, clarifying, recommending steps for coping, and/or changing medications can 
have a powerful effect on medication satisfaction and use (Bultman & Svarstad, 2000).   
These studies relied on patient perception of communication and satisfaction, whereas this 
study relied on observational assessment of communication and the impact on satisfaction.  
The differences between their significant findings and the lack thereof in this study may be 
partially due to the measurement differences.  Research has shown greater correlation 
between perception measures of behavior and satisfaction than observation measures 
(Street, 1992).  However, patients’ perceptions of physician behavior or medical visit 
activities are components of their perception of satisfaction so it makes sense that these two 
are highly correlated (Arora, 2003).  This measurement issue may contribute to the finding 
of significant associations between perceptions of communication and satisfaction and limits 
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the ability to draw meaningful conclusions from the data.  While such measurement issues 
were not present in this study because of the use of observed communication measures, the 
results demonstrated no clear relationships between communication characteristics and 
medication satisfaction, inviting further research. 
It is also important to note that, while this study asked patients to rate their 
medication satisfaction, it is possible and perhaps even likely patients’ feelings about overall 
treatment or healthcare delivery system satisfaction influenced their medication satisfaction 
ratings (Shikiar & Rentz, 2004).  Medication cost communication and communication about 
patient-initiated medication regimen changes may have only had minor influence on patient 
satisfaction ratings.  If patients’ satisfaction ratings were influenced by factors beyond 
medications and their medication communication was a minor influence on their ratings, this 
would further explain the lack of clear relationship between the communication variables of 
interest and patient-rated medication satisfaction. 
 
Implications 
 Communication about medication costs and medication management are features of 
medical visits between patients with RA and rheumatologists.  Medication cost 
communication and patient disclosure about self-initiated regimen changes are multifaceted 
concepts with implications for patient care. 
Active discussion about medication costs during the prescription decision-making 
process may have several benefits.  First, it may increase the likelihood that physicians and 
patients will agree on a course of treatment.  Second, engaging patients in medication cost 
discussions may facilitate patient participation in the larger clinical decision-making process.  
Third, studies have shown that for older patients, both with and without prescription drug 
coverage, levels of OOP medication costs seem to influence drug utilization (R. E. Johnson, 
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Goodman, Hornbrook, & Eldredge, 1997; Steinman et al., 2001). Thus, initiating 
conversations about medication use in relation to cost gives physicians opportunities to 
assess and negotiate treatment options until both parties are comfortable with a particular 
plan.  Fourth, prescription drug coverage clearly matters in facilitating or hampering access 
to medications for RA patients.  In the absence of universal prescription medication 
coverage, physicians can inquire about patient drug coverage and dialogue about 
medication costs to help their patients make difficult choices among medically beneficial 
medicines (Piette, Heisler, & Wagner, 2006).  Without such consultation, patients are 
making these decisions without physician input and advice. 
Patients’ disclosures of self-initiated regimen changes are admissions of non-
adherence since they fundamentally represent a departure from the prescribed medication 
regimen.  Labeling patients as non-adherent is negative and labeling communication about 
such disclosures this way certainly cannot be expected to facilitate patient admissions of 
regimen changes.  Further, use of adherence as a standard of behavior presupposes that 
patients are better off taking all their medications as prescribed, a finding that may not 
always be true.  Research examining the use of NSAIDs found that patients who adapted 
their medication intake and varied their dose according to their symptoms were less likely to 
be hospitalized for upper gastrointestinal bleeding than patients who rigidly adhered to 
prescribed doses (Herxheimer, 1998; Wynne & Long, 1996).   
A more flexible approach on the part of physicians and health services researchers 
to medication taking behaviors and communication in the medical visit may be in order.  The 
results of this study demonstrated that patients disclosing regimen changes were active 
managers of their medications and disclosure about their behaviors in the visit was an 
important gateway to medication communication.  Further, the strong relationship between 
communication about medication costs and patient-initiated regimen changes may indicate 
the presence of a disclosure effect in the medical visit where communication about 
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medication costs may lead to communication about patient-initiated medication regimen 
changes and visa versa.  Encouraging medical visit communication that facilitates patient-
involvement and disclosure may be more likely to elicit greater information from patients.  
Reducing the emphasis on medication adherence and compliance and encouraging greater 
patient participation in medication communication and decision-making are core concepts of 
medication concordance.  Concordance advocates the sharing of power in the patient-
physician relationship and is used specifically to describe communication about 
medications.  The aim of concordance is to,  “involve patients in making decisions about 
their medicines, to ensure that they have enough information for doing this, and to support 
them with any problems they might have (Pound et al., 2005).”   Issues of medication cost 
and management are not uncommon for patients with chronic illness and recognition and 
explicit support of these issues in medical visits is likely to benefit both patients and 
physicians.   
 The lack of clear association between communication about medication costs or 
medication management and patient-reported medication satisfaction, as well as the other 
study findings encourage revision of the conceptual framework that guided this study.  
Figure 5 presents a revised conceptual framework that builds on the results of this study and 
was developed to understand factors that influence medical visit communication and the 
factors that impact medication selection and use.  The framework draws upon the results of 
this study and emphasizes areas of potential impact and intervention.  To increase the 
applicability of the framework, it emphasizes potential alterable medical visit communication 
factors rather than insurance and financial system factors which are highly variable and 
more challenging to change.     
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Figure 5.  Revised conceptual framework for understanding medical visit 
communication about medication costs and medication management and the impact 
on medication selection and use. 
Physician Medical Visit Communication
Communication about medication management
* Follow-up with patients who disclose taking more, less, or substituting
medications
* Ask patients in a nondirective open-ended way about how they use   
their medications to elicit actual patient medication management    
behaviors
Communication about medication costs
* Engage patients in conversation about medication costs when 
prescribing medications
*Ask about prescription drug coverage
*Ask about patient perception of medication affordability
* Assess patient medication cost burden and ability to afford current
medications
*Direct patients to medication assistance programs for which they
are eligible 
Predisposing Factors                                      Communication Factors                                                 Outcomes                                                     
Financial Pressures
• Drug coverage
• Cost-sharing
Physician 
Characteristics
• Socio-demographics
Patient 
Characteristics
• Socio-demographics
• Disease status
Patient Medical Visit Communication
Communication about medication management
*Share details about medication taking behaviors
Communication about medication costs
*Engage in medication cost conversations
Selection of 
medications that fit 
patients’ context
Patient adherence to 
prescribed 
medications
 
 This framework emphasizes the significant predictors of patient and physician 
medical visit communication and subsequent medication selection and use, while placing 
heavy emphasis on potential areas of intervention. Moving from left to right, the following 
paragraphs describe each of the model elements. 
The quantitative results emphasized the influence of financial pressures on medical 
visit communication about medication costs.  Results revealed that patients lacking 
prescription drug coverage were more likely to discuss medication costs in their medical 
visits than patients who had partial or generous drug coverage.  In addition, the qualitative 
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results revealed that insurance coverage was a major theme of medication cost 
communication in the studied medical visits.  Qualitative results revealed the impact of 
insurance coverage on OOP costs to be a subcategory of insurance coverage, with 
communication largely focusing on co-payments or coinsurance amounts that would be 
incurred through the prescription of particular medications.  Based on these results, both 
drug coverage and cost sharing are thought to be important financial pressures that can 
precipitate communication about medication costs.  Physicians who believe their patients 
are more likely to be burdened by medication costs may be more likely to discuss costs in 
the medical visit and patients who are more burdened by medication costs may have more 
incentive to discuss medication costs and medication management in the medical visit. 
Lacking drug coverage and high medication cost-sharing arrangements have been 
shown to influence cost-related medication non-adherence (Briesacher, Gurwitz, & 
Soumerai, 2007).  Patients are more likely to modify their regimens by taking less 
medication or substituting less expensive medications in their regimens if they lack 
prescription drug coverage or have unfavorable cost-sharing arrangements.  When 
physicians are aware that cost is an issue, they are more likely to prescribe medications for 
patients they can afford (Lundin, 2000).  Therefore, financial pressures can be expected to 
directly influence the medications selected for patients and patients’ subsequent adherence 
to those medications. 
In the revised conceptual model, physician characteristics are the second proposed 
influence on patient and physician medical visit communication and subsequent medication 
selection and use.  The results of this study indicated that physician demographic 
characteristics were significantly associated with communication about patient-initiated 
medication regimen changes, as well as medication regimen changes overall.  While the 
small number of physicians in the study tempers the results, findings in the research 
literature show differences in patient and physician communication by physician 
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characteristics.  The literature documents that older physicians generally use less 
participatory decision-making than younger physicians (Epstein et al., 2004).  Female 
physicians have been shown to engage in more patient centered communication than males 
(D. L. Roter & Hall, 2004).  Further, physician race has been shown to influence perceptions 
of participatory decision-making when patients are in racially concordant relationships 
(Cooper-Patrick et al., 1999) Therefore, physician characteristics are likely to influence 
physician communication in the medical visit.  
Physician characteristics also have the potential to impact patient communication in 
the medical visit.  Patients in this study were more likely to initiate medication cost 
conversations in medical visits if physicians were younger.  This finding is consistent with 
other medical visit communication research, which found that patients were more likely to 
ask questions of younger physicians (Sleath et al., 1999).It could be that patients feel more 
comfortable raising issues or asking questions of younger physicians or it could be that 
younger physicians are less proactive about raising certain issues or provide less 
information than older physicians.  Other communication research has also demonstrated 
the potential impact of physician characteristics on patient communication.  A study by 
Cooper and colleagues (2003) examining recorded medical visits found that patients display 
more positive affect in medical visits with physicians of the same race than when patient and 
physician were of different self-identified race.  In the study, positive affect was a summation 
of patient engagement, interest, friendliness, and responsiveness in the medical visit 
(Cooper et al., 2003).  Based on the results of my study and the findings in the research 
literature physician demographics can be expected to influence patient communication in 
the medical visit.  
Finally, physician characteristics can be expected to directly influence the medicines 
selected in the medical visit.  For patients with chronic illnesses like RA physicians can 
choose from a number of therapies from inexpensive generics to expensive branded drugs 
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(Fischer & Avorn, 2004).  While there are guidelines for the selection of medications in 
rheumatoid arthritis, there are over 170 possible DMARD combinations from among the non-
biologic DMARDs alone (Saag et al., 2008).  Physicians are able to exercise a good deal of 
discretion in selection medications for the treatment of rheumatoid arthritis.  Further, 
physician demographics have been shown to influence medication selection (Davidson, 
Molloy, & Bedard, 1995; Schnitzer et al., 2003).   With physician latitude in physician 
prescribing and differences in prescribing by physician demographics, physician 
characteristics can be expected to directly influence medication selection.  
In the third box down on the left side of the revised conceptual model, patient 
characteristics are expected to influence physician communication, patient communication, 
and medication selection and use.  Most communication about insurance coverage and all 
communication about the impact of insurance coverage on OOP costs happened with 
patients who identified as White/Caucasian.   Quantitative results supported these findings 
indicating that patients who identified as White/Caucasian were more likely to have 
medication costs discussed in their medical visits than patients who identified as African 
American or other race/ethnicity.  This finding points both to patient and physician 
communication because it indicates that physicians were less likely to address medication 
costs with patients who were non-White and non-White patients were less likely to bring up 
medication costs.  Other research looking at the impact of patient race on physician 
communication found opposite results to those reported here but nonetheless the results 
underscored the influence of patient race on physician communication.  Heisler and 
colleagues (2004) found that, independent of whether they reported experiencing burdens 
related to medication costs, patients who were African American or of other minority 
race/ethnicity had higher odds of being asked by physicians about medication cost problems 
than white patients. 
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Patient gender is another factor that affects both physician and patient medical visit 
communication.  Female patients receive more information, ask more questions, and have 
more collaborative relationships with physicians than male patients (Cooper-Patrick et al., 
1999; Sleath & Rubin, 2002).  By virtue of asking more questions and being more actively 
involved in medical visit communication, female patients not only communicate differently 
than their male counterparts they also receive different responses and reactions from 
physicians. Thus, female patient gender influences patient communication and also 
physician communication since physicians tend to build more collaborative medical visit 
relationships with female patients than male patients.  More educated patients have also 
been be shown to want to participate more actively in medical visit communication than less 
educated patients (Sleath & Rubin, 2002).   Similarly, younger patients often prefer to be 
more involved in medical decision-making than older patients (Chewning & Sleath, 1996).  
Active participation on the part of patients may mean that they are more likely to provide 
information to physicians about their medication management and cost issues or their active 
participation may trigger physicians to ask more about medication cost and use.   As an 
example, in this study younger patient age had a bivariate association with disclosure of 
patient-initiated regimen changes.  This means that younger patients were more likely to 
disclose their regimen changes and physicians were more likely to elicit information on 
patient-initiated regimen changes from younger as opposed to older patients. 
Beyond patient demographics, patient pain and disease severity may influence 
patient desire to address medication management and cost issues.  In this study, patients 
were more likely to initiate medication cost conversations if they rated their pain lower than 
patients who did not initiate medication cost conversations.  Patients with lower pain levels 
may have felt more flexibility discussing medication costs than patients with highly 
symptomatic RA.  Based on these results, patient disease severity can be expected to 
influence patient medical visit communication.  From the physician point of view, research 
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has shown that physicians may be more likely to ask patients taking more medications 
about medication costs than patients taking fewer medications (Heisler, Wagner et al., 
2004).  Patients with more active disease are more likely to take more medications; in this 
way patient disease and treatment status can be expected to impact physician visit 
communication about medication costs.  In sum, both patient characteristics like disease 
severity and demographics can be expected to influence patient and physician medical visit 
communication.   
Characteristics of the patient can also be expected to directly impact medication 
adherence generally and cost-related medication non-adherence more specifically. Non-
white Americans have been shown to be more likely than Caucasians to report cutting back 
on medication use due to cost reasons, even when controlling for OOP costs, overall health, 
drug coverage, income and health status indicators (Steinman et al., 2001).  Older patients 
are less likely to forego medications when facing cost pressures than younger patients 
(Piette et al., 2004a; Steinman et al., 2001). 
Moving from the predictors of communication to the communication itself in Figure 5, 
physician communication can be expected to have a major impact on patient communication 
and subsequent medication selection and use.  Qualitative analysis in this study revealed 
the importance of communication about medication costs and medication management in 
the medical visit and specific communication in each of these areas are targeted as a guide 
for future intervention and research. The following paragraphs discuss physician medication 
cost and management communication and the recommended interventions in each area. 
Looking first at physician communication about medication management, study 
results revealed that approximately one out of five patients disclosed independently making 
changes to their regimens.  Conversations revealed many of these patients were taking 
more or less medication than prescribed with a few substituting a medication for one they 
had been prescribed.  To find out how patients actually use their medications and to 
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discover all the medications patients take, physicians should ask nondirective, open-ended 
questions about medication use.  Patients generally want to please their physicians and 
sometimes will respond to physicians with the answers they believe physicians want to hear.  
By acknowledging the difficulties of continual medication use and asking in a nonjudgmental 
way about medication use, physicians can make patients more comfortable and facilitate 
candid disclosure of their medication taking behaviors (Osterberg & Blaschke, 2005).  
Physicians can be taught skills that encourage nondirective communication and asking 
open-ended questions.  Physician education sessions using small groups that are learner 
centered and incorporate cognitive, experiential, and behavioral components have been 
shown to improve physician question-asking in the medical visit  (Fallowfield et al., 2002; 
Jenkins & Fallowfield, 2002; D. L. Roter, Cole, Kern, Barker, & Grayson, 1990).  These 
sessions can be tailored to focus on physician communication about patient medication use 
to encourage open-ended questions and open communication.  Similarly, small group skills 
training using presentations, discussions, simulated patients, and feedback to participating 
physicians has been successfully used to engender shared decision-making in medical 
visits (Edwards et al., 2004).  Principles of shared decision-making encourage patient 
involvement in the medical visit and nondirective communication.  The evidence 
demonstrating the success of small group skills training for physicians suggests that small 
group education sessions that focus on nondirective communication and open-ended 
question asking and then give physicians an opportunity to practice these skills and receive 
feedback may be highly effective in changing physician communication behavior.   
Once patients reveal to physicians that they are taking more, less, or substituting one 
medication for another, it is important that physicians follow-up with patients about these 
behaviors.  Study results indicated that some patients were taking potentially dangerous 
combinations of medications and some were substituting medications that were known to be 
less effective.  Physician skills training should focus on communication follow-up to find out 
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why patients have altered their medication regimens.  Patients may alter their regimens 
because of side effects, issues with medication administration, dose timing, or cost.  
Differentiating among the causes of patient-initiated regimen changes is critical for 
addressing the root causes of the regimen changes.  For example, a physician that asks a 
patient in a nondirective way about a medication regimen change and discovers the patient 
has made the change because of the OOP costs of the medication can work to address the 
cost issue by directing the patient to assistance programs or selecting an alternative, more 
affordable medication. 
To make a difference in the area of physician communication about medication 
management, an intervention study could be designed that focuses on using small group 
educational techniques to build physician communication skills to elicit patient disclosure of 
medication regimen changes and then to follow-up on those disclosures.  The intervention 
should capitalize on the experience gained from previous studies and use cognitive, 
behavioral, and experiential components with repeated sessions to improve physician 
uptake.  The effect of the intervention should be tested through a randomized trial 
comparing physicians who have had the training to physicians using usual practices to see if 
physicians who have had the skills training elicit greater patient disclosure of regimen 
changes and to see if there is a difference in medication selection and use between the 
groups. 
 As mentioned throughout this study, medication cost and medication management 
communication appear to have a relationship with each other and physician communication 
about medication costs is just as important as communication about medication 
management.  Study results indicated that communication about medication costs occurred 
in approximately one-third of recorded medical visits and slightly more than half of those 
conversations were initiated by physicians.  Medication cost conversations provided 
physicians with information on patient insurance coverage as it would affect prescribing, 
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patients who had purchased medication from abroad, and patients who needed assistance 
paying for their medications.   
Because of the potentially significant impact of medication costs on medication use 
and the helpful information elicited in conversations about medication costs, physicians 
should routinely engage in conversations about medication costs when prescribing 
medications.  Physicians should be prompted to routinely ask about patients’ prescription 
drug coverage. With the diversity of drug plans and changing tier copayment levels within 
plans, asking about prescription drug coverage can initiate communication about medication 
costs.  Physician prompts to discuss insurance coverage could come from patient pre-visit 
questionnaires, prompt screens in electronic medical records, or flags included in patient 
charts.   
Beyond asking about insurance coverage alone, physicians should probe patients 
about their perceptions of the affordability of the medications they are considering 
prescribing.   Different patients will perceive the same out-of-pocket medication costs 
differently.  The results of this study showed that medication cost conversations were not 
limited to only the very expensive biologic medications.  For patients who face other barriers 
to adherence, even relatively minor out-of-pocket costs may lead to medication underuse 
(Piette, Heisler, Horne et al., 2006).  To sensitize physicians to out-of-pocket medication 
costs and prompt communication about those costs simple tools can be given to physicians 
that list the relative out-of-pocket costs for commonly prescribed medications.  A previous 
study that provided physicians with pocket guides with the average wholesale prices of 
commonly prescribed drugs listed found  the guides had a modest effect on physicians’ 
awareness of medication costs and willingness to consider those costs when prescribing 
(Korn, Reichert, Simon, & Halm, 2003).  However, it may not be the costs of individual 
medications that impact patients the most.  To really understand the impact of out-of-pocket 
medication expenses, physicians need to understand patients total medication cost burden.  
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As was revealed in the exchanges in this study, many times it is not the out-of-pocket 
expense of a particular medication but the total monthly expenditure for all medications 
taken that was problematic for patients.  To address this issue, patients’ medication lists 
could be updated to include out-of-pocket expense amounts.  This information could be 
gathered by nurses and/or other allied health professionals that routinely collect pre-visit 
information from patients.  By tracking this information physicians would be aware of 
patients’ overall medication burdens when prescribing medications. 
By having documentation of patients’ overall medication cost burden, physicians 
could also initiate conversations about patients’ ability to afford their medications and direct 
patients to medication assistance programs for which they are eligible.  In this study, 
medication assistance programs discussed were operated by the pharmaceutical 
companies manufacturing the medications, a local hospital system, and the federal 
government.  With a limited number of assistance programs available for any given 
medication, assistance programs available for medications could be listed in a pocket guide, 
just as out-of-pocket costs could be listed.  In fact, it would be possible to create rheumatoid 
arthritis-specific cost-conscious prescribing guides.  This pocket reference could easily list 
commonly prescribed RA medications, their relative out-of-pocket costs by typical health 
plan or based on average wholesale prices and medication assistance programs by 
medication.   
Through communication about medication costs and medication management 
physicians become more aware of the personal context for patients’ medication taking.  
Through such communication physicians are better able to select medications that fit within 
patients’ contexts by prescribing medications that patients can afford to use and fit within 
their life circumstances.  Also, by communicating about medication management and cost 
issues physicians can impact patients’ subsequent medication adherence.  Prior research 
has demonstrated that patients’ medication adherence is better when physicians actively 
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assess potential barriers to adherence and provide clear messages about medication use 
(DiMatteo, 1995).  
In the conceptual model presented in Figure 5, physician and patient communication 
have a reciprocal relationship where communication from one impacts the communication of 
the other.  In addition to targeting physicians for communication interventions, it is important 
to also intervene with patients to improve their participation in medical visit communication.  
Efforts can be targeted toward patient activation to encourage their participation in the 
medical visit.  
In order for physicians to understand how patients are using their medications, 
patients must share this information.  To that end, it is important that patients be activated to 
share the details of their medication taking behaviors.  Written intervention materials in the 
form of patient workbooks could be provided to patients in the waiting room that focus on 
models of desirable communication and prompts for recording and discussing their 
medication information.  The written materials would prompt patients to think about medical 
visit communication and specific areas to discuss in advance of the visit.  Cegala and 
colleagues (2000) were able to demonstrate that provision of a workbook to patients prior to 
their scheduled medical visit increased the amount and quality of information these patients 
provided to their physicians (Cegala, McClure, Marinelli, & Post, 2000).  For patients that are 
routinely accompanied to the medical visit by a family member or friend, communication 
training efforts could be targeted at both the patient and family.  Intervention techniques 
using models of social support could be utilized to encourage support of patient 
communication about medications in the medical visit and active responses to physician 
inquiries.  Specifically, interventions could be aimed at both the patient and family 
member/friends to coach them on model communication behaviors and then provide them 
both an opportunity to practice those communication skills with each other. 
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Further, patients should be encouraged to engage in medication cost conversations.  
In this study some patient responses to physician inquiries about prescription drug coverage 
or out-of-pocket medication costs led to conversations that impacted the selection of 
medications.  Patients need to be encouraged to engage in medication cost conversations 
and provide enough detail to facilitate prescription decision-making.  To prompt patients to 
engage in medication cost communication, they must understand that the issue is of 
importance to the physician.  To demonstrate that the issue is of importance and to gather 
information for physicians, as mentioned above, nurses or other allied health professionals 
could routinely ask patients about out-of-pocket medication expenses as part of the pre-visit 
routine.  The nurse or allied health professional collecting the medication cost information 
could also ask patients the degree to which they feel burdened by their out-of-pocket costs 
and prompt patients to discuss the issue with physicians, if they indicate that they feel 
burdened by the costs.  The pre-visit exchange would also offer an opportunity for patients 
to practice communicating about medication costs and the nurse could provide 
encouragement and prompts to pursue particular topics with the physician in the medical 
visit.   
Patients who have been exposed to communication training interventions have been 
shown to provide physicians with more information and elaborate more in response to 
physician questions (Cegala et al., 2000).  The more information that patients can provide to 
physicians about their use of medications and medication costs, the more likely that 
medication prescribed in the medical visit will fit within the context of patients’ current 
medication use and financial constraints.  The more that prescribed medications fit within 
patients’ lives, the more likely it is that patients will use those medications.  In this way, 
patient communication can directly impact the selection of medications and subsequent 
medication adherence. 
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 The revised conceptual framework draws both upon the study findings and the 
research literature and heavily emphasizes interventions to improve communication.  
Patient-physician communication has shown to be a relatively consistent predictor of 
patients’ subsequent medication use (Osterberg & Blaschke, 2005).   Therefore, directing 
interventions toward altering patient and physician communication has the potential to 
impact and improve patients’ medication use.  Directing communication interventions at both 
patients and physicians is incredibly important because of the interdependent nature of 
medical visit communication.  Teaching patients and physicians communication skills to 
improve discussions about medication costs and medication management is sort of like 
teaching dance steps to two partners where the skills learned in each step come together to 
form a single flowing movement.  Through mutual interactions and genuine information 
exchanges, medications are more likely to be selected that are appropriate for the condition 
needing treatment and fit within the context of patients’ lives.  When medications are 
selected that fit the patients’ needs both medically and personally, patients are more likely to 
use those medications and to derive optimal therapeutic benefit.   
 
Limitations 
 This study has several limitations.  First, we examined only patients with RA and 
rheumatologists.  The results, therefore, may not generalize to other physician specialties or 
patient populations.  However, RA is an excellent model to study medication costs and 
management because it is a symptomatic disease that requires medications, many of which 
are very expensive.   Second, both patient and physician samples were convenience 
samples; self-selection biases are possible.   
Third, there was uneven recruitment by physician.  In the original study, it was 
difficult to recruit an even number of RA patients for each physician.  Physicians tended to 
specialize in seeing patients with different types of rheumatic conditions, resulting in 
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different patient pools for recruitment.  The uneven recruitment by physician necessitated 
grouping low-enrolling physicians together for regression analyses.  The fourth limitation, 
and an analysis issue, was the use of multiple testing.  Numerous statistical tests were 
performed, increasing the chances of Type I error.   
Fifth, some categories of the outcome variables of interest were small.  A larger 
sample size would have been beneficial to detect meaningful differences in the outcome 
variables of interest.  Future studies with larger sample sizes should provide more 
information.  
Sixth, the cross-sectional study design does not permit determinations of causal 
relationships among the variables.  The design is appropriate given that there is little other 
examination of actual medication cost communication, especially in an RA population and a 
deeper understanding of the communication itself was sought.  The study results should be 
considered exploratory in nature.  Given that this was an initial exploration, measurement of 
particular constructs was limited and the full set of factors affecting communication and 
medication satisfaction may not have been examined.  There was limited information on 
patients’ health insurance and there was no information available on patients’ particular 
prescription drug plans when constructing the plan generosity variable.  Therefore, the 
generosity of coverage had to be constructed from indirect information and may not reflect 
true plan generosity.  Further, there was no information on formularies of various plans, 
which would itself restrict drug choice and possibly medication communication.  There may 
be mediating variables that affect the relationship between patient-physician communication 
and medication satisfaction. The extent to which patients were burdened by OOP costs was 
not measured so there was no way to assess how many people needed help with 
medication costs but did not discuss it.  Nor was there information on whether patients 
restricted their medication use for cost reasons.  In fact, there were no measures of patient 
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medication taking behavior at the time of the medical visit so it is unclear how regularly 
patients were taking their medications that did not talk about cost or regimen changes. 
Finally, the presence of a tape recorder may have altered physician and patient 
behavior in the medical visit.  Although this seems unlikely to meaningfully affect 
conclusions since the data were collected for another purpose.  Patients and physicians 
were blind to research hypotheses, reducing the likelihood that they would have specifically 
altered their behavior in the areas of medication cost communication or disclosure about 
regimen changes. 
 
 
Strengths 
 
 Despite the limitations, this study has several strengths and makes an important 
contribution to the knowledge base about medication cost and management communication 
in RA medical visits.  First, this study is one of the first to examine communication about 
medication costs in a population of patients with RA.  Second, this study is one of the first to 
look simultaneously at medication cost communication and patient disclosure of medication 
regimen changes.  Third, the study looked at actual medical visit communication about 
medication costs and management, providing a deeper understanding of the content of such 
communication than has previously been reported.   The findings of specific categories and 
subcategories of medication cost and management communication add to our 
understanding of the taxonomy of these concepts.  Fourth, the use of both qualitative and 
quantitative methods permitted examination of both the content of medical visit 
communication and predictors of communication and outcomes.  Finally, the study provides 
practical guidance for clinical practice by identifying a strong relationship between disclosure 
of patient regimen changes and medication cost communications.  Medical visit disclosure 
of patient-initiated regimen changes may reveal cost issues and visa versa.  Through open 
communication and elicitation of patient thoughts and concerns both issues can be 
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addressed in the medical visit.  The revised conceptual model provides direct guidance on 
how open communication might be facilitated in the medical visit and may serve as a 
starting point for future efforts. 
 
Directions for Future Research 
 
 Both the implications and limitations discussed above suggest a number of future 
directions for research on medical visit communication about medication costs and 
management in RA and more generally.  First, the revised conceptual framework has 
interesting potential for further exploring and advancing communication about medications 
and warrants additional research.  Future studies should utilize intervention components 
mentioned in the revised conceptual framework to begin to systematically test the impact of 
these interventions on medical visit communication, as well as medication selection and 
use.  In the absence of comprehensive policies to address to medication cost issues, 
directing efforts to improve communication about cost and management could potentially 
have immediate impacts on medical visits and treatment selections.   
Second, the types of communication about medication costs and management may 
serve as a useful starting point for designing studies looking at the different constructs of 
cost and management.  The findings from the qualitative study are limited to the particular 
sample in which they were discovered.  Future studies examining the content of 
communication about medication costs and management in a different population of patients 
with RA would provide insight into whether the concepts are consistent across populations.  
Also, future studies should examine the order in which medication cost and management 
topics are discussed because there may be meaningful patterns based on the order topics 
are discussed within the visit.  It is possible that certain cost or management topics reliably 
lead to discussion of other cost or management topics.   Discerning these communication 
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patterns may provide guidance on how to maximize the benefit of communication focused 
educational interventions for patients and physicians. 
Third, there is a need to look at medical visit communication about cost and 
management in a larger patient-physician population.  With only eight physicians it was 
difficult to tell whether physician differences were true differences of merely a function of the 
small sample.  Also, given the patient bias toward reporting high medication satisfaction, a 
greater patient sample and use of confidential satisfaction reporting would perhaps reveal 
greater variation in satisfaction and permit the detection of meaningful differences in 
communication and predictors of satisfaction. 
 Fourth, the use of a cross-sectional study design in the present study provided only a 
snapshot of the patient-provider relationships.   Using a longitudinal study design would 
permit the assessment of changing communication over time and improve the ability to 
make causal inferences among communication characteristics and measured outcome 
variables.  Further, in the context of longitudinal study designs, future research should 
attempt to identify important mediators and moderators of communication about cost and 
management and the impact of these variables on outcomes.  Patients’ trust in physicians, 
socio-cultural differences between patients and physicians, and patients’ assessments of 
their willingness to pay for medications are just some of the factors that may mediate or 
moderate the relationship between communication and patient outcomes.  Further research 
on medication cost discussions and health outcomes is especially important with the advent 
of Medicare Part D given the number of specific plans and the variable impact that different 
plan types may have on individuals’ OOP medication expenses (Safran et al., 2005).   
 Fifth, future studies should include both observational and perception measures of 
communication. Direct observation of communication permits reliable assessment of time 
spent discussing certain topics and the content of communication but it fails to capture 
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whether patients understood the information provided.  In assessing the revised conceptual 
framework, for example, it would be important to not only assess the content of the 
communication about pharmacologic treatments but also patients’ understanding and 
opinions about their involvement in medical visit communication and decision-making.  
 Finally, no organizational or social factors were measured and may have influenced 
the individual level results obtained in the study.  It is entirely possible that the clinics in 
which patients were seen or the geographic differences in populations may have influenced 
patient-physician relationships and communication.  To address this complexity, future 
studies need to take into account the influence of organizational and structural factors on 
communication and outcomes.  Multilevel study designs should be employed to assess the 
impact of higher-level determinants. 
 
 
Conclusion 
 This study helps address gaps in the literature regarding communication between 
physicians and patients about medication costs and medication management.  While the 
healthcare literature has stressed the importance of patient-physician communication about 
medication costs, this was one of the first studies to examine the content and predictors of 
actual discussions of medication cost in the context of medication management (Alexander 
et al., 2003; Alexander & Tseng, 2004).  Study results indicate that both medication cost and 
management communication are complex concepts, which take several forms in routine 
medical visits.   This information, combined with the significant predictors of communication 
about medication costs and management, facilitated the development of a new framework to 
conceptualize communication about medications.  The study results along with the revised 
framework may facilitate the development of interventions that focus on patient and 
physician communication to activate discussion of medication costs and medication 
management issues in rheumatology.  Even with significant policy changes affecting the 
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price and availability of medications, communication about medication in medical visits is 
likely to remain a salient issue.  Interventions utilizing technologies to bring cost and 
prescribing information to the point of care and those using allied health professionals to 
activate discussion of critical medication topics may go a long way to improving 
communication in medical visits where the number topics to cover far exceeds the time 
allotted.
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MEDICAL RECORD INFORMATION ~ Older Adults and Drug Decisions Study  
Patient ID_______  Medical Record #___________Baseline Visit Date:____________ Med Rec Collected 
Date:____________ 
 
Directions 
 
Please review the patient medical record and mark the following: 
1. Number of prior visits – look through the records mark the number of prior visits the patient has had with the 
physician that saw them on their baseline visit date.  The baseline visit is the visit in which the patient and 
physician had their interaction audiotape recorded.  The patient may have seen other doctors at the clinic so be 
certain to record only the number of visits the patient has had with the doctor seen for the baseline visit. 
 
2. Weight – please record the medical chart noted patient weight from the baseline visit.  The weight may be 
recorded in pounds (lbs.) or kilograms (kg). It is incredibly important that weights be recorded for patients receiving 
Infliximab (Remicade®) infusions. 
 
3. Medications – please mark all the recorded rheumatoid arthritis medications noted in the medical record on the 
date of the baseline visit.  This means medications that the patient is supposed to be taking before seeing the 
physician for the baseline visit.  Check the box next to the medication name, circle or record the dosage (if known), 
and indicate the date the medication was started.  If the dose or medication start dates are unknown indicate that 
on the sheet. For the medication notes please review physician notes from the baseline visit and follow-up visits 
through 12 months and follow these guidelines: 
a. Adherence – record any notes in the medical record that refer to patient adherence/non-adherence on the 
date of the baseline visit. For example, if the physician records a note that the patient has only been taking 
been taking prednisone and no other medications – record verbatim the physician’s notes in the adherence 
box. 
b. Cost – record any notes in the medical record that refer to medication cost or issues with insurance, etc. 
that affect cost.  For example, if the record contains a note about a patient applying for a prescription drug 
assistance program, Medicaid, etc. write verbatim the physician’s note in the cost box. 
c. Regimen Changes – record any physician notes about regimen changes or proposed regimen changes.  
Record notes on regimen changes made at the baseline visit up through one year of follow-up visits.  Next 
to each regimen change notes write the date of the visit in which the change occurred.  For example, if the 
record contains a note about starting a patient on a TNF-alpha inhibitor based on insurance authorization, 
write verbatim the physician’s note in the cost box and 11/20/03. Alternately, if the physician recommends 
a prednisone taper record that kind of note as well along with the date. 
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4. Other medications – in this section record notes about medications in the medical record that are not mentioned in 
#2 above.  These medications may or may not be medications for treating rheumatoid arthritis.  Be sure to record 
all details contained in the record including: medication name, dose, route of administration, frequency of 
administration, start and/or stop date, and reason for stopping (if noted).   
 
5. Health insurance – please circle the type of health insurance noted in the medical record. If category is not 
immediately clear, record verbatim what is in the record. In addition, to the health insurance category please note 
any information provided in the record about the patient’s prescription drug plan or prescription drug assistance 
programs if included in the record.  Definition of the categories are as follows: 
 
a. Private or employer sponsored insurance – these are programs provided by companies such as Blue 
Cross and Blue Shield of North Carolina, the state employees health plan, Aetna, Cigna, etc.  This 
category contains all the insurance types that are not directly funded and maintained as either a state or 
federal entitlement program. 
b. Medicare with supplemental insurance – this category includes people who have Medicare listed as their 
primary insurance and then have a secondary private or employer sponsored insurance program listed in 
the record.   
c. Medicare only – this category includes people who only have Medicare listed as their health insurance 
provider 
d. Medicaid only – this category includes people who only have Medicaid listed as their health insurance 
provider 
e. Medicare + Medicaid – this category includes people who have both Medicare and Medicaid listed as 
health insurance providers. 
f. Self-pay – this category includes people who have a note that they are self-pay customers and/or have a 
note that they have no known health insurance provider. 
 
6. Other notes – record any notes in this section that seem relevant to the patient’s medications or medication taking 
that are not contained in any other area. 
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APPENDIX 2:  MEDICAL VISIT AUDIOTAPE CODING TOOL 
 
Tape ID# _____________  Coder Initials ____________     Date Coded ____________          
 
Date of Medical Visit:    _______________ Length of Physician Visit: _____________  
 
Other professionals present:  Y   N ____________________   (write in identity of person present) 
                                                                     
    Yes No                                       
Is a friend and/or family member present in the exam room?   1  2      
 
If Yes: relationship ____________________________ 
 
If Yes, 
 
____Patient initiated medication cost 
discussion 
 
____Physician initiated medication cost 
discussion 
 
Did the patient or 
physician discuss issues 
related to medication 
costs?  
 
Record discussion of direct 
medication costs (e.g. out-
of-pocket costs incurred by 
patients) or indirect 
medication costs (e.g. 
prescription drug assistance 
programs or prescription 
drug insurance coverage) 
Yes      No            
 
Time of Discussion (1) :  
____________________ 
                                             
Time of Discussion (2) :  
____________________ 
 
Time of Discussion (3) :  
____________________ 
 
Time of Discussion (4) :  
____________________ 
 
Time of Discussion (5) :  
____________________ 
 
Tally number of questions from all cost-
related discussions 
 
___________Number of questions patient 
asked about medication cost-related issues 
 
___________Number of questions physician 
asked about medication cost-related issues 
 
Did the medical visit 
include discussion of 
patient-initiated changes 
to the medication 
regimen?  
 
Patient-initiated changes to 
the medication regimen are 
a facet of medication self-
management.  These are 
independent, purposeful 
patient changes in the drug 
regimen requiring a 
behavior change. 
Discussions include but are 
not limited to: patients 
taking less medication than 
originally prescribed, 
altering times of 
medication administration, 
pill-splitting, adding a 
medication, or substituting 
one medication for another. 
 
Yes      No    
 
Time of Discussion (1) :  
____________________ 
                                             
Time of Discussion (2) :  
____________________ 
 
Time of Discussion (3) :  
____________________ 
 
Time of Discussion (4) :  
____________________ 
 
Time of Discussion (5) :  
____________________ 
If Yes, 
 
Brief Description of Topic(s) 
Discussed: 
 ___________________________________ 
 
___________________________________ 
 
___________________________________ 
 
___________________________________ 
 
___________________________________ 
 
___________________________________ 
 
___________________________________ 
 
___________________________________ 
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APPENDIX 3:  MEDICAL VISIT AUDIOTAPE CODING RULES 
 
Cost as a Feature of Medication Management Communication in Medical Visits 
 
Audiotape Coding Rules 
Preparations for Coding: 
 
For this analysis all the audiotapes should be from the baseline or initial recorded visit.  All baseline audiotapes 
should end with an “a”. 
 
A warm-up time of approximately 2-3 minutes is recommended for each tape. Use the warm-up time to listen to 
the tape and get used to the voices and dialects of the physician and the patient. During the warm-up, the coder 
may also complete some of the information about the tape on the coding sheet. 
 
When Coding: 
 
1. Use a dark-lead pencil to code the information on the coding tool. 
 
2. Listen to each file at least 2 or more times in order to correctly code the visit.   
a) Use the first time to code information on the issues outlined on the following pages. There is a great 
chance that you will not be able to capture all information. 
b) Use the second time to capture the information that you have missed during the first time, and to 
verify that you have followed the rules for coding. 
 
3. Make sure that each item and category is coded (circled) appropriately. We recommend double-checking 
your work.    
 
4. Code legibly and complete all relevant details requested. 
 
5. In order to make accurate assessments pay special attention to the Notes and Examples throughout the 
rulebook to clarify anything that you may be confused about.   
 
6.  In general, more information is always preferred. If you are unsure of how to code an interaction, record as 
much detail about the encounter and record any notes or questions that may be helpful in determining why a 
particular coding decision was made.  
 
7.  Whenever you feel that a tape is incomplete (i.e. part of the tape was cut off, etc.), complete the coding tools 
to the best of your ability. Then, for the parts of the coding tools that you are unsure about, indicate this with a 
marker and write the reason you think the tape was incomplete.  
 
To Code: 
 
Header: Tape Identification and General Information 
 
 Tape ID#:  Be sure to put the patient’s 4-digit, single-letter identification number. It should be in the 
following format:  
Example:  2303a  
 2303 is the patient ID number for the project. The first two digits identify the 
physician and the second two identify the patient. In this case, physician 23 is seeing 
patient 03.  
 “a” indicates that the tape is from the baseline/initial medical visit 
 
 Coder Initials:  Put your initials here. 
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 Date Coded: Record the current date on which you are coding the tape. 
 
 Date of Medical Visit: Write down the date that the medical visit was audiotape recorded.  For the 
date of the medical visit, record the date listed as the second half of the patient ID.  As an example, if 
the ID is 2303a_051505, the date of the medical visit is May 15, 2005.  
Note:  
1. The physician or research assistant may mention the date on the actual tape recording but 
do NOT record this as the medical visit date. 
 
 Length of Physician Visit: Write in the time (duration/length) of physician visit in minutes. Only 
record the time that the physician and patient are interacting.  The final time should be recorded 
once the physician or patient has left the room for good, or there is no dialogue between the two 
signaling that the interview has ended.  The duration of the exam can be seen on the digital apparatus 
you are using to listen to the interview, whether you are using a computer, CD player, etc. Also, keep 
track of how long the patient is alone or with a clinician other than the primary physician and subtract 
it from the total length of the tape.  
Note: 
1. Do not include the time when the patient interacts with a nurse (or another clinician) after 
the physician has completed the exam, nor when the patient is alone in the exam room.  
2. The coder should stop coding when the interaction with the physician has ceased.  This 
time may be shorter than the total length of time displayed for the digital recording. 
 
 Other Professionals Present:  Circle Yes/No if another healthcare provider or social worker, etc. is 
present in the room during the interview. If it is clear, also write the title of person present. 
Examples of others present:  
 nurse 
 training physician 
 social worker 
 translator 
Note:  Please write “Clinician” if the identity of the healthcare provider is unclear 
 
Initial Page Content: Friends/Family Present for Medical Visit Exam 
 
 Friend and/or family present:  
 Circle Yes if a friend/family member is present in the exam room during the taping of the 
interview.   
 Circle No if there is not a friend/family member in the room during the taping of the 
interview.   
Example of friends/family:  
 Spouse (husband/wife) 
 Mother, father, sister, brother, daughter, son 
 Other family member (aunt, uncle, etc.) 
 Pastor and/or other church members 
 Neighbor or friend 
Note:   
1. Please write “Unknown” if the identity of the caregiver is unclear. 
2. During the exam interview, if the caregiver at anytime asks a question, or initiates a 
discussion about medication costs or medication management – the occurrence of these 
events should be coded on the coding form but it should be noted that it was the caregiver 
and NOT patient bringing up the question/conversation.  For example, (Caregiver) can be 
written after coding for a conversation item initiated by the caregiver to separate it out 
from conversation initiated by the patient. 
 
Table: Medication Costs and Medication Self-Management 
 
Notes about Medications 
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 For the purposes of this study, we are interested in medications used to treat arthritis and medications 
commonly prescribed to persons with rheumatoid arthritis. See Appendix A for a list of medications 
that might be discussed during the medical visit. 
 Medication conversations of interest should involve medications the patient is taking, has taken, or 
may take. Do NOT code medication conversations that center around medications that the patient’s 
family, friends, etc. are taking. 
 This includes medications that the patient should have been taking since the last visit, medications the 
patient has stopped taking or calibrated since last visit, new medications that are being prescribed 
during this visit, medications that are to be started contingent on something or are just being 
considered, medications that are just mentioned, and/or medications that are administered in the clinic.  
 This also includes medications that the patient is taking regardless of whether or not they were 
prescribed by the medical visit physician.  
 
 
Medication Costs 
 
Medication cost conversation includes both indirect and direct communication about medication costs.  
Direct communication involves explicit communication about the prices patients pay for medications, 
the total sum a patient has to pay for medications, or the retail price of a medication.  As a general rule, 
direct communication can be thought of as discussion about the dollars and cents of medication costs.  
Indirect communication, on the other hand, is likely to not involve expression of cost numbers.  Such 
communication may center on physician provision of samples to offset medication costs, prescription 
drug assistance programs run by pharmaceutical companies and foundations to provide medications at 
little or no charge, or the influence of patients’ prescription drug insurance coverage.   
 
If Yes, 
 
____Patient initiated medication cost discussion 
 
____Physician initiated medication cost discussion 
 
Did the patient or 
physician discuss 
issues related to 
medication costs?  
 
Record discussion of 
direct medication costs 
(e.g. out-of-pocket costs 
incurred by patients) or 
indirect medication costs 
(e.g. prescription drug 
assistance programs or 
prescription drug 
insurance coverage) 
Yes      No            
 
Time of Discussion (1) :  
____________________ 
                                             
Time of Discussion (2) :  
____________________ 
 
Time of Discussion (3) :  
____________________ 
 
Time of Discussion (4) :  
____________________ 
 
Time of Discussion (5) :  
____________________ 
 
Tally number of questions from all cost-related 
discussions 
 
___________Number of questions patient asked about 
medication cost-related issues 
 
___________Number of questions physician asked about 
medication cost-related issues 
 
 
 Did the patient or physician discuss issues related to medication costs? 
 
The coder must circle Yes or No.  While multiple discussions of medication cost may occur within a 
single visit, one conversation about medication costs is sufficient to circle Yes. 
 
When do we circle Yes? 
 
Code Yes whenever: 
1. The patient and/or physician discuss direct medication costs (i.e. the dollars and cents of medications). 
Example: 
 
Physician – So it would be nice … we talked about the new medicines the biologic agents: Enbrel, 
Remicade, Humira. Those are alternatives.   
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Patient – I’d rather hold off on Enbrel. Remicade the insurance probably won’t pay for it. Someone 
told me it’s like $3000/month.  
Physician – It should be around $1200 a month. 
 
2. The patient and/or physician discuss the provision of medication samples. 
Example: 
 
Physician – You are still taking that Evista, right? 
Patient – Yes 
Physician – I think I have some samples in my cupboard that I can give you, I know it can be 
expensive. 
 
3. The patient and/or physician discuss pharmaceutical assistance programs. 
Example: 
 
Patient – Someone told me that if you completed this form I could get the company to pay for my 
medication. 
Physician – I’d be happy to complete the form. Do you need us to fax it for you? 
 
4. The patient and/or physician discuss patient’s insurance coverage and how that might influence 
prescribing.  Discussions about Medicare Part D and the influence of Part D on patients’ medication 
costs are also relevant insurance coverage communication. 
Example: 
 
Physician – What kind of insurance do you have for your prescription drugs? 
Patient – I only have my Medicare and a small supplement to pay for my medications. 
Physician – It pays for a percentage of the cost of your medicines? 
Patient – Yes 
Physician – Okay, in terms of making medication decisions I think we need to recognize the potential 
cost barrier. 
 
When do we circle No? 
 
We circle No whenever: 
1. The patient and/or physician are discussing cost issues beyond medications.  Conversations about 
procedure costs or the cost of medical visits and services are separate and should not be coded 
affirmatively. 
2. The patient and/or physician discuss medication costs for someone other than the patient. 
3.  The patient and/or physician discuss abstract medication costs not related to the patient or 
medication decision-making for the patient (e.g. the influence of direct-to-consumer medication 
advertising on medication prices broadly speaking). 
4. The patient and/or physician discuss follow-up tests, procedures, etc. that would be required in 
the future by taking a medication (e.g. regular blood testing for patients taking methotrexate).  
While further tests and procedures will mean future costs, such costs are not guaranteed and are 
variable.  For the purposes of coding consistency and reliability, do not code for adjuvant 
medication costs unless there is specific and direct cost discussion related to medication-related 
tests and procedures. 
 
 
 Time of Discussion 
 
For each conversation about medications costs in the medical visit record the start and end time of the 
conversation as is listed on the digital audio player. The start and end time of conversation about 
medication costs should be recorded for each conversation about cost occurring in the visit.  As an 
example, for a conversation beginning at 04.05 and ending at 10.20, the coder should record both the 
start and end time on the Time of Discussion line.  There may be multiple conversations about cost as 
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patients and physicians begin a conversation go on to something else and then return to the cost 
conversation.  This should be repeated for each cost conversation.  Five “Time of Discussion” lines are 
provided but please record all instances of discussion even if this goes beyond five.  
 
(If Yes) Coding Specific Elements of Communication about Medication Costs 
 
 Patient initiated medication cost discussion 
 
Patient initiated medication cost discussion should receive a mark if the patient brought up a 
medication cost topic, either direct or indirect, before the physician in the medical visit.  This means 
that if a patient asks the physician about obtaining a medication from a prescription drug assistance 
program or makes a statement about the cost of a prescription prior to the physician asking the patient 
a question about medication costs or making a statement about medication costs then the coder should 
mark that the patient initiated medication cost discussion.  As has been written previously, multiple 
discussions of cost may occur in the visit.  However, for the purposes of coding this item, we are 
interested only in who first brings up the topic within the medical visit since multiple discussions are 
likely to flow from first initiation of the topic. 
 
 Physician initiated medication cost discussion 
 
Physician initiation of medication cost discussion should be coded in the manner described above 
except the physician must bring up a medication cost topic in the visit, either direct or indirect, before 
the patient.  Again, it means that if the physician asks a question about prescription drug insurance 
coverage or details a medication cost before the patient asks a question or makes a statement about it 
then the coder should mark that the physician initiated medication cost discussion. 
 
 Number of questions that patient asked about medication cost-related issues 
 
Throughout all the medication cost discussions keep a tally of the number of questions that patients 
ask.  These questions may be open or closed-ended but should be related to the medication cost 
discussion.  Below are some examples of patient questions: 
 Patient – How much does this Arava usually cost? 
 Patient – Do you think I might qualify for the patient assistance program? 
 Patient – Do you know if there is a way I can receive my medications at a lower  
 price? 
Coders should also count questions that may be framed as statements or semi-questions where it is still 
clear that the patient is inquiring about medication costs. 
 Patient – I assume it is okay for me to buy generic Naprosyn to save money. 
 Patient – Methotrextate is cheaper than Arava, right? 
 
 Number of questions that physician asked about medication cost-related issues 
 
Again this should be coded in the same manner as questions patient asked.  A tally should be kept of 
all types of medication-related questions asked during medication cost conversations.  Below are some 
examples of physician questions: 
 Physician – What kind of prescription drug insurance do you have? 
 Physician – How much do you generally pay a month for your medicines? 
 Physician – Would you like me to put you in touch with our payment specialist to 
           see if we can help you get those medicines? 
Coders should also count questions that may be framed as statements or semi-questions where it is still 
clear that the physician is inquiring about medication costs. 
 Physician – You’re on disability (?) 
 Physician – You’re not paying for Humira, right? 
 
Patient-Initiated Changes to the Medication Regimen 
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Patient-initiated changes to the medication regimen can be considered a facet of medication self-management 
and are of interest in this study because their relationship to medication cost.  For our purposes, medication self-
management is defined as a patient’s ability to manage symptoms through medications and deal with physical 
and psychosocial consequences of their medication-taking.  Effective management involves a continuous 
feedback loop of monitoring one’s condition, taking medications, and managing medication effects.  
Rheumatoid arthritis patients must make decisions about the amount, timing, and quantity of medication to take 
based on a number of personal factors, including the cost of their medications. Using this concept of self-
management as a base, we are interested in examining patient initiated changes to the medication regimen that 
require a behavior change.  Patients may choose to take less or more medication than prescribed, split-pills to 
stretch out the time between prescription fills, alter their dosing schedule to accommodate their lifestyle, add or 
drop medications from their regimens, or substitute one medication for another. These examples do not make up 
the entire universe of possible conversations about patient-initiated changes in the regimen but should provide 
some guide for the types of discussions likely to occur.  In the context of this study, we are primarily interested 
in the discussions between patients and physicians about patients’ independent, purposeful actions to manage 
their medications. Physicians may actively participate in these discussions but the changes to the regimen 
should be patient initiated and directed. 
 
Did the medical visit include 
discussion of patient-initiated 
changes to the medication regimen?  
 
Patient-initiated changes to the 
medication regimen are a facet of 
medication self-management.  These 
are independent, purposeful patient 
changes in the drug regimen requiring 
a behavior change. Discussions 
include but are not limited to: patients 
taking less medication than originally 
prescribed, altering times of 
medication administration, pill-
splitting, adding a medication, or 
substituting one medication for 
another. 
 
Yes      No    
 
Time of Discussion (1) :  
____________________ 
                                             
Time of Discussion (2) :  
____________________ 
 
Time of Discussion (3) :  
____________________ 
 
Time of Discussion (4) :  
____________________ 
 
Time of Discussion (5) :  
____________________ 
If Yes, 
 
Brief Description of Topic(s) Discussed: 
 ________________________________ 
 
_________________________________ 
 
_________________________________ 
 
_________________________________ 
 
_________________________________ 
 
_________________________________ 
 
_________________________________ 
 
_________________________________ 
 
 Did the medical visit include discussion of patient-initiated changes to the medication regimen? 
 
The coder must circle Yes or No.  While multiple discussions of patient’s changes to the medication 
regimen may occur within a single visit, one conversation about a patient-initiated change to the 
regimen is sufficient to circle Yes. 
 
When do we circle Yes? 
 
Code Yes whenever: 
1. The patient and/or physician discuss how the patient is purposefully taking less medication than 
prescribed.  This may involve patients splitting pills or taking fewer doses per day. 
Example: 
 
Patient – I’ve felt pretty well and didn’t want to take all that prednisone.  I’ve only been taking one pill 
every other day.   
Physician – Okay, so you’re only taking 5mg every other day instead of every day? 
 
2. The patient and/or physician discuss the patient purposefully taking more medication than prescribed. 
Example: 
 
Physician – You’re taking 5mg of prednisone daily? 
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Patient – No, I’m taking 10mg a day.  I was feeling so achy and stiff that I started taking 10mg a day 
instead 5mg. 
Physician – Hmm… all right. How long are you stiff in the morning? 
 
3. The patient and/or physician discuss the patient taking over-the-counter medicines or medicines that 
were not prescribed by the medical visit physician for the patient’s arthritis. 
Example: 
 
Patient – When it got cold outside I started to feel more aches and pains so I got some Aleve at the 
pharmacy and have been taking that. 
Physician – How many do you take a day? 
Patient – I usually take two. 
 
4. The patient and/or physician discuss the patient substituting one medication for another. 
Example: 
 
Patient – I just didn’t like Bextra.  I didn’t think it was doing anything for me so I’ve been taking 
Naprosyn instead? 
Physician – I don’t think I have a problem with that.  How many milligrams are you taking? 
 
When do we circle No? 
 
We circle No whenever: 
1. The physician is prescribing medications for the patient and making the prescribing decisions.  To 
count as patient initiated changes to the regimen there must be some initiation/discretion on the part of 
the patient about managing the medication regimen.  The change has to be independently and 
purposefully chosen on the patient’s part so code No if the patient accidentally takes more or less 
medication or if the change is initiated by another physician. 
2. The patient and/or physician are discussing medication-taking broadly.  If the patient and physician are 
discussing general patient medication management strategies, then code No for this item.  An 
example, would be discussing what people in general do to manage their medicines like pill splitting.  
In order to code Yes, it needs to be clear that the discussion is centering on changes to the patient’s 
regimen that he/she has initiated. 
 
 Time of Discussion 
 
For each conversation about patient-initiated changes to the regimen in the medical visit record the 
start and end time of the conversation as is listed on the digital audio player. The start and end time of 
conversation should be recorded for each conversation about management occurring in the visit.  As an 
example, for a conversation beginning at 04.05 and ending at 10.20 the coder should record the start 
time and end time on the Time of Discussion line.  There may be multiple conversations so this should 
be repeated for each patient-initiated change to the regimen conversation.  Five “Time of Discussion” 
lines are provided but please record all instances of discussion even if this goes beyond five.  
 
(If Yes) Brief Description of the Topics Discussed 
 
In this space please record the topic areas discussed during the patient-initiated changes to the medication 
regimen discussions.  As described above, topics may include alternate dosing schedules, pill splitting, taking 
more medication than prescribed, or substituting one or more medications for another.  However, these are just 
sample topics so to help better understand the universe of topics discussed as part of this aspect of patient 
medication self-management coders are requested to write the topics in this section.  If you are unsure whether 
the topic constitutes a patient-initiated change in the medication regimen please record the topic and a note 
indicating the ambiguity.  Differences or questions among coders will be resolved by consensus.   
 
 
 Record any helpful notes about the visit below the coding table. 
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If the tape is difficult to hear, the dialects are hard to understand, or there appear to be important gaps in the 
medication conversations, please record them below the coding table.  Coders are encouraged to please record 
any information that you believe will be helpful for understanding your coding decisions and/or the content of 
the audiotape.   
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Appendix A 
 
RHEUMATOID ARTHRITIS MEDICATONS 
 
Antimetabolites  
 
1. Methotrexate   (Rheumatrex)  
 
Antirheumatic agents  
 
1. Sulfasalazine      (Azulfidine)  
2. Leflunomide      (Arava)  
3. Hydroxychloroquine     (Plaquenil)  
 
Immunomodulators  
 
1. Entanercept      (Enbrel)  
 
Immunosuppressive  
 
1. Azathioprine      (Imuran)  
2. Mycophenolate mofetil     (Cellcept)  
 
Monoclonal antibodies  
 
1. Infliximab      (Remicade) 
2. Adalimumab      (Humira) 
 
Corticosteroids 
 
1. Prednisone     (Deltasone, Sterapred) 
2. Dexamethasone     (Decadron) 
3.  Methylprednisolone    (Medrol) 
4. Triamcinolone     (Aristocort) 
5. Hydrocortisone     (Aristocort) 
6. Prednisolone     (Orapred) 
 
 
PAIN MEDICATIONS 
 
Opioid Agonists 
 
1. Codeine      (Methylmorphine) 
2. Fentanyl      (Sublimaze, Actiq, Duragesic) 
3. Hydromorphone     (Dilaudid) 
4. Levorphanol     (Levo-Dromoran) 
5. Meperidine     (Demerol) 
6. Methadone     (Dolophine, Methadose) 
7. Morphine Sulfate     (Avinza, MS Contin, Kadian, Roxanol,  
Oramorph SR, MSIR) 
8. Oxycodone     (Roxicodone, OxyContin, Percolone,  
OxyFAST, OxyIR) 
9. Oxymorphone      (Numorphan) 
10. Propoxyphene     (Darvon-N, Darvon Pulvules) 
11. Methyldihydromorphinone   (Metopon) 
12. Hydrocodone     (Vicodin-Zygon) 
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Opioid Antagonists 
 
1. Nalmefene     (Revex) 
2. Naloxone     (Narcan) 
 
Opioid Agonist-Antagonists 
1. Buprenorphine     (Buprenex) 
2. Butorphanol      (Stadol, Stadol NS) 
3. Nalbuphine     (Nubain) 
4. Pentazocine     (Talwin)  
 
Other Analgesics 
 
1. Acetaminophen      (Tylenol) 
2. Tramadol     (Ultram) 
3. Lidocaine Patch     (Lidoderm) 
 
Non-selective NSAIDs 
 
1. Aspirin*      (Bayer, Bufferin, Ecotrin, etc) 
2. Diclofenac     (Voltaren, Cataflam) 
3. Diflunisal     (Dolobid) 
4. Etodolac     (Lodine, Lodine XL) 
5. Fenoprofen     (Nalfon) 
6. Fluriprofen     (Ansaid) 
7. Ibuprofen      (Motrin, Advil, Nuprin, Rufen) 
8. Indomethacin      (Indocin) 
9. Ketoprofen     (Orudis, Acton, Oruvail, Orafen) 
10. Ketorolac     (Toradol) 
11. Meclofenamate     (Meclomen) 
12. Meloxicam     (Mobic) 
13. Nabumetone     (Relafen) 
14. Naproxen      (Naprosyn, Aleve, Anaprox, Naprelan) 
15. Oxaprozin      (DayPro) 
16. Piroxicam     (Feldene) 
17. Sulfasalazine     (Azulfidine, Azulfidine EN-tabs) 
18. Sulindac      (Clinoril) 
19. Tolmetin     (Tolectin) 
 
*  At least 325 mg of aspirin should be taken every 4 hours to adequately treat pain. Baby aspirin or 81 mg 
every day is used for coronary artery disease prevention and not for pain treatment.  
 
Selective COX-2 NSAIDs 
 
1. Celecoxib     (Celebrex) 
2. Rofecoxib     (Vioxx) 
3. Valdecoxib     (Bextra) 
 
Opioid Analgesic Combinations 
 
1. Acetaminophen + codeine    (Tylenol #2,#3,#4, Capital with Codeine  
suspension) 
2. Acetaminophen + hydrocodone   (Anexsia, Arexsia, Lorcet, Lortab,  
Maxidone, Vicodin, Zydone) 
3. Acetaminophen + propoxyphene   (Darvocet, Wygesic) 
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4. Hydrocodone + ibuprofen    (Vicoprofen) 
5. Oxycodone + Acetaminophen   (Percocet, Tylox) 
6. Oxycodone + Aspirin    (Percodan) 
7. Acetaminophen+butalbital+caffeine+codeine   (Fioricet with Codeine) 
8. ASA+bulalbital+caffeine+codeine   (Fiorinal with Codeine) 
 
Non-Opioid Analgesic Combinations 
 
1. Aspirin+Acetaminophen+caffeine    (Excedrin, Goody’s Headache Powder, BC  
Powder) 
2. Acetaminophen+Butalbital+caffeine  (Fiorcet, Esgic) 
3. Aspirin+butalbital+caffeine   (Fiornal) 
4. Acetaminophen+tramadol    (Ultracet) 
5. ASA+MgAl+Ca Carbonate   (Ascriptin) 
6. Carisprodol+ASA    (Soma Compound) 
7. Orphendrine+ASA+caffeine   (Norgesic) 
 
Muscle Relaxants  
 
1. Baclofen     (Lioresal) 
2. Carisoprodol     (Soma) 
3. Chlorzoxazone      (Paraflex, Parafon Forte DSC, Remular-S) 
4. Cyclobenzapine      (Flexeril) 
5. Dantrolene      (Dantrium) 
6. Diazepam     (Valium, Diastat) 
7. Diclofenac+mistoprostol    (Arthrotec) 
8. Metaxalone     (Skelaxin) 
9. Methocarbamol     (Robaxin, Robaxin-750) 
10. Orphenadrine     (Norflex) 
11. Quinine sulfate 
12. Tizanidine     (Zanaflex) 
 
Adjuvant Pain Medications 
 
1. Amitriptyline      (Elavil) 
2. Carbamazapine     (Tegretol) 
3. Gabapentin      (Neurotin) 
4. Nortriptyline     (Pamelor) 
 
Herbal or Nutritional Supplements 
 
1. Glucosamine 
2. Glucosamine chondroitin     (Osteo Bi-Flex, etc) 
3. MSM       (Methylsulfonylmethane) 
4. SAMe 
 
Topical Analgesics 
 
1. Arthritis Hot 
2. Aspercreme 
3. Ben-Gay Cream 
4. Capsaicin 
5. Deep Heating 
6. Icy Hot 
7. Mineral Ice 
8. Thera-gesic Cream 
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Common Drug Information Fact Sheet 
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APPENDIX 4: AUDIOTAPE TRANSCRIPTION RULES 
 
Cost as a Feature of Medication Management Communication in Medical Visits 
Audiotape Transcribing Rules  
 
For this analysis all the audiotapes should be from the baseline or initial recorded visit.  All baseline audiotapes 
should end with an “a”. 
 
See sample transcript 
 
1. Name the word file the tape’s number – the tape should be numbered with a 4 initial digits indicating 
tape ID number, the letter “a”, an underscore, and then six digits indicating the date of the recording 
(e.g. 2099a_020203). 
2. At the top of each file put the tape ID number, the total time of the visit according to the digital player, 
the transcriber’s initials, the date of the transcription, and a key indicating the shorthand used for the 
people in the visit (e.g. D – Doctor, P-Patient, S-Spouse, U – Unknown). If there is more than one 
physician, etc. in the exam room number use letters and numbers (e.g. P1 – Main physician, P2 – 
Resident physician). 
3. Insert line numbers and page numbers using the word functions 
4. A new line should be started each time a new person speaks.  The new line should begin with the key 
initial of the person speaking (e.g. D – Doctor).   
5. If an interruption occurs (e.g. phone call, knock at door)-type interruption in capital letters on a new 
line. If the interruption is a person walking in the room please transcribe what is said and put what the 
person says who enters the room in brackets.  For example: 
Interruption: [nurse:  ] 
If the interruption is a phone call type Interruption: Phone Call 
6. Put a “.” For every second of silence. 
Example: 
…… (These dots would indicate 6 seconds of silence) 
7. If you are unclear of what they are saying put it in parentheses. 
Examples:  (foot)   (words) 
8. Use question marks and periods 
9. If a speaker breaks off in the middle of a word or phrase, this is marked by a hyphen as in “haven’t felt 
like-“ 
10. Double parentheses enclose descriptions 
Examples: 
  ((cries)) 
  ((laughs)) 
 ((annoyed)) 
11. To protect confidentiality, blank lines substitute for proper names. Do not transcribe any patient, 
caregiver, clinic, town, or provider first or last names. Do not transcribe phone numbers. However, do 
put doctor before reference to another doctor (e.g. Dr. ___).  Also if the relationship of the person 
named is known, please include in parentheses the relationship (e.g. patient’s cousin, patient’s 
cardiologist). 
Examples: 
   _________ (patient’s cousin) 
Dr. _______ 
 
For the purposes of this study, we are interested in medications used treat arthritis and medications commonly 
prescribed to persons with rheumatoid arthritis. See below for a list of medications that might be discussed 
during the medical visit. 
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RHEUMATOID ARTHRITIS MEDICATONS 
 
Antimetabolites DRUG CLASS 
 
Methotrexate GENERIC NAME  (Rheumatrex) BRAND NAME 
 
Antirheumatic agents  
 
Sulfasalazine      (Azulfidine)  
Leflunomide      (Arava)  
Hydroxychloroquine      (Plaquenil)  
 
Immunomodulators  
 
Entanercept*      (Enbrel)  
 
Immunosuppressive  
 
Azathioprine      (Imuran)  
Mycophenolate mofetil     (Cellcept)  
 
Monoclonal antibodies  
 
Infliximab*       (Remicade) 
Adalimumab*      (Humira) 
 
* These medications are also collectively called TNF-alpha inhibitors 
 
Corticosteroids 
 
Prednisone      (Deltasone, Sterapred) 
Dexamethasone     (Decadron) 
Methylprednisolone     (Medrol) 
Triamcinolone     (Aristocort) 
Hydrocortisone     (Aristocort) 
Prednisolone      (Orapred) 
 
 
PAIN MEDICATIONS 
 
Opioid Agonists 
 
Codeine      (Methylmorphine) 
Fentanyl      (Sublimaze, Actiq, Duragesic) 
Hydromorphone     (Dilaudid) 
Levorphanol      (Levo-Dromoran) 
Meperidine      (Demerol) 
Methadone      (Dolophine, Methadose) 
Morphine Sulfate     (Avinza, MS Contin, Kadian, Roxanol,  
Oramorph SR, MSIR) 
Oxycodone      (Roxicodone, OxyContin, Percolone,  
OxyFAST, OxyIR) 
Oxymorphone      (Numorphan) 
Propoxyphene     (Darvon-N, Darvon Pulvules) 
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Methyldihydromorphinone    (Metopon) 
Hydrocodone     (Vicodin-Zygon) 
 
Opioid Antagonists 
 
Nalmefene      (Revex) 
Naloxone      (Narcan) 
 
Opioid Agonist-Antagonists 
Buprenorphine     (Buprenex) 
Butorphanol       (Stadol, Stadol NS) 
Nalbuphine      (Nubain) 
Pentazocine      (Talwin)  
 
Other Analgesics 
 
Acetaminophen      (Tylenol) 
Tramadol      (Ultram) 
Lidocaine Patch     (Lidoderm) 
 
Non-selective NSAIDs 
 
Aspirin      (Bayer, Bufferin, Ecotrin, etc) 
Diclofenac      (Voltaren, Cataflam) 
Diflunisal      (Dolobid) 
Etodolac      (Lodine, Lodine XL) 
Fenoprofen      (Nalfon) 
Fluriprofen      (Ansaid) 
Ibuprofen       (Motrin, Advil, Nuprin, Rufen) 
Indomethacin      (Indocin) 
Ketoprofen      (Orudis, Acton, Oruvail, Orafen) 
Ketorolac      (Toradol) 
Meclofenamate     (Meclomen) 
Meloxicam      (Mobic) 
Nabumetone      (Relafen) 
Naproxen       (Naprosyn, Aleve, Anaprox, Naprelan) 
Oxaprozin       (DayPro) 
Piroxicam      (Feldene) 
Sulfasalazine     (Azulfidine, Azulfidine EN-tabs) 
Sulindac      (Clinoril) 
Tolmetin      (Tolectin) 
 
Selective COX-2 NSAIDs 
 
Celecoxib      (Celebrex) 
Rofecoxib      (Vioxx) 
Valdecoxib      (Bextra) 
 
Opioid Analgesic Combinations 
 
Acetaminophen + codeine     (Tylenol #2,#3,#4, Capital with Codeine  
suspension) 
Acetaminophen + hydrocodone   (Anexsia, Arexsia, Lorcet, Lortab,  
Maxidone, Vicodin, Zydone) 
Acetaminophen + propoxyphene   (Darvocet, Wygesic) 
Hydrocodone + ibuprofen    (Vicoprofen) 
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Oxycodone + Acetaminophen    (Percocet, Tylox) 
Oxycodone + Aspirin     (Percodan) 
Acetaminophen+butalbital+caffeine+codeine    (Fioricet with Codeine) 
ASA+bulalbital+caffeine+codeine   (Fiorinal with Codeine) 
 
Non-Opioid Analgesic Combinations 
 
Aspirin+Acetaminophen+caffeine    (Excedrin, Goody’s Headache Powder, BC  
Powder) 
Acetaminophen+Butalbital+caffeine   (Fiorcet, Esgic) 
Aspirin+butalbital+caffeine    (Fiornal) 
Acetaminophen+tramadol    (Ultracet) 
ASA+MgAl+Ca Carbonate    (Ascriptin) 
Carisprodol+ASA     (Soma Compound) 
Orphendrine+ASA+caffeine    (Norgesic) 
 
Muscle Relaxants  
 
Baclofen      (Lioresal) 
Carisoprodol      (Soma) 
Chlorzoxazone      (Paraflex, Parafon Forte DSC, Remular-S) 
Cyclobenzapine      (Flexeril) 
Dantrolene       (Dantrium) 
Diazepam      (Valium, Diastat) 
Diclofenac+mistoprostol    (Arthrotec) 
Metaxalone      (Skelaxin) 
Methocarbamol     (Robaxin, Robaxin-750) 
Orphenadrine     (Norflex) 
Quinine sulfate 
Tizanidine      (Zanaflex) 
 
Adjuvant Pain Medications 
 
Amitriptyline      (Elavil) 
Carbamazapine     (Tegretol) 
Gabapentin       (Neurotin) 
Nortriptyline      (Pamelor) 
 
Herbal or Nutritional Supplements 
 
Glucosamine 
Glucosamine chondroitin     (Osteo Bi-Flex, etc) 
MSM       (Methylsulfonylmethane) 
SAMe 
 
Topical Analgesics 
 
Arthritis Hot 
Aspercreme 
Ben-Gay Cream 
Capsaicin 
Deep Heating 
Icy Hot 
Mineral Ice 
Thera-gesic Cream 
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